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ABSTRACT 
 
 
Due to the complex structure and complicated disposition pattern of therapeutic 
macromolecules, their pharmacokinetic interpretation has many challenges. Two of these 
challenges were investigated in this dissertation: 1) the error of classical bioavailability 
assessment observed during subcutaneous (SC) administration of therapeutic 
macromolecules that undergo target-mediated drug disposition (TMDD) and 2) the 
ontogeny of the neonatal Fc receptor (FcRn) expression along with its effect on the 
pharmacokinetics of monoclonal antibodies (mAbs) during development. 
 
TMDD often well describes the pharmacokinetics of therapeutic proteins that 
have high specificity and affinity of binding to their target receptors. The target receptors 
can be saturated by therapeutic proteins under therapeutic concentration due to their 
limited expression and availability in the body. Consequently, clearance through this 
pathway will reach its maximum and nonlinear pharmacokinetics will be observed upon 
further increasing dose if TMDD is a major elimination process. This, in turn, will impact 
the bioavailability estimation. Bioavailability estimations based on the classic AUC 
approach can be erroneous in this situation, mainly due to the incorrect assumption of 
dose-independent constant clearance that cannot be applied to therapeutic proteins that 
undergo TMDD. To shed light on this issue, a simulation study was performed with two 
model drugs: filgrastim and denosumab. Their published structural pharmacokinetic 
models and model parameters were employed in the simulations of plasma concentration-
time profiles at different IV and SC doses. The bioavailability was calculated as the ratio 
of dose-normalized AUC after SC administration to that after IV administration. 
 
The overestimation was extreme when high SC and low IV doses of both protein 
drugs were used for the estimations, whereas excessive underestimation was observed 
with the combination of low SC and high IV doses. These biases in the bioavailability 
estimation resulted from the transition from low plasma concentration (at low doses) to 
high plasma concentration (at high doses), which shifted the major elimination pathway 
from TMDD to the unspecific linear clearance pathway. The changes in clearance 
resulted in parallel changes in dose-normalized AUCs and were very dynamic in the dose 
range of 0.1 ? 5 ?g/kg for filgrastim and below 60 mg for denosumab; thus caution is 
necessary when bioavailability of these two therapeutic proteins is estimated in these 
dose ranges using conventional method. To minimize the error of conventional 
bioavailability estimation of protein drugs that undergo TMDD, the bioavailability should 
be estimated at similar IV and SC doses or the assessment should be performed in dose 
ranges that yield constant dose-normalized AUCs (0.01 ? 0.1 ?g/kg or 5 ? 10000 ?g/kg 
for filgrastim, and 60 ? 210 mg for denosumab). Moreover, an alternative estimation 
method could be applied, which determines the ratio of IV and SC doses that generate 
equally shaped concentration-time profile by applying a variable rate IV infusion, thereby 
resulting in equal AUCs as suggested by ??????? 
 
FcRn has been evidenced as a salvage pathway from lysosomal clearance for 
mAbs and Fc conjugated proteins; thus it can prolong the existence of these protein drugs 
 vi 
in systemic circulation. The ontogeny of FcRn expression and its effect on the 
pharmacokinetics of mAbs should be of special concern if therapeutic mAbs are used in 
both pediatrics and adults. The down-regulation of FcRn during the development may 
shortened the half-life of therapeutic mAbs observed in adults. To address this problem, 
FcRn expression was quantified in various organs of C57BL/6J mice from postnatal days 
2 through 70, the pharmacokinetics of AMG589 were studied in different age groups of 
C57BL/6J mice, and the correlation between the FcRn expression levels and the 
pharmacokinetics of AMG589 at various developmental stages of mice were explored 
using a nonlinear-mixed effects modeling-based population pharmacokinetic approach. 
 
FcRn showed ontogenetic changes in liver, lungs, and kidneys. Two-fold 
increases in FcRn expression were observed in liver and lungs of 10-day-old mice, 
whereas FcRn expression in the kidneys was doubled in 10- and 42-day-old mice. 
However, the ontogeny of FcRn expression could not be correlated to the prolonged 
persistence of AMG589 observed in 42 day old mice. A population pharmacokinetic 
approach revealed that after accounting for the effect of body weight by allometric 
scaling, age and FcRn expression in skin influenced the pharmacokinetics of AMG589 in 
different age groups of mice. Decreasing volume of distribution of AMG589 was 
observed during development. Interestingly, clearance of AMG589 was negatively 
correlated with the expression of FcRn in the skin, even though FcRn expression in skin 
did not show any ontogeny. These results suggest that body weight, age, and FcRn 
expression in skin could affect the pharmacokinetics of fully-human mAbs. However, 
regardless of the species difference in physiology, body weight should be considered 
during dosage regimen design, especially for pediatric patients who show a highly 
dynamic change in body size at early age. 
 
In summary, the findings in this dissertation have pointed out the weakness of the 
classical bioavailability estimation for protein drugs that undergo TMDD and have 
determined the factors that should be considered for dose adjustments of therapeutic 
mAbs in different-aged populations. 
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CHAPTER 1.    BACKGROUND 
 
 
Advances in biotechnology have created a new era of therapeutic molecules, 
transitioning from chemically-defined small molecules to biotechnologically-derived 
large proteins. The application of biotechnologically-derived products as therapeutics has 
gained much attention due to several advantages they have over small molecule drugs. 
These advantages include a highly-specific and complex set of functions that cannot be 
mimicked by simple chemical compounds, a low propensity of adverse events due to 
their oftentimes highly-specific effect on a defined target with limited or no off-target 
activity, and far-reaching patent protection as a consequence of the unique forms and 
functions defined by their complex in vivo production process [1]. These superiorities 
have resulted in the expanded use of therapeutic proteins in clinical therapy. 
 
 Similar to small molecule drugs, successful therapy with therapeutic proteins can 
only be achieved with an effective dosage regimen that has been designed with the 
appreciation and application of pharmacokinetic and pharmacodynamic principles. The 
challenges in the pharmacokinetics and pharmacodynamics of protein drugs arise from 
some of their specific properties, including the structural similarity to endogenous 
proteins and nutrients, their intimate involvement in physiologic processes on the 
molecular level that often include regulatory feedback mechanisms, and their large 
molecular weight and macromolecule character [2, 3]. To gain insight into the 
pharmacokinetic properties of protein therapeutics, all relevant processes are described in 
general in this chapter as background for further discussion in subsequent chapters. 
Further interest in the pharmacokinetics of therapeutic proteins should be referred to 
several extensive reviews that were used as a basis for this chapter [2-8]. 
 
 
Pharmacokinetics of Protein Therapeutics 
 
 The in vivo disposition of protein drugs can be predicted to a large extent from 
their physiological function. The short elimination half-life can be expected from small 
proteins with hormone activity, which is desirable for close regulation of endogenous 
levels and thus function. In contrast, long half-lives of several days are usually observed 
for proteins with transport function (such as albumin) and long-term immune function 
(such as immunoglobulins) to ensure the continuous maintenance of physiologically-
necessary concentrations in systemic circulation [2, 3]. Similar to small-molecule 
compounds, the processes involved in the pharmacokinetics of protein drugs generally 
include absorption, distribution, and elimination. However, the special processes entailed 
in the disposition of protein drugs may involve target receptor-mediated drug disposition, 
and interaction with Fc receptors. These two pathways play major roles in the 
pharmacokinetics of monoclonal antibodies (mAbs). 
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Absorption 
 
 The susceptibility of proteins to the digestive enzymes in the gastrointestinal tract, 
along with their physicochemical properties such as size and charge, hampers their 
absorption process through the gastrointestinal membranes and creates challenges in 
delivering protein therapeutics in oral dosage forms. Because of this limitation, the 
currently available dosages for protein therapeutics is injection or infusion via 
intravenous (IV), subcutaneous (SC), or intramuscular (IM) administration. 
 
 However, these administration routes have many drawbacks. Although IV 
administration such as bolus injection or infusion is preferred as a means to directly 
deliver peptides and proteins into the systemic circulation, it is inconvenient and might 
not provide the desired concentration-time profile. Moreover, the potentially decreased 
bioavailability with SC and IM injections is a disadvantage that has to be considered. The 
decreased bioavailability is due to variables such as local blood flow, injection trauma, 
protein degradation at the site of injection or in the lymphatic system, and limitations of 
uptake into the systemic circulation related to effective capillary pore size, convection, 
and diffusion. 
 
 After SC administration, proteins may enter the systemic circulation via blood 
capillaries or lymphatic vessels. The primary pathways for systemic absorption include 
diffusion across blood vessels distributed near the injection site and convective transport 
through lymphatic vessels and into the blood. There appears to be a linear relationship 
between molecular weight and the proportion of the dose entering the lymphatic system. 
The absorption into the systemic circulation after SC or IM administration is slow and it 
generally takes a few days to one week to reach peak plasma concentrations. The 
absolute bioavailability of mAbs is generally reported between 50 and 100% [5, 6]. The 
bioavailability of mAbs depends on the rates of extravascular degradation (e.g., 
proteolysis), antibody endocytosis (e.g., receptor-mediated or fluid-phase endocytosis), 
and recycling through interaction with the neonatal Fc-receptor (FcRn). 
 
 Other extravascular administration routes through nasal, buccal, rectal, vaginal, 
transdermal, ocular, and pulmonary drug delivery have also been shown promising 
results and are under development to improve bioavailability through improved systemic 
absorption. 
 
 
Distribution 
 
 Similar to conventional small-molecule drugs, protein drugs have to extravasate 
across the endothelial walls of vascular capillaries, pass through the interstitium, and 
reach the target sites in order to exert their pharmacological activity. The extravasation of 
protein drugs to the target site can involve convection or transcytosis. The rate and extent 
of protein extravasation are determined largely by their size and molecular weight, 
physiochemical properties (e.g. charge, lipophilicity), protein binding, and their 
dependency on active transport processes. Biological factors including regional 
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differences in capillary structures, the disease state of an organ or tissue, and the flow rate 
of blood can also affect the extravasation and distribution of macromolecules. Due to 
their high molecular weight and large size, the distribution of most proteins is limited to 
the extracellular space. This leads to small apparent volumes of distribution for most 
proteins. Protein drugs with higher molecular weights will distribute in smaller 
distribution volumes than protein drugs with lower molecular weights, resulting in lower 
interstitial concentrations with increasing molecular weights. However, active tissue 
uptake and binding to extravascular proteins and other structures can substantially 
increase the apparent volume of distribution of protein drugs. 
 
 In contrast to small-molecule drugs, convection rather than diffusion is the main 
process that transports proteins from the vascular space into the interstitial space of 
tissues. The convection process occurs as a unidirectional fluid flux from the vascular 
space through paracellular pores into the interstitial tissue space. This process is the main 
pathway of protein transport and is largely determined by the rate of fluid movement 
from blood to tissue and by the sieving effect of paracellular pores in the vascular 
endothelium. The sieving effect is mainly determined by the size and tortuosity of 
membrane pores and by the size, shape, and charge of protein drugs. As pore size 
decreases and the tortuosity increases, there is an increased resistance to the movement of 
macromolecules. Proteins in the interstitial tissue space are subsequently removed by 
convective transport via lymph drainage back into the systemic circulation. Compared to 
extravasation, lymph drainage is a much more efficient process due to the much larger 
size of paracellular pores in lymphatic vessels compared to the vascular endothelium. As 
a consequence of the difference in the efficiency of convective uptake into tissue and 
convective drainage of proteins from tissue, protein concentrations in tissue interstitial 
fluid are substantially lower than protein concentration in plasma. However, higher 
concentrations of proteins can be observed in tissues with leaky vasculature (e.g. bone 
marrow and spleen). 
 
 In addition to the size-dependent sieving of macromolecules through the capillary 
walls, the charge may also play an important role in the biodistribution of proteins. Due 
to the abundance of glycosaminoglycans in the extracellular matrix that impart a negative 
charge on most cell surfaces, the rate and extent of distribution into tissues is increased 
by the electrostatic attraction between negatively-charged cell membranes and proteins 
that are positively charged. 
 
 Another pathway for the transfer of protein molecules from the vascular to the 
interstitial space is transcytosis, which is a transcellular transport pathway that couples 
endocytosis and exocytosis on the opposite plasma membranes of cells. However, for 
most proteins, convection is quantitatively more important than transcytosis in terms of 
extravasation of protein drugs from the systemic circulation. 
 
 Protein binding is another factor that can affect the volume of distribution and 
cause an inhibitory or stimulatory effect on the biological activity of protein therapeutics. 
Upon binding, endogenous binding proteins can serve as the storage depot for therapeutic 
proteins that result in prolonged plasma concentration-time profiles; alternately, they can 
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enhance protein clearance. Moreover, cellular uptake processes may be facilitated by 
interaction with specific binding proteins and thus affect the pharmacodynamics. 
 
 Besides physicochemical properties and protein binding, site-specific receptor-
mediated uptake can also substantially affect the distribution of protein therapeutics. 
Elimination and pharmacodynamics can also be influenced by this receptor-mediated 
uptake process, which can be explained by target-mediated drug disposition (TMDD) 
pharmacokinetics. This is normally observed for therapeutic mAbs that are designed to 
bind membrane-standing target antigens with high affinity, which will affect the 
distribution of the drug and result in low volumes of distribution (approximately equal to 
the plasma volume). This is due to the tight binding of mAbs to cells near the sites of 
antibody extravasation, which is known as the ????????-??????????????????????????
However, antibody fragments consisting of only an antigen-binding portion (Fab 
fragments) or single-chain variable fragments can cross the blood-tissue barrier more 
easily and are less hindered by the binding-site barrier. 
 
 After IV administration, proteins usually follow a bi-exponential plasma 
concentration-time profile well described by a two-compartmental model. The central 
compartment in this two-compartmental model principally represents the vascular space 
and the interstitial space of well-perfused organs such as liver and kidneys, which have 
permeable capillary walls. The peripheral compartment illustrates the interstitial space of 
the poorly-perfused organs with the slow equilibrium of the drug concentration [2, 3, 7]. 
 
 
Elimination 
 
 Protein therapeutics use the same catabolic pathways as endogenous or dietary 
proteins, which feeds into an amino acid pool that can be reused for the biosynthesis of 
structural or functional body proteins. The elimination processes of proteins include 
proteolysis, renal elimination, hepatic elimination, or receptor-mediated endocytosis. 
However, non-metabolic elimination pathways such as renal or biliary excretion are 
negligible for most proteins. If biliary excretion occurs, it is usually followed by 
metabolic degradation in the gastrointestinal tract. The metabolic rate for protein 
degradation generally increases with decreasing molecular weight from large to small 
proteins to peptides. The degradation rate also depends on other factors, such as size, 
charge, lipophilicity, functional groups, and glycosylation pattern as well as secondary 
and tertiary structure.  
 
 
 Proteolysis. Protein therapeutics can be metabolized throughout the body because 
of the ubiquitous availability of proteolytic enzymes. Thus, locations of intensive peptide 
and protein metabolism are not only limited to liver, kidney, and gastrointestinal tract but 
can also include blood and other body tissues. Proteases and peptidases are also located 
within cells; thus, intracellular uptake per se is more an elimination than a distribution 
process. There are two major mechanisms by which proteins are degraded intracellularly 
?the lysosomal pathway and the ubiquitin-mediated pathway. These two pathways work 
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together in the degradation of intracellular proteins and exogenous proteins. While 
peptidases and proteases in the gastrointestinal tract and in lysosomes are relatively 
nonspecific, soluble peptidases in the interstitial space and exopeptidases on the cell 
surface have a higher selectivity and determine the specific metabolism pattern of an 
organ. 
 
 
 Renal Elimination [2, 3, 7]. The kidneys are a major site of metabolism for 
smaller-sized proteins that undergo glomerular filtration. The cut-off size for glomerular 
filtration is approximately 60 kDa with the effective molecule diameter (based on 
molecular weight and conformation) or hydrodynamic radius as a potential limiting 
factor. However, glomerular filtration is most efficient for proteins that are smaller than 
30 kDa. 
 
 Peptides and small proteins (<5 kDa) are filtered very efficiently, and their 
glomerular filtration clearance reaches the maximal glomerular filtration rate (GFR, ~ 
120 mL/min in humans). In contrast, the filtration rate of proteins greater than 30 kDa 
abruptly declines. In addition to size, charge selectivity has also been observed for 
glomerular filtration. Anionic macromolecules pass through the filtration membranes less 
readily than neutral macromolecules, which in turn pass through less readily than cationic 
macromolecules. 
 
 Renal elimination of small proteins can occur through one of three routes, 
resulting in negligible amounts of intact molecules detected in urine. The first route 
involves glomerular filtration of larger, complex peptides and proteins followed by 
reabsorption into endocytic vesicles in the proximal tubule, and subsequent hydrolysis 
into small peptide fragments and amino acids. The second major route entails glomerular 
filtration followed by intraluminal metabolism by brush border membrane enzymes 
located on the luminal membrane of the proximal tubule. The resulting peptide fragments 
and amino acids are reabsorbed into the systemic circulation. The third route is the 
peritubular extraction of proteins from postglomerular capillaries with subsequent 
intracellular metabolism. 
 
 For the first two mechanisms, glomerular filtration is the rate-limiting step as 
subsequent degradation processes are unsaturated under physiologic conditions. Due to 
this limitation, the renal contribution to the overall elimination of proteins is dependent 
on the proteolysis that occurs in other regions of the body. If proteolysis is high in other 
body regions, renal contribution to total clearance will be limited, and becomes negligible 
in the presence of nonspecific degradation throughout the body. If metabolic activity for 
proteins is low in other tissues, or distribution to the extravascular space is limited, the 
renal contribution to the overall clearance may reach 100%. In general, mAbs are not 
eliminated by this pathway due to their large size, preventing renal filtration. However, 
Fab fragment-based therapeutics can be excreted to some extent by the kidneys. 
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 Hepatic Elimination [2, 3]. A prerequisite for hepatic metabolism of proteins is 
the uptake into one of three cell types in the liver: hepatocytes, Kupffer cell, and 
endothelial cells. 
 
 Hydrophobic small peptides can either cross the hepatocyte membrane via simple 
passive diffusion if they have sufficient hydrophobicity or be taken up by the hepatocytes 
via a carrier-mediated transport. After internalization into the cytosol, these peptides are 
usually metabolized by microsomal enzymes. Peptides that enter the liver via carrier-
mediated transport are typically excreted into the bile by active export transporters. 
 
 Uptake of larger peptides and proteins is facilitated via various carrier-mediated, 
energy-dependent transport processes such as receptor-mediated endocytosis. In receptor-
mediated endocytosis, circulating peptides and proteins are recognized by specific 
hepatic receptor proteins, which are usually integral membrane glycoproteins with an 
exposed binding domain on the extracellular side of the cell membrane. For 
glycoproteins, if a critical number of exposed sugar groups (such as mannose, galactose, 
fucose, N-acetylglucosamine, N-acetylgalactosamine, or glucose) is exceeded, receptor-
mediated endocytosis through sugar-recognizing receptors is an efficient hepatic uptake 
mechanism. Important carbohydrate receptors in the liver are the asialoglycoprotein 
receptor in hepatocytes and the mannose receptor in Kupffer and hepatic endothelial 
cells. Moreover, low-density lipoprotein (LDL)-receptor-related protein (LRP) is a 
member of the LDL receptor family, responsible for endocytosis of several important 
lipoproteins, proteases, and protease-inhibitor complexes in the liver and other tissues. 
 
 Uptake of proteins by hepatic cell types is followed by transport to an intracellular 
compartment for metabolism. Proteins internalized into vesicles via an endocytotic 
mechanism undergo intracellular transport towards the lysosomal compartment near the 
center of the cell. The endocytotic vesicles then fuse with or mature into lysosomes, 
which are specialized acidic vesicles that contain a variety of hydrolases capable of 
degrading all biological macromolecules. The hepatic metabolism of glycoproteins may 
occur more slowly than with naked proteins because protecting oligosaccharide chains 
need to be removed first. Peptide and protein metabolites in lysosomes from hepatocytes, 
hepatic sinusoidal cells, and Kupffer cells may be released into the systemic circulation. 
Degraded proteins in hepatocyte lysosomes can also be delivered to the bile canalicul and 
excreted by exocytosis. 
 
 Another intracellular, usually minor elimination pathway for proteins is the direct 
shuttle or transcytotic pathway. The endocytotic vesicle formed at the cell surface 
traverses the cell to the peribiliary space, where it fuses with the bile canalicular 
membrane, releasing its contents by exocytosis into bile. 
 
 
 Receptor-Mediated Metabolism/Target-Mediated Drug Disposition (TMDD). 
Unlike conventional small molecule drugs, receptor-mediated metabolism is a substantial 
elimination pathway for many therapeutic proteins. This is due to their high binding 
affinity to their target receptors along with the significant amount of protein drugs that is 
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normally involved in the target binding. The binding can lead to cellular uptake by 
receptor-mediated endocytosis and subsequent intracellular lysosomal degradation. This 
high-affinity, low-capacity binding process can occur in any organ and tissue that 
expresses specific receptors for the therapeutic protein, and thus contributes to the 
elimination of therapeutic proteins throughout the body. Thus, the process of receptor-
mediated endocytosis contributes significantly not only to the pharmacodynamics but 
also to the pharmacokinetics of protein drugs. 
 
 For therapeutic proteins that have their target receptors on the cell surfaces, the 
elimination that occurs through receptor-mediated endocytosis can be described by 
target-mediated drug disposition pharmacokinetics. For mAbs, this process occurs via the 
interaction between the Fab portion of mAbs and the target epitopes on the cell surface. 
Since the number of target receptors is limited, this process can be saturated with 
therapeutic concentrations. As a consequence, the clearance of therapeutic proteins that 
go through this process is not constant but dose-dependent and decreases with increasing 
dose. Thus, receptor-mediated elimination constitutes a major source of the nonlinear 
pharmacokinetic behavior of numerous protein drugs that show over-proportional 
increases in systemic exposure with increasing dose. 
 
 
 Elimination via the Reticuloendothelial System (RES). For mAbs, the 
phagocytic cells in the immune system, such as macrophages and monocytes, are 
expected to play a role in the elimination as key factors in the effector functions of 
endogenous IgG. After the Fc portion of the antibody binds to the Fc?-receptors 
expressed on the phagocytic cells, the internalization and subsequent degradation of IgG 
by lysosomes generally occurs. Unlike receptor-mediated metabolism, this route is not 
expected to be saturated by therapeutic mAb doses, because therapeutic mAb 
concentrations are generally a small fraction of total endogenous IgG. However, there is 
evidence that suggests that Fc?-receptor-mediated elimination has limited influence or a 
merely minor effect on the plasma and tissue disposition of monomeric IgG [9-12]. This 
process might be a significant and perhaps dominant pathway when antibody is able to 
form soluble immune complexes containing three or more IgG molecules, and might play 
an important role when antibody binds to suspended cells in blood or other body fluids 
such as viruses, bacteria, platelets, erythrocytes, and leukocytes [9, 13, 14]. 
 
 Polymorphisms in FCGR3A???????????????????????????????-receptor expressed 
by macrophages and natural killer cells, have no influence on the pharmacokinetics of 
horse anti-lymphocyte globulin in renal transplant patients [10]. 2.4G2, an antibody 
directed against the murine FcII receptor on macrophages, is able to clearly reduce the 
rate of clearance of immune complexes but does not alter the rate of clearance of 
monomeric IgG anti-HSA [9]. With ? 85-fold reduction in HAE2-IgE complex binding 
??????????????????????????????????????-type IgG1, high-affinity anti-IgE antibody-2 (HAE2) 
reduces clearance of HAE2-IgE complex and decreases distribution to the liver [13].  
Moreover, mAb blockade of the ???-receptor is shown to prolong the systemic exposure 
of IgG-sensitized red blood cells in vivo [14]. Recent studies also suggest ????????-
receptors play only a minor role in the elimination of murine IgG1 mAb and endogenous 
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IgGs [11, 12]. However, the mechanism of this nonspecific elimination pathway for 
mAbs is still not fully understood and may differ across different mAbs.  
 
 
Target-Mediated Drug Disposition 
 
 The pharmacokinetics of numerous protein therapeutics are characterized by 
target-mediated drug disposition (TMDD), which occurs when binding to the 
pharmacodynamic target molecule affects the pharmacokinetics of a drug compound and 
results in capacity-limited, saturable processes. These saturable processes are caused by 
the limited availability of enzymes, receptors, or other target protein structures with 
which the drug is interacting. This results in nonlinear pharmacokinetics that show a 
disproportional change in plasma concentration with increasing dose. Most notably, 
TMDD is the result of receptor-mediated protein metabolism, which is a frequently-
encountered elimination pathway for many therapeutic proteins that often show saturation 
at therapeutic dosage regimens. However, TMDD can affect distribution as well as 
elimination processes. 
 
 To describe the processes that occur in TMDD, the general TMDD model is used 
[15]. Drugs administered via various routes get into the body and appear in the blood 
circulation (central compartment). The free drug in the blood circulation can distribute to 
the tissues (peripheral compartment) with the first-order rate constant Kpt, and free drug 
in the tissue can distribute back to the blood circulation with the first-order rate constant, 
Ktp. The free drug in the blood circulation can also be eliminated by linear clearance 
pathways such as proteolysis, with the first-order rate constant Ke. The drug in the blood 
circulation can also bind to free receptors at the target site, which are synthesized with the 
zero-order Ksyn rate and degraded with the first-order rate constant Kdeg. Drug and 
receptor will form the drug-receptor complexes with the second-order rate constant Kon. 
The drug-receptor complexes can dissociate back to generate the free drug with the first-
order constant Koff, or they will be internalized with the first-order rate constant Kint and 
subsequently degraded. This general TMDD model can be modified to incorporate 
additional compartments or factors. 
 
For many mAbs, target-mediated elimination is probably a more important 
elimination pathway than proteolysis by cells in the RES [4]. It occurs when the Fab-
portion of mAbs binds to the target antigen and causes internalization and subsequent 
????????????????????????????????????????????????????????????????????????????????????????????
and is saturable because of the limited amount of the target antigen. As a consequence, 
nonlinear pharmacokinetics has often been reported. However, not all mAbs show 
concentration-dependent elimination. Linear elimination, in which the elimination rate 
does not depend on the dose or the plasma concentration, has been reported in some 
mAbs, especially for those that target a soluble antigen (not bound to cells) such as 
vascular endothelial growth factor or TNF?. The reason might be that the concentrations 
in plasma and tissues after therapeutic dose administration do not saturate the target 
antigen, or the target-mediated clearance is of less importance when compared to other 
elimination pathways. 
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The Neonatal Fc Receptor (FcRn) 
 
 The neonatal Fc receptor (FcRn) or Brambell receptor is involved in a 
physiological process that functions as a protective mechanism against metabolism and 
elimination of IgG and albumin [4-7, 16]. Through this process, IgGs show the longest 
elimination half-life compared to other isotypes of immunoglobulins (IgA, IgD, IgE, and 
IgM) [4, 7]. Intact IgGs have a molecular weight of ~ 150 kDa and a valence of 2 (each 
molecule of IgG contains two identical antigen-binding domains). Based on the heavy 
chain structure, the IgG family can be divided into four subclasses, including IgG1, IgG2, 
IgG3, and IgG4 [5, 6]. The structural difference in IgG heavy chains among the 
subclasses leads to the differences in the binding to Fc receptors, and results in subclass-
specific differences in processes mediated by Fc receptors (e.g., activation of 
complement, or antibody-dependent cell-mediated cytotoxicity) [5]. Among the IgG 
family members, IgG3 has a much shorter elimination half-life (7 days) than those of the 
other IgG isotypes (20-21 days) [4, 7]. 
 
The salvage pathway by FcRn is a pH-dependent process since binding of IgG 
and albumin to the FcRn occurs in acidic (pH 6.0 ? 6.5) but not in neutral (pH 7.0 ? 7.5) 
environments. After nonspecific pino- or endocytosis, in which the molecule is engulfed 
by the cell membrane and taken up into the cell, the Fc portion of IgG binds to the FcRn 
in the slightly acidic environment of the endosomes. The IgG-FcRn complex is then 
transported back to the cell surface and released into the systemic circulation at neutral 
pH, whereas unbound IgG and other proteins are degraded to amino acids by intracellular 
lysosomes (Figure 1-1). 
 
 FcRn can transport IgG across cell monolayers in both the apical- to basolateral 
and basolateral- to apical directions. The FcRn protective mechanism has an influence on 
the pharmacokinetics of endogenous IgG and albumin. The long elimination half-life (21 
days) of endogenous IgG and albumin compared to other plasma proteins can be 
explained by this mechanism. Saturation of FcRn can occur at high concentrations of IgG 
that demolish the salvation pathway. However, this is generally not expected at the 
therapeutic dose of mAbs as the usual therapeutic dose of a few hundred milligrams is 
small compared to the endogenous IgG amount of 12 g/L (~50-100 g in an adult). To 
saturate this protective mechanism, very high doses of therapeutic mAbs would be 
needed. 
 
The saturation of FcRn occurs in the treatment of autoimmune diseases. High-
dose intravenous immunoglobulin (IVIG) therapy with pooled human IgG at a dose of 2 
g/kg can sufficiently increase IgG plasma concentrations, leading to an approximately 
threefold increase in IgG clearance [5, 17]. This increase in IgG clearance results in a 
decrease in the plasma concentrations of endogenous, pathogenic autoantibodies. 
However, IVIG therapy is very expensive due to the requirement of high doses for the 
therapy. To achieve a similar effect to that of IVIG therapy, anti-FcRn antibodies can be 
administered at a ~100-fold lower dose than IVIG therapy [5, 18]. These anti-FcRn 
antibodies are specifically directed against FcRn or have a modified Fc portion that can 
form more stable complexes with FcRn. As a result, an increase in the elimination rate of 
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Figure 1-1. Schematic illustration of the FcRn mediated recycling pathway 
(A) IgG and albumin circulating in the bloodstream are continuously taken up by fluid 
phase pinocytosis and enter early endosomes where FcRn predominantly resides. (B) The 
acidified milieu herein facilitates binding of IgG and albumin to FcRn. (C) The ternary 
complex is then recycled to the cell surface where exposure to physiological pH of the 
bloodstream triggers release of IgG and albumin into the circulation. (D) When the 
concentrations of IgG and albumin are high, FcRn is saturated and unbound ligands 
undergo lysosomal degradation. (E) FcRn may also transcytose IgG and albumin to the 
basolateral side of the cell for release into extravascular space. 
Source: Reprinted with permission from The Japanese Society for the Study of 
Xenobiotics (JSSX). Andersen, J.T. and I. Sandlie, The versatile MHC class I-related 
FcRn protects IgG and albumin from degradation: implications for development of new 
diagnostics and therapeutics. Drug Metab Pharmacokinet, 2009. 24(4): p. 318-32. 
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mAbs and endogenous IgG can be achieved after the administration of anti-FcRn 
antibodies [4]. 
 
 The binding affinity between IgG and FcRn is species specific. High binding 
affinity is observed between human FcRn and human IgG as well as guinea pig and 
rabbit IgG [19]. However, human FcRn has a very low affinity to mouse, rat, bovine, and 
sheep IgG. As a result, the very rapid elimination of murine mAbs in human is observed. 
In contrast, mouse FcRn binds to IgG from all aforementioned species. Moreover, mouse 
FcRn has higher binding affinity to human IgG1 than that observed between human FcRn 
and human IgG1 [19, 20]. The difference in promiscuity for IgG-FcRn interaction 
between mouse and human has raised the concerns regarding the validity of using mice as 
a model to predict the pharmacokinetics of therapeutic mAbs in humans. The suitability 
of mouse models for the pharmacokinetic evaluation of therapeutic mAbs has been 
further called into question by another study when engineered human IgG1 was tested in 
murine and human systems and exhibited different pharmacokinetics and FcRn recycling 
behaviors [21]. As a consequence, a humanized FcRn transgenic mouse has been 
developed and has proved to be an effective surrogate for studying the pharmacokinetics 
of therapeutic mAbs and Fc-fusion proteins [22-24]. 
 
 
Effect of Immunogenicity on the Pharmacokinetics of Therapeutic Proteins 
 
 The origin of therapeutic proteins is important since xenogenic proteins can 
trigger immune responses (immunogenicity) that cause anti-drug antibodies (ADA) to be 
produced. Immunogenicity can occur when animal-derived proteins are applied in human 
clinical studies as well as when human proteins are administered to animals during 
preclinical studies [3]. ADAs that recognize epitopes on therapeutic proteins that are not 
essential for their bioactivity are referred to as non-neutralizing antibodies (binding 
antibodies) and usually result in fewer clinical consequences [8]. In contrast, ADAs that 
neutralize the biological activity of therapeutic proteins by binding to their active sites 
(neutralizing antibodies) frequently cause loss of efficacy. Immunogenicity can influence 
the pharmacokinetics of peptide and protein drugs by altering distribution and clearance. 
The direction of the immunogenic effect on pharmacokinetics is difficult to predict. The 
elimination rate can be either increased or decreased, depending on the number of 
antigenic sites on the exogenous proteins against which the endogenous antibodies are 
directed and the size of the resulting immune complexes [4-6]. In case, only one or two 
endogenous anti-drug IgGs bind to exogenous peptides or proteins, the half-life of those 
exogenous peptides or proteins can approach that of endogenous IgGs that act as a depot 
for therapeutic peptides or proteins. A prolonged duration of pharmacological action can 
occur in this case if the antibody is not neutralized. On the other hand, simultaneous 
binding of three or more anti-drug IgGs to the exogenous peptides and proteins can lead 
to the very rapid elimination of the immune complex through phagocytosis by the RES. 
This pharmacokinetic change resulting from the formation of antibodies against 
administered proteins can affect therapeutic efficacy. 
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 In addition to the similarity between exogenous and endogenous proteins, the 
degree of aggregation of therapeutic protein products, along with the duration of therapy, 
dose, and route of administration, also have an influence on the occurrence and degree of 
immunogenicity [3, 5, 6]. Immunogenicity can increase because of the quantity of 
aggregates in the dosing formulation. The degree of immunogenicity can also increase 
with the duration of therapy. This might be due to the increasing exposure to exogenous 
proteins during prolonged therapy, which can lead to an increasing probability of anti-
drug antibody development against multiple antigenic sites. This in turn may result in the 
rapid elimination of the therapeutic protein. The relationship between dose and 
immunogenicity is difficult to predict. The clearance of drug-antibody complexes may be 
delayed at low doses and increase at high doses due to the formation of aggregates that 
trigger clearance through the RES. However, the inverse relationship between 
immunogenicity and dose can also be observed. This inverse relationship might be due to 
the presence of high amounts of protein drugs in the samples, causing assay interference 
by masking the detection of anti-drug antibodies or due to the consumption of low-level 
ADA by high protein drug concentrations. The route of administration may also influence 
on the immunogenicity. Administration by the SC and IM route can lead to greater 
immunogenicity than that observed following IV administration. The increasing 
incidence of immunogenicity after extravascular administration is probably caused by a 
higher numbers of protein aggregates and precipitates formed at the injection sites, which 
activate immune cells and stimulate clearance through the RES. 
 
 
Effect of Developmental Physiology on the Pharmacokinetics of Therapeutic 
Proteins 
 
 Special considerations should be taken when using therapeutic proteins in 
pediatric patients. This is due to the substantial differences between children and adults in 
terms of disease etiology, the time course of the disease, disease complications or 
prognosis, use of concomitant medications, immune and vaccination status, and 
eventually clinical responses (including therapeutic effects and adverse drug reactions) 
[8]. In addition, developmental changes in physiology that result in dynamic age-
associated changes in body composition and organ function, along with receptor 
ontogeny, can affect the pharmacokinetics of protein drugs in populations of different 
ages [25]. Consequently, age-associated changes in the absorption, distribution, 
elimination, and immunogenicity of therapeutic proteins may be observed in pediatric 
patients. 
 
 
Absorption 
 
 Since therapeutic peptides and proteins are mostly administered through the IV or 
SC route, developmental skin alterations may be a factor that should be considered when 
protein drugs are administered to children. Compared to adults, the presence of a thinner 
stratum corneum in the preterm neonate and the greater extent of cutaneous perfusion and 
hydration of the epidermis throughout childhood might contribute to enhanced 
 
 
13 
 
percutaneous absorption of drugs during infancy [25]. The higher ratio of total body 
surface area to body mass in infants and young children compared to adults is another 
factor that might affect the absorption of drugs. However, it is still inconclusive whether 
differences between adults and children in the thickness of SC tissue and local lymphatic 
flow at the injection site affect the absolute bioavailability of a therapeutic protein after 
SC administration [8, 26]. 
 
 
Distribution 
 
 Developmental changes in body composition may not have a significant impact 
on the biodistribution of therapeutic proteins [8]. However, a considerable alteration in 
the distribution of protein drugs may be caused by changes in the composition and 
amount of circulating plasma proteins and tissue targets [8, 25]. Steady-state levels of the 
target antigen may differ between adult and pediatric populations due to differences in 
either the production or degradation rate of the targeted antigens, which can result in 
differences in the biodistribution of the therapeutic protein upon dosing [8]. Nevertheless, 
the target antigens are usually overwhelmed by therapeutic proteins about a hundred- or 
thousand-fold at therapeutic concentrations. Thus, the biodistribution of therapeutic 
proteins at steady state might not be significantly altered by developmental changes in 
antigen production or degradation rates. Instead, such differences would more likely lead 
to inequalities in the elimination of therapeutic proteins if TMDD is the main pathway of 
clearance. 
 
 
Elimination 
 
 For many protein drugs, proteolysis occurring throughout the body is considered 
to be the main pathway of clearance. Thus developmental changes in hepatic drug 
metabolizing enzyme systems such as CYP have a negligible impact on the metabolism 
and clearance of therapeutic proteins. Maturation in renal function may have some 
influence on the excretion and elimination of small peptides that can pass through 
glomerular filtration. However, the impact of developmental changes in renal function 
may be negligible depending on the contribution of renal elimination to the overall 
clearance that occurs in the other parts of the body. 
 
 For antibody-based therapeutic proteins, non-specific Fc receptor-mediated 
????????????????????????-receptors in RES and FcRn receptors) and target receptor-
mediated metabolism are considered to be major elimination pathways. The elimination 
through RES af??????????????????-receptors has been shown to have a limited effect on 
the clearance of monomeric mAbs. However, this pathway can accelerate the elimination 
of antigen-??????????????????????????????????????????????-receptor distribution between 
adults and children, if it exists, might become problematic when immunogenicity occurs. 
??????????????????-receptors, FcRn has been shown to play a significant role in extending 
the presence of mAbs in the systemic circulation after binding to this receptor. Due to its 
considerable role as a salvage pathway from clearance, potential differences in FcRn 
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expression during pediatric development might result in unequal pharmacokinetic 
profiles of therapeutic mAbs across different age groups. Unlike non-specific Fc 
receptor-mediated disposition, target receptor-mediated clearance is a specific process 
that occurs when a therapeutic protein binds to its specific receptor at the target site. The 
efficiency of this mechanism depends on the target receptor expression levels and the 
turnover rates of the target receptors. As a consequence, differences in the target receptor 
levels and turnover rates between adults and children might be a major concern if 
therapeutic proteins are mainly eliminated through this specific pathway [8, 26]. 
 
 
Immunogenicity 
 
 The incidence of immunogenicity from therapeutic proteins may differ between 
children and adults due to variation in patient-related factors that may predispose an 
individual to an immune response [8, 26]. These patient-related factors include 
underlying disease, genetics, immune status, concomitant use of immunomodulators, and 
previous experience using protein therapeutics. Currently, the similarities and 
dissimilarities in immunogenicity between pediatrics and adults are still inconclusive. 
This is due to the limited availability of immunogenicity data in pediatric populations 
along with substantial shortcomings of the current technologies for ADA evaluation and 
quantification. To gain insight into this matter, the improvement of assay technologies 
and standardized evaluation of immunogenicity across clinical trials will be needed. 
 
 
Dose Optimization of Therapeutic Proteins in Pediatric Development 
 
 Currently, the application of therapeutic proteins in pediatrics is often based on 
the extrapolation of clinical findings in adults [8, 26]. The extrapolation approach may be 
useful in the case that no pediatric data are available. However, this approach may 
significantly compromise the efficacy and safety of pediatric patients if the differences 
between children and adults are not explicitly determined. The potential considerable 
differences between children and adults in terms of disease etiology, time course of 
disease, disease complications or prognosis, use of concomitant medications, immune 
and vaccination status, and eventually, clinical responses (including therapeutic effects 
and unwanted adverse events caused by a given therapy) should all be considered in the 
dosage regimen optimization. Moreover, the fundamental comprehension of the 
similarities and dissimilarities in the pharmacokinetics and pharmacodynamics between 
children and adults can assist in determining the rational use of therapeutic proteins in 
pediatric populations. 
 
 A number of potential covariates, including target antigen levels, serum albumin 
levels, disease activity, concomitant medications, and development of ADA may affect 
the pharmacokinetics of protein drugs. However, the effect of body size more often 
warrants dose adjustment in pediatric patients compared relative to other covariates. This 
is due to the differential growth rates during development that create much larger 
variability in body size for children than for adults. Because of this, the effect of body 
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size is a major determinant of the pharmacokinetics of therapeutic macromolecules in 
pediatrics. As a consequence, several dosing approaches that account for size alterations 
during pediatric development have been successfully used in children. 
 
 To account for the size difference, weight-based (mg/kg) dosing, body surface 
area (BSA)-based (mg/m2) dosing, tiered fixed dosing (i.e., a fixed dose for patients in a 
specified narrow weight range), and hybrid dosing (fixed dosing for older children and 
body size-based dosing for younger children) have been successfully applied. However, 
both weight- and BSA-based dosing may not satisfactorily correct the body size effect, as 
clearance of antibody-based therapeutic proteins is often not proportional to either weight 
or BSA. To attain more physiologically-based and more accurate dose adjustment, 
allometric scaling approaches have been used for dosage extrapolation from adults to 
pediatric patients. 
 
 After accounting for the effect of body size, age itself has rarely been identified as 
a covariate that influences the pharmacokinetics of therapeutic proteins. The available 
data show that the proper correction for body size-related pharmacokinetic differences is 
essential for appropriate dose selection of antibody-based therapeutic proteins for 
pediatric patients. However, the body size-based dosing approach might be inefficient for 
designing the dosage regimen of therapeutic proteins that are mainly eliminated through 
target receptor-mediated metabolism. For these therapeutic macromolecules, differences 
in the target antigen expression levels and turnover rates of the target antigens during 
development may become another major determinant of pharmacokinetics. The target 
receptor levels and turnover rates of the target antigen may not always increase with body 
size. As a consequence, physiologically-based dose adjustment may become a better 
approach to achieve a successful therapy in pediatric populations. Only very limited 
clinical data are available for the use of mAbs in very young pediatric patients, including 
term and preterm neonates, and further age-related adjustments beyond body size may be 
warranted in this patient group. 
 
 
Summary 
 
 Because susceptibility to digestive enzymes in the gastrointestinal tract, along 
with limitations due to their physiochemical structure, most therapeutic proteins are 
administered via the IV or SC route. The absorption of protein drugs after SC 
administration occurs via convection through lymphatic vessels and diffusion across 
blood capillaries. The distribution of therapeutic proteins is limited by their size and 
physiochemical properties such as charge, which result in their confinement 
predominantly in the vascular space. Convection and transcytosis are the two main 
pathways that facilitate the distribution of protein drugs. Generally, therapeutic proteins 
exhibit bi-exponential plasma concentration-time profiles upon IV administration. 
Hepatic and renal excretion are negligible for therapeutic proteins. Instead, protein drugs 
are usually degraded by proteolysis, which can occur throughout the body. Moreover, 
target receptor-mediated catabolism is the main clearance pathway for most therapeutic 
proteins that have high binding specificity to their targets. The pharmacokinetics of 
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protein drugs that follow such an elimination pathway can be well described by TMDD. 
For monomeric mAbs, elimination via the RES may be negligible; however, RES 
becomes the main pathway of clearance of antigen-antibody complexes during when 
immunogenicity occurs. The prolonged existence of mAbs in the systemic circulation can 
be explained by the salvage pathway via the FcRn-mediated recycling mechanism. 
Administration of therapeutic proteins can cause immunogenicity, which may lead to 
prolonged exposure or abruptly-increased clearance. The occurrence of immunogenicity 
can result in toxicity or lack of efficacy upon administration of protein drugs. Several 
factors are responsible for the prevalence of immunogenicity, but the occurrence remains 
difficult to predict in the individual patient. 
 
Due to the physiological difference between adults and pediatric patients, the 
pharmacokinetics of protein drugs may be altered during child development. 
Immunogenicity reactions may also be different between adults and children. However, 
current data on these differences are limited and further studies are needed in order to 
elucidate differences between adults and pediatric patients in the pharmacokinetics and 
immunogenicity of therapeutic proteins. Although body size-based dosing is currently 
widely used for therapeutic proteins in pediatric patients, physiologically-based dosage 
regimen design may be necessary for some therapeutic proteins that are influenced by 
additional physiological factors such as target density and turnover. 
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CHAPTER 2.    INTRODUCTION 
 
 
 As discussed in Chapter 1, there are many factors that contribute to the 
regulation of drug disposition for protein therapeutics. As a result, the interpretation of 
the pharmacokinetics for protein therapeutics presents a complex challenge. Two 
challenges in the pharmacokinetic assessment of therapeutic proteins were explored in 
this study. 
 
 The assessment and prediction of bioavailability after SC administration for 
protein therapeutics becomes an important challenge, especially if these drugs exhibit 
target-mediated drug disposition (TMDD) ? a clearance process that is dependent upon 
the expression patterns and turnover rates of its target receptor. As a consequence, the 
clearance of protein drugs may vary with respect to dose. With increasing dose, the 
clearance through TMDD can become saturated and plateaus. However, current 
bioavailability estimations use the approach of comparing dose normalized AUC from 
non-intravenous routes to that of IV administration with the assumption of a dose-
independent clearance. Due to failure in this assumption, an error in bioavailability 
estimation may be observed for protein drugs that undergo TMDD. I hypothesized that 
there is a dose-dependent error in the bioavailability assessment for therapeutic proteins 
that undergo TMDD if the classical approach of dose-normalized AUC is used. The error 
becomes apparent when different doses of IV and SC administration are used for 
bioavailability estimations since the clearances at different IV and SC doses are not 
equal. To test this hypothesis and to evaluate the errors of bioavailability estimation, I 
selected two model drugs filgrastim and denosumab that undergo TMDD. Based on their 
published pharmacokinetic models, the plasma concentration-time profiles of filgrastim 
and denosumab were simulated in Phoenix® WinNonlin 6.3 and their bioavailabilities 
were subsequently estimated. With the current bioavailability estimation approach, the 
bioavailabilities of filgrastim and denosumab were determined at theoretical doses 
ranging from 0.01 ? 10000 ?g/kg for filgrastim and 0.66 ? 210 mg for denosumab. The 
errors of bioavailability assessments at different doses were subsequently determined. All 
findings are described in Chapter 3. 
 
 The second challenge investigated in this study was the pharmacokinetics of 
human monoclonal antibodies (mAbs) with respect to age and development. Published 
studies have shown that neonatal Fc receptor (FcRn) expression is detectable up to 3 
weeks postpartum in mouse intestines. Additionally, it was also postulated that a 
functional role of FcRn is to salvage mAbs and Fc-fusion proteins from the degradation 
or elimination pathways. Therefore, an ontogenic pattern of expression of FcRn may exist 
in different organs and could potentially alter the pharmacokinetic profile of protein 
therapeutics during pediatric development. These findings suggest that there is a critical 
need for better predictions and assessments of PK profiles for protein therapeutics in 
pediatric patients. Therefore, I conducted ex vivo analyzes of the ontogeny of FcRn 
expression and described the in vivo pharmacokinetics of a model human mAb, 
AMG589, in C57BL/6J mice during the post-natal developmental stages (Day 2 ? Day 
70). Based on the current published evidence, my central hypothesis is that a reduced 
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expression of FcRn during early postnatal development will result in a shortened half-life 
of monoclonal antibody AMG589 in adult mice compared to newborn mice. 
 
 To test the main hypothesis regarding the effect of the ontogeny of FcRn 
expression on the pharmacokinetics of mAbs, three experimental aims were framed. In 
the first aim I examined the levels of FcRn expression in organs of C57BL/6J mice from 
postnatal day 2 through day 70 (these results are described and discussed in Chapter 4). 
In my second aim, I analyzed and characterized the pharmacokinetics of AMG589 in 
different age groups of C57BL/6J mice (Chapter 5). Finally, in the third aim I attempted 
to correlate the FcRn expression levels with the pharmacokinetics of AMG589 in the 
differently aged mice using a population pharmacokinetic approach. I hypothesized that a 
decrease in half-life of AMG589 in adult mice is strongly correlated to the reduced levels 
of FcRn during development. To delineate the effect of FcRn expression on the 
pharmacokinetics of AMG589 in different age groups of C57BL/6J mice, body size 
effect was first evaluated by an allometric scaling approach, after which the effect of the 
ontogeny of FcRn expression was subsequently evaluated. The results of these analyses 
and their discussion are presented in Chapter 5. 
 
 The integration of my findings with the TMDD and pharmacokinetic challenges 
of monoclonal antibodies in the early stages of development are summarized and 
discussed in Chapter 6. The findings may help to elucidate the challenges faced in 
developing and optimizing dosing regimens of mAbs for pediatric patients. The presented 
studies strive to make better predictions of the pharmacokinetic profile for protein 
therapeutics in order to achieve a more desirable therapeutic effects while limiting 
toxicity ? this is especially important when considering the highly vulnerable pediatric 
population.  
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CHAPTER 3.    CHALLENGES IN THE APPARENT BIOAVAILABILITY 
ESTIMATION FOR THERAPEUTIC PROTEINS THAT UNDERGO TARGET-
MEDIATED DRUG DISPOSITION 
 
 
Introduction 
 
 Target-mediated drug disposition (TMDD), the process that was first described by 
Levy in 1994 [27], is the most common pathway that can well describe the 
pharmacokinetics of therapeutic proteins that exert specific binding with high affinity to 
pharmacological targets or receptors. Upon binding to the cell surface targets or 
receptors, the internalization of the ligand-receptor complex is usually followed by 
lysosomal degradation. This process causes the irreversible elimination of biotech drugs 
from the body and is often the main pathway of clearance when the number of 
pharmacological targets or receptors is in the same magnitude or larger than the number 
of drug molecules [28]. Through this pathway, the saturable target-binding is responsible 
for observable nonlinear pharmacokinetic behavior [6, 15, 27-32]. 
 
 The evaluation of pharmacokinetic profiles and dose selections for these 
therapeutic proteins are complicated due to this nonlinear pharmacokinetic behavior as it 
results in a dose-dependent effect on the overall distribution and/or elimination 
parameters [15, 29-32]. As a consequence, the rule of superposition cannot be applied 
[30]. One area in which this has resulted in challenges in drug development is the 
assessment of systemic bioavailability after extravascular, particularly subcutaneous 
administration. For classic bioavailability assessments, dose-normalized areas-under-the-
plasma concentration-time curves are compared under the assumption that clearance is 
constant and independent of time and route of administration. This assumption of 
invariant clearance is not valid for therapeutic proteins that undergo TMDD as their 
clearance mediated by the TMDD pathway is highly dependent on the degree of 
saturation of this pathway and thus the concentration of the therapeutic protein. An over-
proportional increase in systemic exposure with increasing dose is usually observed when 
elimination through receptor-mediated endocytosis starts to become saturated [28]. As a 
result, an apparently dose-dependent bioavailability is frequently observed in many 
therapeutic proteins including interferon-?1a (27 ? 71%) [31], filgrastim (62 ? 72%) [33] 
and denosumab (36 ? 78%) [34, 35]. However, much of this apparent dose-dependency is 
likely only the consequence of using bioavailability assessment methodology with the 
invalid assumption of a constant clearance. The potential bias of using the standard 
methodology of bioavailability estimation for therapeutic proteins that exhibit TMDD has 
so far not been evaluated. 
 
 Currently, other than the full TMDD model that was first proposed by Mager et 
al. [15], there are several simplified mechanistic models have been proposed to describe 
the pharmacokinetic profiles of therapeutic proteins that undergo TMDD including quasi-
equilibrium approximation, quasi-steady-state approximation, and Michaelis-Menten 
models [36-39]. The difference among these simplified models is the assumption 
associated with models which can specifically well describe the pharmacokinetics of 
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individual therapeutic proteins in different scenarios. With the quasi-equilibrium model, 
very rapid binding between drugs and target receptors that leads to an instantaneous 
equilibrium of the system is assumed. In this case, the binding process is considered very 
rapid when compare to other processes. Thus, binding (Kon) and dissociation (Koff) rate 
constants in the full TMDD model are difficult to obtain and are replaced by the 
equilibrium dissociation constant (KD) in the quasi-equilibrium model to describe the 
concentration-time profiles of drugs. However, if the rate of the internalization or 
elimination of the complexes is high and cannot be negligible, quasi-steady-state 
approximation model may be preferable since this model incorporates internalization rate 
(Kint) in a new parameter, Kss, for describing the time course of drug concentration. For 
the Michaelis-Menten model, all parameters involving the binding and internalization 
processes are replaced by Km and Vmax parameters that describe capacity limitation. With 
different mechanistic models, the different parameter values are obtained and these can 
have the impact on the time course of drug concentration and bioavailability estimation 
[40, 41]. 
 
 To quantify the error that can possibly occur from the currently used 
bioavailability estimation for therapeutic proteins, two model drugs, filgrastim, and 
denosumab, were selected that undergo TMDD and for which a mechanistic TMDD 
model had been used to quantify bioavailability. With the full TMDD model for 
filgrastim and quasi-steady-state approximation of TMDD model for denosumab, the 
plasma concentration-time profiles of filgrastim and denosumab were simulated at 
different doses. The bioavailability was calculated using the standard AUC approach and 
the effect of dose on the bias in bioavailability assessment was determined.  
 
 
Method 
 
 
Structural Pharmacokinetic Model 
 
 The structural models for filgrastim and denosumab were obtained from the 
literature [34, 42]. A full target-mediated drug disposition (TMDD) model well described 
the pharmacokinetics of filgrastim in healthy adults whereas the pharmacokinetics of 
denosumab in healthy subjects and postmenopausal women with osteopenia or 
osteoporosis was reasonably well described with the quasi-steady-state approximation of 
the TMDD model. 
 
 
TMDD Model for Filgrastim 
 
 The TMDD model for filgrastim, a recombinant methionyl human granulocyte 
colony stimulating factor (r-metHuG-CSF), was developed by Wiczling and colleagues 
for a population pharmacokinetic study in healthy adults [42]. This protein is used to treat 
inherited and acquired neutropenia that can occur during the chemotherapy as well as to 
mobilize the hematopoietic stem cells and progenitors for transplantation. The developed 
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TMDD model well described the pharmacokinetics of intravenously (IV) and 
subcutaneously (SC) administered filgrastim in healthy adults. 
 
 After IV and SC administration, filgrastim enters the body and is distributed 
throughout the central compartment with the assumption that free G-CSF in the serum 
(As) is in instantaneous equilibrium with the bone marrow and can bind to the G-CSF 
receptors on neutrophilic granulocytes in blood and bone marrow. The absorption of 
filgrastim after SC administration appears to follow parallel zero- and first-order 
processes that concurrently occur for 6.6 hours (D2). Thereafter, there is only the first-
order absorption process present. The bioavailability associated with the first- and zero-
order absorption processes are F1 and F2, respectively. The overall bioavailability is the 
summation of the bioavailability from zero- and first- order processes. In addition to G-
CSF from filgrastim, G-CSF is naturally synthesized at the zero-order rate which is 
described by KG-CSF. Free G-CSF in the serum is eliminated with  the first-order rate 
constant Ke or bound to G-CSF receptors (AR) that are synthesized at the zero-order rate 
Ksyn and degraded by the first-order process Kdeg. The binding process is a second-order 
process with the rate constant Kon. Upon binding, the G-CSF-receptor complex is 
internalized by a first-order process described by Kint or dissociates with the first-order 
rate constant Koff generating free G-CSF. 
 
 Mathematically, the pharmacokinetics of filgrastim is described by the following 
differential equations (Equations 3-1 to 3-3): 
 
???
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(Eq. 3-1) 
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(Eq. 3-2) 
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(Eq. 3-3) 
 
where As is the quantity of G-CSF in the serum, AR is the quantity of free receptor, and 
ARC is the quantity of filgrastim-receptor complex. Kon, the association constant, is 
determined by ????
??
 in which KD is an equilibrium dissociation constant. The input 
process can be specified by Equation 3-4. 
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(Eq. 3-4) 
 
where tinf is the infusion duration (0.5 hours), Ka is the first-order absorption rate 
constant, F1 is the bioavailability of the first-order absorption process, F2 is the 
bioavailability of the zero-order absorption process, D2 is the duration of zero-order 
absorption, IV is the intravenous administration, and SC is the subcutaneous 
administration. The absolute bioavailability equals (Equation 3-5): 
 
? ? ?? ? ?? 
(Eq. 3-5) 
 
 The system is assumed to be in a steady-state condition prior to the administration 
of the drug. Thus the relationships at baseline can be implied as (Equations 3-6 to 3-8): 
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(Eq. 3-6) 
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(Eq. 3-7) 
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(Eq. 3-8) 
 
where Cs,0 is the endogenous serum concentration of G-CSF, AR0 is the endogenous 
amount of G-CSF receptors in blood and bone marrow, and ARC0 is the pre-treatment 
amount of G-CSF bound receptor complexes. The concentration of G-CSF in the serum, 
Cs, is determined by Equation 3-9. 
 
?? ? ?
??
??
 
(Eq. 3-9) 
 
 
Quasi-Steady-State Approximation of the TMDD Model for Denosumab 
 
 An open, two-compartment pharmacokinetic model with a quasi-steady-state 
approximation of the TMDD model was developed by Sutjandra and colleagues to 
describe the pharmacokinetics of denosumab in healthy subjects and postmenopausal 
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women with osteopenia or osteoporosis [34]. Denosumab (AMG 162; Prolia?) is a fully 
human monoclonal antibody of the IgG2 subclass that has high affinity (KD = 3 × 10-12 
mol/L) and specificity for the receptor activator of nuclear factor ?-B ligand (RANKL). 
Upon binding of denosumab to RANKL, it prevents the binding between RANKL and its 
receptor, RANK, which is expressed on pre-osteoclasts and mature osteoclasts. 
Consequently, terminal differentiation, activation and survival of osteoclasts are 
hampered. This results in a reduction in bone resorption and an increase in bone mineral 
density (BMD). 
 
 After the SC administration of denosumab, the drug is absorbed with the first-
order process Ka. Absolute bioavailability (F) is estimated by simultaneously analyzing 
the serum free denosumab concentration obtained after SC and IV administration. After 
IV bolus dosing or SC absorption, free denosumab is distributed into the central 
compartment that has the volume of distribution represented by V1. The non-specific 
distribution from the central compartment into the peripheral compartment is 
characterized by intercompartmental clearance (Q) and the peripheral volume of 
distribution (V2). The free denosumab in the central compartment is eliminated by a 
linear pathway quantified by CLlin, or by binding to RANKL (R) following a second-
order process (Kon) to form the denosumab-RANKL (RC) complex. The denosumab-
RANKL complex is dissociating according to a first-order process (Koff) and generates 
free denosumab and RANKL, or is internalized through a first-order process, represented 
by the rate constant Kint. RANKL is assumed to be produced following a zero-order 
process, characterized by Ksyn, and degraded by a first-order process (Kdeg). 
 
However, the denosumab-RANKL association and dissociation processes are 
substantially faster than the change in denosumab disposition and elimination of the 
RANKL and denosumab-RANKL complex. Therefore, the quasi-steady-state 
approximation of the TMDD model is considered more suitable to describe the 
pharmacokinetics of denosumab with the assumption that the drug-receptor complex is at 
steady-state. Consequently, the binding rate is balanced by the sum of the dissociation 
and internalization rates. Moreover, the steady-state constant (Kss), defined as ?? ??
? ???
???
, 
is estimated since the denosumab ?RANKL binding affinity (KD), defined as  
????
???
, 
cannot be estimated independently. 
 
The differential equations that are used to describe the amount of denosumab and 
RANKL in the body are as follows (Equations 3-10 to 3-12): 
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(Eq. 3-10) 
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(Eq. 3-11) 
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(Eq. 3-12) 
 
where AD, Ap, and AC represent an amount of denosumab in the depot, peripheral, and 
central compartment, respectively. Rtot is the total amount of RANKL receptors which 
include free and bound receptors. The total amount of denosumab (Atot) in the serum is 
introduced as the sum of serum free and bound denosumab and can be estimated by the 
differential Equation 3-11. The serum free denosumab concentration (Cfree = ??
??
) and the 
denosumab-RANKL complex are calculated as followed (Equations 3-13 to 3-14): 
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(Eq. 3-13) 
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(Eq. 3-14) 
 
 The total clearance in Equation 3-11 can be estimated by Equation 3-15. 
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(Eq. 3-15) 
 
 The initial conditions of these differential equations (Equations 3-10 to 3-12) are 
set as (Equation 3-16): 
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(Eq. 3-16) 
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Data Simulation 
 
 By using the reported population pharmacokinetic parameters of filgrastim and 
denosumab that were estimated in the original studies (Table 3-1), the plasma 
concentration-time profiles for filgrastim and denosumab after IV and SC administration 
were reproduced in Phoenix® WinNonlin 6.3 from the sets of equations that were 
described in the structural pharmacokinetic model section. For denosumab, the 
population pharmacokinetic parameters estimated from the data set that includes BLQ 
data were used. The input bioavailability of SC administered filgrastim and denosumab 
were set to the values of the estimated bioavailability from the original study (0.691 and 
0.638 for filgrastim and denosumab, respectively [34, 42]). Simulation was also 
performed with an absolute bioavailability of 1 for easier assessment of the deviation 
between nominal bioavailability and the bioavailability determined by comparing AUCs. 
To study dose effect on the bias of bioavailability estimation, simulations were performed 
to generate the plasma concentration-time profiles of filgrastim and denosumab at various 
IV and SC doses, 0.01 ? 10000 ?g/kg for filgrastim; and 0.66 ? 210 mg for denosumab. 
These dose ranges were selected based on the evidence of usual therapeutic doses and 
doses that were studied for clinical evidence or pharmacokinetic profiles of filgrastim and 
denosumab. For filgrastim, the pharmacokinetic study was performed in the dose range of 
2.5 ? 10 ?g/kg for SC administration and at 5 ?g/kg for IV administration [42]. The usual 
therapeutic dose range for filgrastim is 1.2 - 10 ?g/kg [43]. For denosumab, the 
population pharmacokinetic meta-analysis was implemented on the pooled data from 11 
clinical studies which covered the dose range of 6 ? 210 mg of denosumab [34]. The 
recommended therapeutic dose of denosumab is 120 mg via SC administration every 4 
weeks [44]. However, the dose ranges that were used for simulation in this study were 
expanded to the extremes, especially for filgrastim, in order to capture the dynamic of the 
errors that possibly occur from the current approach of bioavailability estimation. All the 
parameter values used in the simulations to study the dose effect are summarized in 
Table 3-1. 
 
 To further evaluate the influence of other TMDD parameters on the 
bioavailability estimation of therapeutic proteins that undergo TMDD, the plasma 
concentration-time profiles of filgrastim in the dose range of 0.01 ? 10 ?g/kg were 
simulated with the variation of KD (0.001 ? 50 ng/mL), Kint (0.0001 ? 50 h-1), Koff (0.001 
? 50 h-1), and Kon (0.001 ? 50 mL/ng·h). The respective parameter values and results for 
these estimations are listed as supplemental data to this dissertation. 
 
 
Data Analysis 
 
 Non-compartmental analysis was performed in Phoenix® WinNonlin 6.3 to 
determine the area under the concentration-time curve (AUC) of the simulated profiles. 
The absolute bioavailability estimation was calculated from Equation 3-17 under the 
assumption of a dose-independent, constant clearance. 
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Table 3-1. Summary of the estimated population pharmacokinetic parameters of 
filgrastim and denosumab following IV and SC administration that were used for 
simulation to determine the dose effect on bioavailability estimation 
 
Model drug Dose Parameters Fixed-effect estimate 
Filgrastim 0.01, 0.05, 
0.1, 0.5, 1, 
2.5, 5, 10, 
50, 100, 
500, 1000, 
1500, 5000, 
and 10000 
?g/kg 
F 
Ka (h-1) 
F2 
D2 
Ke (h-1) 
Vd (L) 
KD (ng/mL) 
Kint (h-1) 
Kdeg (h-1) 
AR0 (?g) 
Koff (h-1) 
Cs,0 (ng/mL) 
0.691, 1.0 
0.403  
0.586  
6.6  
0.26  
2.03  
0.308  
0.0438  
0.215  
12.7  
0.389  
0.0253 
Denosumab 0.66, 1.98, 
6, 6.6, 14, 
15, 19.8, 30, 
60, 66, 100, 
120, 198, 
and 210 mg 
F 
Ka (d-1) 
CLlin (mL/day/66 kg)a 
V1 (mL/66 kg) 
Q (mL/day/66 kg)a 
V2 (mL/66 kg) 
Kss (ng/mL) 
Kint (d-1)a 
Kdeg (d-1)a 
R0 (ng/mL) 
0.638 
0.212 
73.44 
2490 
909.6 
1360 
138 
0.1908 
0.03552 
614 
 
a The parameter values were converted to day base unit. 66 kg is the typical weight of 
postmenopausal women with osteoporosis in the original study [34]. 
NOTE: F = absolute bioavailability; Ka = first-order absorption rate constant; F2 = 
bioavailability of the zero-order absorption process of filgrastim; D2 = duration of zero-
order absorption of filgrastim; Ke = first-order elimination rate constant; Vd = volume of 
distribution of filgrastim; KD = equilibrium dissociation constant which equals to 
????
???
; 
Kint = first-order internalization rate constant; Kdeg = first-order degradation rate constant; 
AR0 = pretreatment amount of G-CSF receptors in the blood and bone marrow; Koff = 
first-order dissociation rate constant; Cs,0 = pretreatment concentration of G-CSF; CLlin = 
linear clearance; V1 = central volume of distribution; Q = intercompartmental clearance; 
V2 = peripheral volume of distribution; Kss = quasi-steady-state constant; R0 = baseline 
RANKL level 
Source: a) Wiczling, P., P. Lowe, E. Pigeolet, F. Ludicke, S. Balser, and W. Krzyzanski, 
Population pharmacokinetic modelling of filgrastim in healthy adults following 
intravenous and subcutaneous administrations. Clin Pharmacokinet, 2009. 48(12): p. 
817-26. 
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Table 3-1. (Continued) 
 
b) Sutjandra, L., R.D. Rodriguez, S. Doshi, M. Ma, M.C. Peterson, G.R. Jang, et al., 
Population pharmacokinetic meta-analysis of denosumab in healthy subjects and 
postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet, 2011. 
50(12): p. 793-807. 
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? ?
????? ????
????? ????
? 
(Eq. 3-17) 
 
where F is the absolute bioavailability, AUCSC is the AUC from SC administration, 
AUCIV is the AUC from IV administration, DSC is the SC dose, and DIV is the IV dose. To 
determine dose effect, F was calculated for the different combinations of doses after SC 
and IV administration of filgrastim or denosumab. Dose normalized AUCs (AUC_D) and 
average clearance (CL) at different doses were calculated to determine the effect of dose 
on these parameters by using Equations 3-18 and 3-19 respectively. 
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(Eq. 3-18) 
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(Eq. 3-19) 
 
 To quantify the error in the bioavailability assessment, %prediction error was 
calculated by Equation 3-20. 
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(Eq. 3-20) 
 
where Fsim is the bioavailability calculated from the simulated data, and Fref is the 
reference bioavailability which is the absolute bioavailability that was used to simulate 
the plasma concentration-time profiles of filgrastim or denosumab. The reference values 
are 0.691 or 1.0 for filgrastim, and 0.638 or 1.0 for denosumab. 
 
 
Results 
 
 With reported population pharmacokinetic parameters and models for filgrastim 
and denosumab, plasma concentration-time profiles at various IV and SC doses of both 
protein drugs were simulated and shown in Figure 3-1. Notably, the pattern of plasma 
concentration-time profile of both filgrastim and denosumab showed transition during 
variation of IV and SC doses. 
 
Subsequently, with the combinations of different IV and SC doses of filgrastim at 
the reference bioavailability value of 0.691 (Fref = 0.691), the dose variation from 0.01 ? 
10000 ?g/kg yielded the bioavailability estimations presented in Table 3-2. The absolute 
bioavailability resulted from the dose effect varied from 0.172 ? 2.74 showing the 
deviation from the reference bioavailability (Fref = 0.691) that was used for the drug input 
in the TMDD model simulation. The corresponding prediction errors ranged from -75.1  
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Figure 3-1. Simulated plasma concentration-time profiles of filgrastim and 
denosumab after IV and SC administration 
Plasma concentration-time profiles were simulated in the dose range of 0.01 ? 10000 
?g/kg for filgrastim (A) and 0.66 ? 210 mg for denosumab (B). 
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Table 3-2. Dose effect on the bioavailability estimation of filgrastim with reference bioavailability (Fref) equals to 0.691a 
 
IV dose SC dose (?g/kg) 
(?g/kg) 0.01 0.05 0.1 0.5 1 2.5 5 10 50 100 500 1000 1500 5000 10000 
0.01 0.683 
(-1.11) 
0.694 
(0.462) 
0.711 
(2.91) 
0.929 
(34.4) 
1.32 
(91.7) 
1.94 
(180.) 
2.26 
(227) 
2.46 
(256) 
2.67 
(287) 
2.70 
(290.) 
2.73 
(295) 
2.73 
(296) 
2.74 
(296) 
2.74 
(296) 
2.74 
(296) 
0.05 0.663 
(-4.05) 
0.674 
(-2.52) 
0.690 
(-0.141) 
0.901 
(30.4) 
1.29 
(86.0) 
1.88 
(172) 
2.19 
(217) 
2.39 
(245) 
2.59 
(274) 
2.62 
(279) 
2.65 
(283) 
2.65 
(284) 
2.65 
(284) 
2.66 
(284) 
2.66 
(285) 
0.1 0.627 
(-9.29) 
0.637 
(-7.85) 
0.652 
(-5.60) 
0.852 
(23.3) 
1.22 
(75.8) 
1.78 
(157) 
2.07 
(200.) 
2.26 
(226) 
2.44 
(254) 
2.48 
(258) 
2.50 
(262) 
2.51 
(263) 
2.51 
(263) 
2.51 
(263) 
2.51 
(264) 
0.5 0.345 
(-50.1) 
0.350 
(-49.3) 
0.359 
(-48.1) 
0.469 
(-32.2) 
0.668 
(-3.32) 
0.977 
(41.3) 
1.14 
(64.7) 
1.24 
(79.5) 
1.34 
(94.5) 
1.36 
(97.0) 
1.38 
(99.2) 
1.38 
(99.5) 
1.38 
(99.7) 
1.38 
(99.9) 
1.38 
(99.9) 
1 0.261 
(-62.3) 
0.265 
(-61.7) 
0.271 
(-60.7) 
0.355 
(-48.7) 
0.506 
(-26.8) 
0.739 
(6.95) 
0.861 
(24.7) 
0.938 
(35.8) 
1.02 
(47.2) 
1.03 
(49.1) 
1.04 
(50.8) 
1.04 
(51.0) 
1.04 
(51.1) 
1.05 
(51.3) 
1.05 
(51.3) 
2.5 0.211 
(-69.5) 
0.214 
(-69.0) 
0.220 
(-68.2) 
0.287 
(-58.5) 
0.409 
(-40.8) 
0.598 
(-13.5) 
0.697 
(0.851) 
0.759 
(9.88) 
0.823 
(19.1) 
0.833 
(20.6) 
0.843 
(22.0) 
0.844 
(22.2) 
0.845 
(22.3) 
0.846 
(22.4) 
0.846 
(22.4) 
5 0.194 
(-72.0) 
0.197 
(-71.5) 
0.201 
(-70.8) 
0.263 
(-61.9) 
0.375 
(-45.7) 
0.549 
(-20.6) 
0.639 
(-7.47) 
0.697 
(0.811) 
0.755 
(9.28) 
0.765 
(10.6) 
0.773 
(11.9) 
0.775 
(12.1) 
0.775 
(12.2) 
0.776 
(12.3) 
0.776 
(12.3) 
10 0.184 
(-73.4) 
0.187 
(-72.9) 
0.192 
(-72.3) 
0.250 
(-63.8) 
0.357 
(-48.3) 
0.522 
(-24.5) 
0.608 
(-12.0) 
0.663 
(-4.12) 
0.718 
(3.94) 
0.727 
(5.23) 
0.735 
(6.44) 
0.737 
(6.62) 
0.737 
(6.68) 
0.738 
(6.78) 
0.738 
(6.80) 
50 0.175 
(-74.6) 
0.178 
(-74.2) 
0.182 
(-73.6) 
0.238 
(-65.5) 
0.340 
(-50.8) 
0.497 
(-28.1) 
0.579 
(-16.2) 
0.631 
(-8.71) 
0.684 
(-1.04) 
0.692 
(0.195) 
0.700 
(1.34) 
0.701 
(1.51) 
0.702 
(1.58) 
0.703 
(1.67) 
0.703 
(1.69) 
100 0.174 
(-74.8) 
0.177 
(-74.4) 
0.181 
(-73.8) 
0.237 
(-65.8) 
0.337 
(-51.2) 
0.493 
(-28.7) 
0.575 
(-16.9) 
0.626 
(-9.41) 
0.679 
(-1.80) 
0.687 
(-0.579) 
0.695 
(0.560) 
0.696 
(0.731) 
0.696 
(0.792) 
0.697 
(0.883) 
0.697 
(0.905) 
500 0.173 
(-75.0) 
0.175 
(-74.6) 
0.180 
(-74.0) 
0.235 
(-66.0) 
0.335 
(-51.5) 
0.489 
(-29.2) 
0.570 
(-17.5) 
0.621 
(-10.1) 
0.674 
(-2.51) 
0.682 
(-1.30) 
0.690 
(-0.166) 
0.691 
(0.00402) 
0.691 
(0.0642) 
0.692 
(0.155) 
0.692 
(0.177) 
1000 0.173 
(-75.0) 
0.175 
(-74.6) 
0.180 
(-74.0) 
0.235 
(-66.1) 
0.334 
(-51.6) 
0.489 
(-29.2) 
0.570 
(-17.5) 
0.621 
(-10.2) 
0.673 
(-2.61) 
0.681 
(-1.40) 
0.689 
(-0.272) 
0.690 
(-0.103) 
0.691 
(-0.0427) 
0.691 
(0.0483) 
0.691 
(0.0699) 
1500 0.172 
(-75.0) 
0.175 
(-74.6) 
0.179 
(-74.0) 
0.234 
(-66.1) 
0.334 
(-51.6) 
0.489 
(-29.3) 
0.570 
(-17.6) 
0.621 
(-10.2) 
0.673 
(-2.65) 
0.681 
(-1.44) 
0.689 
(-0.310) 
0.690 
(-0.141) 
0.690 
(-0.0808) 
0.691 
(0.0101) 
0.691 
(0.0317) 
5000 0.172 
(-75.1) 
0.175 
(-74.7) 
0.179 
(-74.0) 
0.234 
(-66.1) 
0.334 
(-51.6) 
0.488 
(-29.3) 
0.569 
(-17.6) 
0.620 
(-10.2) 
0.672 
(-2.71) 
0.681 
(-1.50) 
0.688 
(-0.368) 
0.690 
(-0.199) 
0.690 
(-0.139) 
0.691 
(-0.0481) 
0.691 
(-0.0265) 
10000 0.172 
(-75.1) 
0.175 
(-74.7) 
0.179 
(-74.0) 
0.234 
(-66.1) 
0.334 
(-51.7) 
0.488 
(-29.3) 
0.569 
(-17.6) 
0.620 
(-10.3) 
0.672 
(-2.72) 
0.681 
(-1.51) 
0.688 
(-0.382) 
0.690 
(-0.213) 
0.690 
(-0.153) 
0.691 
(-0.0620) 
0.691 
(-0.0404) 
 
a %Prediction errors are reported in the brackets. Bioavailabilities with minimum bias are reported in bold. 
Light gray area demonstrates overestimated bioavailability with prediction error exceeds 20%. 
Dark gray area demonstrates underestimated bioavailability with prediction error exceeds 20%. 
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to +296. The overestimations tended to appear in the right upper area of the table when 
high SC doses and low IV doses of filgrastim were used for bioavailability calculations; 
whereas the underestimations of bioavailability were observed in the left lower area of 
the table in which low SC doses and high IV doses of filgrastim were used for 
bioavailability estimations. The acceptable prediction errors considered as ±20% were 
attained when bioavailability was estimated from IV and SC filgrastim in the dose ranges 
of 0.01 ? 0.1 ?g/kg and 5 ? 10000 ?g/kg irrespective of the combination of IV and SC 
doses. The minimum biases tended to occur in the diagonal area of the table when the 
similar doses of IV and SC filgrastim were used for the bioavailability estimation. 
However, higher SC doses than IV doses were required in order to achieve the lowest 
bias of bioavailability estimation except for IV dose of 0.1 ?g/kg that showed the 
minimum error when it was paired with the same dose of SC administration. A similar 
result was also observed when the input bioavailability for simulation was set to 1.0 (data 
is shown in Table A-1 in the Appendix A section). However, the least deviation of 
bioavailability estimation seemed to be mostly achieved with the same doses of IV and 
SC administration when input bioavailability was set to 1.0. 
 
Notably, even with the same doses of IV and SC filgrastim used for the 
bioavailability assessment, some bias still occurred in the dose range of 0.01 ? 10 ?g/kg, 
especially at 0.5 and 1 ?g/kg that showed a prediction error greater than 20% in the case 
of input bioavailability was set to 0.691. In this dose range, the highest error of 
bioavailability estimation occurred at 0.5 ?g/kg with prediction errors equaled to -32.2% 
and -19.6% when Fref = 0.691 and Fref = 1.0 respectively (Figure 3-2). 
 
Similarly to the full TMDD model for filgrastim, estimation of absolute 
bioavailability for denosumab with the quasi-steady state approximation to the TMDD 
model was also affected by dose variation. The results for dose variation from 0.66 ? 210 
mg of IV and SC administered denosumab at Fref = 0.638 are shown in Table 3-3. The 
absolute bioavailability varied from 0.0264 ? 12.5, substantial deviation from Fref = 
0.638. The corresponding prediction errors ranged from -95.9 to +1862%. Most 
overestimation was observed in the upper right corner of Table 3-3 when high SC and 
low IV denosumab doses were used for bioavailability estimation; whereas the absolute 
bioavailability was underestimated in the lower half left of Table 3-3 when low SC and 
high IV doses were used for calculation. Bioavailability with acceptable prediction error 
(± 20%) was estimated in the dose range of 60 ? 210 mg denosumab (lower right area of 
the table) regardless of the combination of IV and SC doses. The least bias tended to be 
presented along the diagonal area of the table when similar doses of IV and SC 
denosumab with mostly higher SC doses than IV doses were used for bioavailability 
estimation. Similar to filgrastim, simulation results of denosumab with Fref = 1.0 also 
showed the same pattern and comparable magnitude of error (-95.5 ? 1926% prediction 
error) as of those resulting from Fref = 0.638 (Table A-2 in Appendix A section). 
Moreover, as in the case of filgrastim, the least deviation of bioavailability estimation 
was achieved with mostly the same doses of IV and SC administered denosumab when 
Fref = 1.0. 
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Figure 3-2. %Prediction error of bioavailability estimation by dose effect in 
filgrastim 
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Table 3-3. Dose effect on the bioavailability estimation of denosumab with the reference bioavailability (Fref) equals to 
0.638a 
 
IV dose SC dose (mg) 
(mg) 0.66 1.98 6 6.6 14 15 19.8 30 60 66 100 120 198 210 
0.66 0.535 
(-16.1) 
0.760 
(19.1) 
2.51 
(294) 
2.84 
(344) 
5.82 
(812) 
6.09 
(855) 
7.17 
(1024) 
8.63 
(1252) 
10.5 
(1550) 
10.7 
(1583) 
11.5 
(1707) 
11.8 
(1752) 
12.5 
(1852) 
12.5 
(1862) 
1.98 0.256 
(-59.8) 
0.364 
(-43.0) 
1.20 
(88.5) 
1.36 
(113) 
2.79 
(337) 
2.92 
(357) 
3.44 
(438) 
4.13 
(548) 
5.04 
(690.) 
5.14 
(706) 
5.52 
(766) 
5.66 
(787) 
5.96 
(835) 
5.99 
(839) 
6 0.0750 
(-88.2) 
0.107 
(-83.3) 
0.352 
(-44.8) 
0.398 
(-37.7) 
0.816 
(27.8) 
0.855 
(33.9) 
1.01 
(57.7) 
1.21 
(89.6) 
1.48 
(131) 
1.51 
(136) 
1.62 
(153) 
1.66 
(160.) 
1.75 
(174) 
1.75 
(175) 
6.6 0.0693 
(-89.1) 
0.0984 
(-84.6) 
0.325 
(-49.0) 
0.367 
(-42.4) 
0.754 
(18.1) 
0.790 
(23.8) 
0.930 
(45.7) 
1.12 
(75.2) 
1.36 
(114) 
1.39 
(118) 
1.49 
(134) 
1.53 
(140.) 
1.61 
(153) 
1.62 
(154) 
14 0.0439 
(-93.1) 
0.0624 
(-90.2) 
0.206 
(-67.7) 
0.233 
(-63.5) 
0.478 
(-25.1) 
0.500 
(-21.6) 
0.589 
(-7.68) 
0.708 
(11.0) 
0.865 
(35.5) 
0.882 
(38.2) 
0.947 
(48.4) 
0.970 
(52.1) 
1.02 
(60.3) 
1.03 
(61.1) 
15 0.0426 
(-93.3) 
0.0605 
(-90.5) 
0.200 
(-68.6) 
0.226 
(-64.6) 
0.463 
(-27.4) 
0.486 
(-23.9) 
0.572 
(-10.4) 
0.687 
(7.74) 
0.839 
(31.5) 
0.856 
(34.1) 
0.919 
(44.0) 
0.942 
(47.6) 
0.992 
(55.5) 
0.997 
(56.3) 
19.8 0.0383 
(-94.0) 
0.0544 
(-91.5) 
0.180 
(-71.8) 
0.203 
(-68.2) 
0.417 
(-34.7) 
0.437 
(-31.5) 
0.514 
(-19.4) 
0.618 
(-3.10) 
0.755 
(18.3) 
0.770 
(20.6) 
0.826 
(29.5) 
0.847 
(32.7) 
0.892 
(39.9) 
0.897 
(40.6) 
30 0.0339 
(-94.7) 
0.0482 
(-92.4) 
0.159 
(-75.0) 
0.180 
(-71.8) 
0.369 
(-42.2) 
0.387 
(-39.4) 
0.455 
(-28.7) 
0.547 
(-14.2) 
0.668 
(4.70) 
0.681 
(6.79) 
0.732 
(14.7) 
0.750 
(17.5) 
0.790 
(23.8) 
0.794 
(24.4) 
60 0.0297 
(-95.3) 
0.0421 
(-93.4) 
0.139 
(-78.2) 
0.157 
(-75.3) 
0.323 
(-49.4) 
0.338 
(-47.0) 
0.398 
(-37.6) 
0.479 
(-25.0) 
0.584 
(-8.42) 
0.596 
(-6.59) 
0.640 
(0.287) 
0.656 
(2.78) 
0.691 
(8.31) 
0.694 
(8.85) 
66 0.0293 
(-95.4) 
0.0416 
(-93.5) 
0.137 
(-78.5) 
0.155 
(-75.7) 
0.318 
(-50.1) 
0.334 
(-47.7) 
0.393 
(-38.4) 
0.472 
(-26.0) 
0.576 
(-9.65) 
0.588 
(-7.84) 
0.631 
(-1.05) 
0.647 
(1.41) 
0.682 
(6.86) 
0.685 
(7.40) 
100 0.0279 
(-95.6) 
0.0396 
(-93.8) 
0.131 
(-79.5) 
0.148 
(-76.8) 
0.303 
(-52.4) 
0.318 
(-50.2) 
0.374 
(-41.3) 
0.450 
(-29.5) 
0.549 
(-13.9) 
0.560 
(-12.2) 
0.602 
(-5.72) 
0.616 
(-3.38) 
0.650 
(1.82) 
0.653 
(2.33) 
120 0.0274 
(-95.7) 
0.0390 
(-93.9) 
0.129 
(-79.8) 
0.145 
(-77.2) 
0.298 
(-53.2) 
0.313 
(-51.0) 
0.368 
(-42.3) 
0.443 
(-30.6) 
0.540 
(-15.4) 
0.551 
(-13.7) 
0.591 
(-7.30) 
0.606 
(-4.99) 
0.639 
(0.114) 
0.642 
(0.620) 
198 0.0265 
(-95.9) 
0.0375 
(-94.1) 
0.124 
(-80.5) 
0.140 
(-78.0) 
0.288 
(-54.9) 
0.301 
(-52.8) 
0.355 
(-44.4) 
0.426 
(-33.2) 
0.520 
(-18.4) 
0.531 
(-16.8) 
0.570 
(-10.7) 
0.584 
(-8.44) 
0.616 
(-3.52) 
0.619 
(-3.03) 
210 0.0264 
(-95.9) 
0.0374 
(-94.1) 
0.124 
(-80.6) 
0.140 
(-78.1) 
0.286 
(-55.1) 
0.300 
(-53.0) 
0.353 
(-44.6) 
0.425 
(-33.4) 
0.519 
(-18.7) 
0.529 
(-17.1) 
0.568 
(-11.0) 
0.582 
(-8.77) 
0.613 
(-3.87) 
0.616 
(-3.38) 
 
a %Prediction errors are reported in the brackets. Bioavailabilities with minimum bias are reported in bold. 
Light gray area demonstrates overestimated bioavailability with prediction error exceeds 20%. 
Dark gray area demonstrates underestimated bioavailability with prediction error exceeds 20%. 
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However, with the same doses of IV and SC denosumab, the bias of 
bioavailability estimation was more pronounced than for filgrastim, especially in the case 
of Fref = 0.638 as can be observed in Figure 3-3. At Fref = 0.638, a prediction error greater 
than 20% was observed in the dose range of 1.98 ? 15 mg denosumab with the highest 
bias occurring at 6 mg. In contrast to filgrastim that showed the bias peaks at the same 
dose at different Fref, the most error occurred at 1.98 mg denosumab when Fref was set at 
1.0. 
 
The dose effect on dose-normalized AUC of filgrastim and denosumab were 
investigated and shown in Figure 3-4. For filgrastim, at both Fref = 0.691 and Fref = 1.0, 
dose-normalized AUC increased as the doses increased and exhibited the S-shaped curve 
which could be observed in Figures 3-4A and 3-4B respectively. The rapid increase of 
dose-normalized AUC occurred in the dose range of 0.1 ? 5 ?g/kg filgrastim. Similarly, 
the same pattern of the dose effect on dose-normalized AUC were observed for 
denosumab at both Fref = 0.638 (Figure 3-4C) and Fref = 1.0 (Figure 3-4D). The slightly 
S-shaped curves showed an increasing of dose-normalized AUC as the doses increased in 
the range of 0.66 ? 210 mg. The sharp increase of dose-normalized AUC occurred at the 
dose of 1.98 mg onward and seemed to reach a plateau at very high dose. Notably, dose-
normalized AUC tended to level off at 60 mg IV and SC doses of denosumab. 
 
The alteration of dose-normalized AUC during dose variation may imply the 
disproportional change in filgrastim and denosumab plasma concentrations at different 
doses resulted from the concentration-dependent clearance. The dynamic of clearance 
alteration at different doses was subsequently investigated and the results are shown in 
Figures 3-5 and 3-6 for filgrastim and denosumab, respectively. Dose effect on clearance 
was linked by a peak plasma concentration (Cmax) since the rate of elimination depends 
on available systemic concentration. 
 
Upon increasing dose, Cmax after IV and SC administration was increased. 
However, the increasing pattern of Cmax after SC administration was slightly different 
from what was observed after IV administration with the extra reflection points in the 
dose range of 0.1 ? 5 ?g/kg for filgrastim (Figure 3-5A) and below 60 mg for denosumab 
(Figure 3-6A). Different degrees of clearance at various IV and SC doses of filgrastim 
and denosumab were subsequently correlated with the corresponding Cmax. To truly 
represent clearance for protein drugs that undergo TMDD at various doses, average 
clearance determined from plasma concentration-time profiles after IV administration 
was used as a reference. 
 
Due to the wrong assumption of dose-independent clearance that was used for 
bioavailability estimation for protein drugs that undergo TMDD, average clearances that 
were determined from plasma concentration-time profiles of SC administration showed 
bias with the deviation from average clearance after IV administration (Figures 3-5B and 
3-6B for filgrastim and denosumab, respectively). F that was used in the calculation for 
determining the average clearance after SC administration (Equation 3-19) only 
accounted for bias within apparent clearance that associated with dose- independent 
elimination. Thus, average clearance determined from concentration-time profile after SC 
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Figure 3-3. %Prediction error of bioavailability estimation by dose effect in 
denosumab 
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Figure 3-4. Dose effect on the dose normalized AUC of filgrastim and denosumab 
The effect of dose on dose-normalized AUC of filgrastim exhibited an S-shaped curve 
with dose normalized AUC increased as dose increased in the range of 0.1 ? 10 ?g/kg at 
both F = 0.691 (A) and F = 1.0 (B). Similarly, the effect of dose on dose-normalized 
AUC of denosumab showed a slightly S-shaped curve with dose normalized AUC 
increased as dose increased in the range of 0.66 ? 210 mg at both F = 0.638 (C) and F = 
1.0 (D). 
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Figure 3-5. The correlation between dose and average clearance of filgrastim 
through the alteration of plasma concentration 
Due to increasing dose, peak plasma concentration of IV and SC administered filgrastim 
(Cmax) was increased (A). At various Cmax, different degrees of clearance were observed 
(B). 
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Figure 3-6. The correlation between dose and average clearance of denosumab 
through the alteration of plasma concentration 
Due to increasing dose, peak plasma concentration of IV and SC administered 
denosumab (Cmax) was increased (A). At various Cmax, different degrees of clearance 
were observed (B). 
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administration may warrant at very low or very high doses when linear elimination 
process was dominated. 
 
For filgrastim, clearance showed a perfect S-shaped correlation to the various 
degree of Cmax with a high degree of constant clearance at low Cmax and low invariant 
clearance at high Cmax (Figure 3-5B). It should be noted that a very active dynamic in the 
alteration of clearance occurred in the plasma concentration range corresponding to 0.1 ? 
5 ?g/kg filgrastim regardless of administration route. In contrast to filgrastim, clearance 
of denosumab did not show an S-shaped pattern (Figure 3-6B). However, similar to 
filgrastim, minimum constant clearance was achieved at the high dose. A dynamic 
change in clearance of denosumab was observed in the plasma concentration range that 
was corresponded to doses lower than 60 mg for both IV and SC administration. 
 
 
Discussion 
 
 With dose-dependent clearance and subsequent non-linear pharmacokinetics, 
bioavailability estimations are difficult to perform for drugs that undergo a TMDD 
process since the standard methodology for bioavailability estimation is calculated under 
the assumption of dose-independent, constant clearance. As a consequence of an 
assumption violation, the dose-dependent bioavailability that is usually observed when 
the standard methodology is used in drugs that exhibit TMDD pharmacokinetics is 
misleading. This notion is supported by this simulation study when the bioavailability of 
filgrastim and denosumab were determined at various doses. 
 
 Although, the assumption and limitation of pharmacokinetic models can impact 
the simulated concentration-time profiles [41] in which they might deviate from the real 
pharmacokinetic profiles, the full TMDD model and the quasi-steady-state approximation 
of the TMDD model that were proven to adequately describe the pharmacokinetics of 
filgrastim [42] and denosumab [34], respectively, should be able to fairly reproduce the 
pharmacokinetic profiles of both protein drugs. Transition in the characteristics of plasma 
concentration-time profiles of filgrastim and denosumab during variation of doses is also 
observed in a study of the dynamics of TMDD by Peletier and Gabrielsson [41]. The 
nonlinear pharmacokinetics and dose-dependent bioavailability that were observed in 
both therapeutic proteins in this study have also been reported in other studies [33] and 
for several other protein drugs that undergo TMDD [29, 31]. 
 
 Dose-dependent bioavailability that was observed in filgrastim and denosumab 
was a result from a change in dose-normalized AUC during dose alteration. Regardless of 
the assumed nominal bioavailability Fref and the applied pharmacokinetic model, the dose 
had an effect on the dose normalized AUC of both therapeutic proteins, filgrastim, and 
denosumab. As doses increased, the dose-normalized AUCs tended to increase which 
were very obvious in the dose range of 0.1 ? 5 ?g/kg for filgrastim and 1.98 mg onward 
for denosumab. This dose effect on the dose normalized AUC was also observed in 
population pharmacokinetic-pharmacodynamic modeling of filgrastim in healthy 
volunteers [33] and during a population pharmacokinetic study of AMG 317, a fully 
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human monoclonal antibody against IL4 receptor [45] in which the increasing dose 
caused an increase in dose-normalized AUC during non-compartmental analysis. 
 
 The increment in dose-normalized AUC upon increasing dose of filgrastim and 
denosumab may indicate a disproportionate increase in plasma concentration, which may 
subsequently imply the alteration in clearance due to the variation of dose. The results 
showed that different degrees of clearance could be observed at various plasma 
concentrations (Cmax) resulting from different IV doses of filgrastim and denosumab. The 
cooperation between two elimination pathways, a linear clearance and a target receptor-
mediated elimination, may impart the dynamic in the alteration of clearance during dose 
variation. Similar to what is described in the dynamics of TMDD study [41], different 
plasma concentrations of ligand determine which elimination pathway becomes 
predominant. At low plasma concentration (low dose) of protein drugs, target receptors 
still have the capacity for the elimination of ligands, thus TMDD is considered as the 
main pathway of clearance. However, increasing plasma concentration upon increasing 
dose until target receptor becomes partially saturated, the contribution of TMDD to the 
overall clearance may decrease and protein drugs are more potentially eliminated via a 
linear clearance pathway. After all target receptors are saturated at very high plasma 
concentration (high dose) of therapeutic proteins, the linear clearance pathway is 
dominated. The transition between these two elimination pathways during dose variation 
may not only cause a change in the degree of clearance but also influence the transition in 
the characteristics of plasma concentration-time profile as could be observed in filgrastim 
and denosumab. 
 
 For both protein drugs, the average clearance tended to decrease as plasma 
concentration increased and this decreasing was very obvious in the corresponding dose 
range of 0.1 ? 5 ?g/kg for filgrastim and below 60 mg for denosumab. The dose-
dependent or concentration-dependent clearance observed in this study was also observed 
in interferon-?1a [31], other several therapeutic monoclonal antibodies [29] such as 
tocilizumab [46], PF-04840082 (Dickkopt-1 antibody) [47], panitumumab, cetuximab 
[32], and concizumab [48], a bivalent humanized nanobody [49], and in the study of the 
dynamics of TMDD [40]. At very high doses of both protein drugs, the clearance reached 
the lowest plateau phase, which might be due to the saturation of the targets that are 
responsible for protein degradation. At this plateau phase after high dosing, the linear 
clearance pathway becomes predominant [29, 31, 32, 34, 40, 46, 48]. 
 
 As a consequence of transition between two elimination pathways, change in the 
degree of clearance, and transition in the characteristics of plasma concentration-time 
profile, disproportional increased AUC upon increasing dose may contribute to the 
increment of dose-normalized AUC. Due to these artifacts, if different IV and SC dose 
levels are combined and used for bioavailability estimation, it may cause bias. The results 
showed the overestimation of bioavailability was observed with the combination of high 
SC doses and low IV doses, and the underestimation of bioavailability occurred when the 
combination of low SC doses and high IV doses was used. 
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In the original clinical study, the bioavailability of filgrastim was determined from 
three SC injections of 2.5, 5, and 10 ?g/kg, and one IV infusion of 5?g/kg over half an 
hour. However, according to the results reported in Table 3-2, bioavailability estimation 
within this dose range could result in prediction error ranging from -20.6% to +0.811%. 
For denosumab, pooled data from 11 clinical studies with IV and SC dose range of 6 ? 
210 mg possibly resulted in the bias of bioavailability estimation in the range of -80.6 ? 
+175% (Table 3-3). Thus, the bioavailability obtained for filgrastim and denosumab may 
not represent the true bioavailability. 
 
 However, the bioavailability of filgrastim and denosumab could be estimated with 
±20% prediction error if the assessment was performed in the dose ranges of 0.01 ? 0.1 
?g/kg or 5 ? 10000 ?g/kg for filgrastim, and 60 ? 210 mg for denosumab. Notably, any 
combination within these dose ranges could be used for bioavailability estimation. 
Interestingly, these dose ranges yielded constant dose normalized AUC. The constant 
dose-normalized AUC might result from a proportional increase in plasma concentration 
which was due to the concentration-independent clearance that concurrently occurred 
within these dose ranges. To minimize the bias of bioavailability estimation, similar or 
the same doses of IV and SC administration should be used. It should be noted that if Fref 
was less than 1.0, slightly higher SC dose than IV dose should be combined in order to 
attain the least deviation. This may imply that similar plasma concentration after IV and 
SC administration may be required in order to achieve the minimum bias. It seems 
intuitively possible since similar plasma concentration after IV and SC administration 
may be eliminated with a similar degree through the same pathway of clearance. 
Nevertheless, with the same IV and SC doses, prediction error greater than 20% still 
occurred when bioavailability estimations were calculated in the dose range of 0.5 ? 1 
?g/kg filgrastim and 1.98 ? 15 mg denosumab. The errors that occurred when 
bioavailability was estimated from an equal dose of IV and SC administration might 
result from other factors that affect the clearance of drugs that go through TMDD 
pathway which in turn can affect the drug concentration-time profiles and AUCs. 
 
 Other factors that possibly have an impact on the bioavailability assessments of 
drugs that undergo TMDD are the parameters specific for the TMDD process, the 
dissociation rate constant (KD) which describes the binding (Kon) and dissociation (Koff) 
processes, and the internalization process described by Kint that occurs after drugs bind to 
their receptors. Moreover, for denosumab, the quasi-steady-state constant (Kss) in the 
quasi-steady-state approximation to TMDD model can be an influential factor. The 
effects of all these parameters were shown to affect the drug concentration vs time 
profiles in the dynamics of TMDD study dependent on the dose of the ligands [40, 41]. 
The impact of these factors was further explored in the supplemental material. 
 
 It should be noted that the bioavailability of therapeutic proteins that follow a 
TMDD pathway should be carefully estimated, especially in the dose range in which the 
target sites are partially saturated and both elimination pathways have equal potential to 
contribute to the overall clearance, since dose-normalized AUC varies actively with dose 
at this state. To overcome this problem, a very low dose of protein drug within the 
capacity of target receptor can be used for bioavailability assessment. However, with the 
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limitation of the sensitivity of the analytical method, this may become problematic. 
Another solution is to perform bioavailability estimation at the high dose of therapeutic 
proteins that saturate all target sites and render the linear clearance pathway to become 
dominant. At this state, the bioavailability estimation is no longer dependent on dose. 
Thus, this saturation phase should be the suitable state for determining the true absolute 
bioavailability with the least bias. In many instances, however, these are supra-
therapeutic doses that cannot practically administer to human subjects or animal. 
 
 Ideally, to get an accurate assessment of bioavailability of protein drugs that 
undergo TMDD, the IV doses should be administered at the amounts that will generate 
the exact same plasma concentration-time profiles as those from SC administrations. 
However, this might be difficult to accomplish since carefully monitoring the drug 
plasma concentration-time profile is required during IV infusion. Even in an ideal 
scenario in which nonlinearity through TMDD can be overcome by high doses (as 
outlined in the previous chapter), other factors can affect the bioavailability assessment of 
therapeutic proteins. One such factor that could result in true nonlinearity in 
bioavailability is the absorption process that occurs in the body. In a study by Zhao et al., 
bioavailability is shown to be sensitive and negatively related to transit time for the drug 
from lymph system to systemic circulation (?) and elimination rate during lymphatic 
transport (Klymph) [50]. Moreover, bioavailability is also found to be sensitive and 
positively related to the lymphatic flow rate when the lymphatic flow rate is set to less 
than 0.5 fold of original value. 
 
 Gibiansky et al suggest another way to determine the absolute bioavailability with 
a minimum bias for drugs that exhibit nonlinear pharmacokinetics , in which the ratio of 
IV and SC doses that provided equal AUCs are used for bioavailability estimation [51]. 
By this method, the approximation underestimates the true bioavailability by no more 
than 5 ? 30% with more precision of approximation achieved when AUC at steady-state 
is used for calculation. Moreover, the bias decreases with the increase of SC absorption, 
true bioavailability, and SC dose. This finding may also imply that equal amount of 
protein drugs presented in the systemic circulation after IV and SC administration is 
required in order to achieve a minimum bias of bioavailability estimation. According to 
this finding, the bioavailability of filgrastim and denosumab may be more accurately 
estimated by determining the ratio of IV and SC doses that possessed equal AUCs. 
 
 In conclusion, with the current methodology and assumptions of bioavailability 
determination, the absolute bioavailability of drugs that undergo a TMDD pathway and 
exhibit nonlinear pharmacokinetics are estimated with bias. The bias is caused by a dose 
effect on the dose-normalized AUC, which is the result of concentration-dependent 
differences in clearance based on differences in the characteristics of the concentration-
time profiles. To achieve more accurate bioavailability estimation, the absolute 
bioavailability should be determined, if possible, at low or high doses when the invariant 
clearance is observed or with the alternate estimation method suggested by Gibiansky et 
al [51]that determines the ratio of IV and SC doses that generate equal AUCs. 
 
  
 
 
43 
 
CHAPTER 4.    THE ONTOGENY OF NEONATAL FC RECEPTOR (FCRN) 
EXPRESSION IN MICE 
 
 
Introduction 
 
 The neonatal Fc receptor (FcRn) (reviewed in [16, 52-56]), also known as the 
Brambell receptor, is a major histocompatibility (MHC) class I-like molecule that is 
encoded by Fcgrt. It is a heterodimeric glycoprotein consisting of one heavy chain with a 
large extracellular part associated with one ?2 microglobulin (?2m) subunit followed by a 
transmembrane segment and a short cytoplasmic tail. The extracellular part of the FcRn 
heavy chain is composed of three subunits denoted as ?1, ?2, and ?3 (Figure 4-1). The 
functions of FcRn include protection of IgG and albumin from catabolism, transportation 
of IgG across epithelial cells, and antigen presentation in immunoprotective systems. 
IgGs and albumins are found to bind noncompetitively and without cooperativity to the 
distinct FcRn binding site. Although FcRn can bind to IgG as a 1:1 complex, most studies 
have shown that two FcRn molecules bind to a single IgG with the stoichiometric ratio of 
2:1 [52, 53, 55]. Mutational and crystallographic studies have revealed the Fc-FcRn 
complex structure, and proposed that FcRn uses the C-terminal portion of the ?2 domain, 
the first residue of ?2-microglobulin and carbohydrate to interact with the Fc CH2-CH3 
interface [57, 58]. Upon the pH-dependent binding process, FcRn does not undergo a 
major conformational change. However, a slight rearrangement of the FcRn side chain 
and chemical alteration of the amino acid residues occurs at the binding interface. 
 
As previously described in Chapter 1, FcRn resides mainly within acidic 
cytoplasmic vesicles inside the cells. The interaction with IgG is initiated when 
circulating IgG is taken up by receptor-mediated endocytosis or fluid-phase pinocytosis, 
and subsequently binds to FcRn in the endosomes (Figure 1-2). The acidic environment 
causes protonation of the histidine residues in the area between the CH2 and CH3 domains 
of the Fc region. The protonated histidine binds to the binding site on the FcRn heavy 
chain. After binding the IgG-FcRn complex returns to the apical or basolateral side of the 
cell surface membrane in the recycling and transcytosis processes, respectively. The 
exposure to physiological pH causes the release of IgG to the blood stream or the 
extracellular fluid. This process occurs in a strictly pH-dependent manner such that the 
binding takes place in an acidic environment (? 6.0 ? 6.5) and the release takes place in 
the physiological or neutral milieu (? 7.4) [59-65]. This pH dependencyis the 
consequence of the presence of the conserved histidine residues on the Fc fragment of 
IgG that bind to the ?2 domain of FcRn [52]. 
 
FcRn expression has been detected in a variety of endothelial, epithelial, and 
hematopoietic cells in various organs throughout the body, including skin [64, 66, 67], 
muscle [66, 68], liver [63, 68-70], kidney [66, 71], spleen [66, 70], lung [70, 72], 
mammary gland [73], intestine [62, 66, 69, 70, 72, 74-79], stomach [69], brain [66, 80, 
81], eye [82], immune cells [65, 83], and placenta [84-87] (Table 4-1). FcRn is expressed 
throughout life and differs across tissue types and species. However, a developmental 
downregulation of intestinal FcRn mRNA and protein are observed in adult rodents  
 
 
44 
 
 
 
Figure 4-1. The crystal structures of human FcRn and rat FcRn-rat IgG Fc 
complex 
(A) The crystal structure of human FcRn. The loci of the amino acids essential for IgG 
(E115, E116, D130, W131, L135 and I1) and albumin (H166) binding are highlighted. 
(B) The co-crystal structure of rat FcRn with a rat IgG Fc fragment. The amino acid 
residues (H310, H435, and I253) at the Fc elbow region involved in binding to FcRn are 
highlighted with numbers and arrows. The glycosylated amino acid residue N297 in the 
CH2 domain of rat Fc is shown as a red spherical ball and numbered. The corresponding 
amino acid residues on rat FcRn involved in IgG Fc (E117, E118, E132, W133, D137, 
and I1) and albumin binding (H168) are indicated as red balls. In both figures, the FcRn 
heavy chain is shown in green and ?2m in orange. 
Source: Reprinted with permission from The Japanese Society for the Study of 
Xenobiotics (JSSX). Andersen, J.T. and I. Sandlie, The versatile MHC class I-related 
FcRn protects IgG and albumin from degradation: implications for development of new 
diagnostics and therapeutics. Drug Metab Pharmacokinet, 2009. 24(4): p. 318-32. 
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Table 4-1. Distribution of FcRn expression in various organs and their functions 
 
Organs Cell types and tissues Functions 
Skin 
 
 
 
 
 
 
 
 
Liver 
 
 
 
 
 
 
 
Kidney 
 
 
 
Lung 
 
 
 
 
 
Intestine 
 
 
 
 
 
 
Muscle 
 
 
 
 
Stomach 
 
Endothelial cell 
- Capillary endothelium [66] 
Epithelial cell 
- Stratum corneum, keratinocytes, 
melanocytes, sebaceous glands, and hair 
follicles [64, 67] 
Hematopoietic cell 
- Histiocytes 
 
Endothelial cell 
- Capillary endothelium [68] 
Epithelial cell 
- Hepatocyte [63, 66, 70], sinusoidal and 
canalicular membranes [63, 66, 68, 69] 
Hematopoietic cell 
- Kupffer cells [66, 69] 
 
Epithelial cell 
- Podocytes, and proximal tubule cells 
[66, 71] 
 
Epithelial cell 
- Apical regions of large and small 
bronchiolar airways, and alveolar [72] 
Hematopoietic cell 
- Macrophages [66] 
 
Epithelial cell 
- Apical membranes of enterocyte villi, 
and crypts of small intestine [66, 75-79] 
Hematopoietic cell 
- Macrophages in intestinal lamina propria 
[65, 69, 77] 
 
Endothelial cell 
- Capillary endothelium [66, 68, 69] 
Epithelial cell 
- Endomysium [68] 
 
Epithelial cell 
- Gastric mucosa [69] 
 
- Homeostasis of IgG [68] 
 
 
 
 
 
 
 
 
- Recycling of IgG [88] 
 
 
 
 
 
 
 
- Recycling of IgG to 
prevent accumulation in 
the kidney 
 
-Absorption of IgG and Fc 
fusion proteins [72] 
 
- Antigen presentation 
process 
 
- Absorption of IgG and 
Fc-fusion proteins 
 
- Antigen presentation 
process 
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Table 4-1. (Continued) 
 
Organs Cell types and tissues Functions 
Spleen 
 
 
 
 
Eye 
 
 
 
 
 
 
 
Central 
nervous 
systems 
 
 
 
Reproductive 
organs 
 
 
 
 
 
 
Mammary 
organs 
 
 
 
Blood 
 
 
 
 
 
Lymph node 
Endothelial cell 
- Capillary endothelium [89] 
Hematopoietic cell 
- Macrophages [66, 89] 
 
Endothelial cell 
- Capillary endothelium [82] 
- Corneal endothelium [82] 
Epithelial cell 
- Corneal, conjunctiva, non-pigmented 
ciliary, optic nerve, and lens epithelium 
[82] 
 
Endothelial cell 
- Capillary endothelium [66, 80, 81] 
Epithelial cell 
- Choroid plexus ependymal cells, and 
peripheral nerve perineurium [66, 80] 
 
Endothelial cell 
- Placental endothelial cells [84] 
(inconsistently detected) 
Epithelial cell 
- Mucosa of uterine and vaginal tissues 
- Syncytiotrophoblasts of placenta [85, 
87] 
 
Epithelial cell 
- Acinar epithelium of mammary glands 
[73] 
 
 
Hematopoietic cell 
- Monocytes, monocyte-derived dendritic 
cells, and polymorphonuclear neutrophils 
(PMN) [65, 83, 89] 
- B cells [89](inconsistently detected) 
 
Hematopoietic cell 
- Macrophages, and dendritic cells [66] 
 
 
 
- Antigen presentation 
process 
 
- Blood-ocular barrier [82] 
 
 
 
 
 
 
 
- Efflux of IgG from the 
brain to blood [81] 
 
 
 
 
- Maternofetal immunity 
transfer 
 
 
 
 
 
 
- Maternofetal immunity 
transfer in rodent 
(Recycling of IgG) 
 
 
- Recycling of IgG during 
homeostasis 
- Antigen presentation 
process 
 
 
- Antigen presentation 
process 
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relative to neonates [62, 74-76]. In the rat, reduction in FcRn mRNA and protein 
expression occurs in an age-dependent manner in the distal to proximal direction until 
FcRn-mediated IgG absorption is no longer detected at 3 weeks postpartum. Moreover, 
an upregulation of the expression of FcRn protein has been shown in mouse brain 
microvessels during aging [81]. These data suggest age-dependent differences in FcRn 
expression at different stages of development which might impact the pharmacokinetics 
of therapeutic proteins that bind to this receptor. To investigate the effect of ontogeny on 
the FcRn, FcRn protein expression in different organs was quantified relative to GAPDH 
expression, in different age groups of C57BL/6J mice in this study. 
 
 Due to preliminary results (data not shown) and information from the literature 
showing that expression of FcRn in adult rodent intestine [74, 75, 79], and stomach [66, 
74] were undetectable, along with the low probability that these organs are involved in 
the homeostasis of therapeutic proteins that bind to this receptor, FcRn expression was 
not quantitated in these organs. Moreover, IgG is found to preferentially distribute to the 
lung, kidney, spleen, liver, and skin [55]. Thus, relative FcRn expression was quantified 
in these organs in 2, 10, 21, 42, and 70 day old animals. Although studies in adult mice 
reveal that FcRn is expressed in a functionally active form in the endothelium of small 
arterioles and capillaries of skin, muscle, liver, adipose tissues [68], and hematopoietic 
cells [66, 89], the potential of functional FcRn in other organs of neonates could not be 
precluded. 
 
 
Materials and Methods 
 
 
Animals 
 
 In order to obtain at least six animals at different ages including 2, 10, 21, 42, and 
70 days of age, nine timed-pregnant C57BL/6J mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME). Animals were shipped at 7 - 15 days of gestation and 
arrived at 10 - 18 days of gestation. All timed-pregnant mice were housed in the animal 
facility for 1 week before the delivery with free access to food and water. Pups delivered 
by pregnant mice were raised to pre-determined ages according to the study design and 
weaned at day 21. The day of birth was assigned as the first day of life (day 1). Males and 
females were housed separately in different cages at the weaning age (day 21) with ear 
tags for background tracking. All animals were housed in standard laboratory cages and 
had free access to food and water throughout the study period. 
 
 
Organ Collection 
 
 At least one offspring from each timed-pregnant C57BL/6J mice was sacrificed 
for tissue collection at ages 2, 10, 21, 42, and 70 days. Each age group contained at least 
six animals, both males, and females. Euthanasia was performed with CO2 and cervical 
dislocation in all age groups except mice at ages 2 and 10 days, which were sacrificed by 
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decapitation. The animal protocol was approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Tennessee Health Science Center. All organs 
including skin, liver, kidneys, lung, spleen, heart, stomach, intestine, and pancreas were 
collected and preserved on ice. Blood was removed from all the organs using ice-cold 
phosphate-buffered saline (PBS). All organs were subsequently stored at -70?C until 
further processing. 
 
 
Tissue Lysate and Total Protein Extract Preparation 
 
 Total protein extract from each organ was prepared using a commercial total 
protein extraction kit (Millipore, Billerica, MA). A 20 ? 40-mg sample of tissue was 
excised from the whole organ and chopped into very small pieces. The tissue was then 
added into Eppendorf tubes containing 1×PI (a cocktail of protease inhibitor) in TM 
buffer (mixture of HEPES (pH 7.9), MgCl2, KCl, EDTA, sucrose, glycerol, sodium 
deoxycholate, NP-40, sodium ortho-vanadate) at a gram of tissue per 2.5 mL solution, 
and were kept on ice for at least 5 minutes. The tissue was subsequently homogenized 
using a micro-homogenizer (Bio-Gen PRO200 model from Pro Scientific, Oxford, CT) at 
a minimum speed of 3 - 5 cycles of alternate homogenizing and resting on ice to 
minimize protein destruction. The tissue homogenate was rotated at 4?C for 20 minutes. 
Subsequently, the tissue lysate was centrifuged at 11,000 rpm at 4?C for 20 minutes. The 
supernatant was subsequently collected and stored at -20?C for further analysis. 
 
 
Protein Quantification 
 
 Total protein in the supernatant from all samples was quantified by using the 
BCA protein assay kit (Novagen®, Billerica, MA). Different concentrations (0 ? 1000 
?g/mL) of bovine serum albumin (BSA) were prepared for a calibration curve. 25 ?L of 
each BSA standard and protein sample were mixed with 200 ?L BCA working reagent (a 
mixture of BCA solution and 4% cupric sulfate) on a 96-well plate. The mixture was then 
incubated at 60?C for 15 minutes before cooling to room temperature. The absorbance at 
562 nm was measured on a plate reader (Beckman Coulter DTX880). The protein amount 
in the samples was determined based on the calibration curve of BSA. 
 
 
Electrophoresis 
 
 Proteins in the isolated extracts were separated by gel electrophoresis. The 
electrophoresis was run for 90 minutes on ice in an XCell SureLockTM Mini-Cell 
(Invitrogen, Carlsbad, CA) system containing NUPAGE® MOPS SDS running buffer 
(Invitrogen, Carlsbad, CA) and 500 ?L of NUPAGE® antioxidant (Invitrogen, Carlsbad, 
CA). The samples loaded on each gel comprise the following: 
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- Protein molecular weight markers: 5 ?L of MagicMarkTM XP (Invitrogen, 
Carlsbad, CA) + 5 ?L of Novex® Sharp pre-stained protein standards 
(Invitrogen, Carlsbad, CA) 
- Positive control: 25 ng of recombinant mouse FcRn (R&D Systems) + 1.5 ?L of 
10× NUPAGE® sample reducing agent (Invitrogen) + 3.75 ?L of 4× NUPAGE® 
LDS sample buffer (Invitrogen) 
- Negative control: 18 ?g of bovine serum albumin + 1.5 ?L of 10× NUPAGE® 
sample reducing agent (Invitrogen) + 3.75 ?L of 4× NUPAGE® LDS sample 
buffer (Invitrogen) 
- Unknown specimens: 20 and 40 ?g of total protein extract from each organ in 
each age group + 1.5 ?L of 10× NUPAGE® sample reducing agent (Invitrogen, 
Carlsbad, CA) + 3.75 ?L of 4× NUPAGE® LDS sample buffer (Invitrogen, 
Carlsbad, CA) 
 
The positive control, negative control, and unknown specimens were heated in a 
water bath at 70?C for 10 minutes before loading into 4 ? 12% NUPAGE® bis-tris gels 
(Invitrogen, Carlsbad, CA). The electrophoresis condition was set to 150 V constant 
voltage with maximum current of 0.13 A. 
 
 
Western Blot 
 
 After electrophoresis, separated proteins were transferred for 2 hours 15 minutes 
onto an Immobilon®-FL polyvinylidene fluoride (PVDF) 0.45 ?m membrane (EMD 
Millipore, Billerica, MA) at 25 V and 0.17 A. The PVDF membrane was first pre-wetted 
in methanol for 1 minute and then rinsed with ultra-purified water followed by soaking in 
a mixture of NUPAGE® transfer buffer (Invitrogen, Carlsbad, CA) containing 20% 
methanol and NUPAGE® antioxidant (Invitrogen, Carlsbad, CA). The transfer process 
was run on ice in the XCell IITM Blot Module (Invitrogen, Carlsbad, CA) system that 
contained a mixture of NUPAGE® transfer buffer that was used to equilibrate the PVDF 
membrane. 
 
 The protein-transferred PVDF membrane was re-wetted for 1 minute in methanol, 
rinsed with ultra-purified water, and soaked in 1×PBS for 2 minutes. To prevent 
nonspecific binding of primary antibodies, the membrane was incubated in the Odyssey® 
blocking buffer (LI-COR, Lincoln, NE) for 1 hour at room temperature. An overnight 
incubation at 4?C was subsequently carried out in a mixture of 1:2000 goat anti-mouse 
FcRn polyclonal antibody (R&D Systems, Minneapolis, MN) and 1:10000 rabbit anti-
mouse GAPDH monoclonal antibody (Cell Signaling, Beverly, MA) that was prepared in 
the Odyssey® blocking buffer containing 0.2%Tween 20. Protein transferred PVDF 
membrane was then rinsed and washed with 0.1% Tween 20 in PBS for four times,five 
minutes each. The incubation with a mixture of secondary antibodies in Odyssey® 
blocking buffer containing 0.2% Tween 20 and 0.01% sodium dodecyl sulfate (SDS) was 
subsequently performed for 1 hour at room temperature under light protection. The 
secondary antibodies in a mixture comprised 1:15000 donkey anti-goat IRDye® 800CW 
IgG (LI-COR, Lincoln, NE) and 1:15000 donkey anti-rabbit IRDye® 680RD IgG (LI-
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COR, Lincoln, NE). After the incubation, rinsing and 5 minutes washing of the blot were 
completed for 4 times prior to rinsing with 1×PBS. Protein bands on the blot were 
detected and the intensity quantified by the Odyssey®Sa Infrared Imaging System (LI-
COR, Lincoln, NE). 
 
 
Data Analysis 
 
 FcRn expression was determined by the relative intensity of GAPDH band in the 
same sample. Within each individual sample set (20 and 40 ?g loading), average relative 
expression of FcRn in each organ was compared across age groups by analysis of 
covariance (ANCOVA). Multiple comparisons with Bonferroni adjustment were 
performed to determine the difference of relative FcRn expression during development. 
Statistical analysis was performed in SAS 9.3 (SAS Institute Inc.). The difference in the 
relative FcRn expression between males and females in each age group was evaluated by 
t-test with unequal sample size. 
 
 
Results 
 
Relative FcRn protein expression in mouse organs was quantified by 
normalization of FcRn expression to the expression of the reference protein GAPDH 
within the same sample. The relative expression of FcRn protein was compared across 2, 
10, 21, 42, and 70 day old mice. The Western blot scans of FcRn and GAPDH protein 
expression in mouse skin, liver, kidney, lung, and spleen from two sample sets (20 ?g 
and 40 ?g loading) are shown in Figure 4-2. The rationale for using two protein loading 
amounts was to assure that FcRn could be detected and quantified across all age groups 
since analytical sensitivity might be a problem with the down-regulation of FcRn. 
However, the results revealed that detection sensitivity was not an issue and FcRn in all 
age groups could be detected and quantified in both sample sets. Nevertheless, due to the 
limitations of protein abundance and the size of the organ, the 40-?g loading amount 
could not be performed in spleen samples from 2 day old mice. 
 
Under reducing conditions of electrophoresis, native FcRn proteins in mouse 
tissues were detected at 45 ? 55 kDa whereas recombinant mouse FcRn, a positive 
control, was consistently detected at a molecular weight ? 45 ? 47 kDa. This observation 
could be explained by the fact that the recombinant protein was synthesized as Ser22 ? 
Val301 with no attached ?2m subunit. Moreover, additional modifications, such as a C-
terminal 6-His tag, may contribute to the observed difference in the molecular weight. In 
contrast to other mouse organs, the Western blot scans showed double bands of FcRn 
protein at 45 ? 55 kDa in mouse liver samples (Figure 4-2B). Broad bands of FcRn were 
observed in the range of 45 ? 55 kDa in some samples, especially those from liver and 
kidney. In addition, an extra band at the molecular weight ? 140 - 150 kDa was always 
present in mouse liver samples, which may be the result of the complex formation of 
FcRn monomers. Alternatively, cross-reactivity of the primary antibody with another  
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Figure 4-2. Western blot scan of FcRn and GAPDH protein expression in mouse 
skin (A), liver (B), kidney (C), lung (D), and spleen (E). 
FcRn expression was quantified relative to GAPDH expression. The expression of FcRn 
was compared across all age groups within each loading sample set (20 ?g and 40 ?g 
loading amount) in each organ. 
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protein might have occurred. Due to this uncertainty, the relative expression of FcRn 
protein in mouse liver was quantitated based on the FcRn monomer at molecular weight 
45 - 55 kDa and compared across all age groups. 
 
Since there was no limitation of analytical sensitivity from loading protein at 20 
?g but the scarcity of protein abundant arose from loading protein at 40 ?g of spleen 
sample obtained from 2 day old mice, the results focused on the 20-?g loading sample 
set. The quantitation results of FcRn protein relative to GAPDH protein expression from 
the 20-?g loading samples are presented in Figures 4-3 to 4-7 while the results of the 40-
?g loading compared to those of the 20-?g loading are available in the Appendix B 
section (Figures B-1 to B-5). Notably, there was a statistically significant difference 
between the relative amounts of FcRn protein expression in the 20-?g and 40-?g loading 
sample sets (p < 0.05). The relative FcRn expression was consistently higher in the 40-?g 
loading sample set than in the 20-?g loading sample set. Nevertheless, FcRn expression 
across all age groups showed the same pattern between two loading sample sets. As a 
result, the relative FcRn protein expression was compared among all age groups within 
each loading sample set. 
 
In mouse skin, relative FcRn protein expression was not different among the 
investigated age groups, although the power to detect a difference was diminished due to 
lower than expected animal numbers in three age groups (Figure 4-3). 
 
In mouse spleen (Figure 4-7), relative FcRn protein expression was also not 
statistically significantly different among the investigated age groups. Notably, the high 
variation observed in the relative FcRn protein expressions obtained from day 2 and day 
10 animals may hinder the detection of significant difference. 
 
In mouse liver; however, the relative FcRn protein expression significantly 
increased approximately two-fold at day 10 compared to other age groups (Figure 4-4). 
The other age groups seemed to express similar levels of FcRn proteins. 
 
The two-fold increase of relative FcRn protein expression in 10-day old mice was 
also observed in mouse lung compared to 2- and 70- day old groups (Figure 4-6). Thus, 
for mouse lung, relative expression was similar in newborn and in adult animals but was 
approximately two-fold higher in 10-day old animals. 
 
In mouse kidney, similar levels of relative FcRn protein expression was observed 
between 10- and 42-day old age groups. However, these two groups showed a two-fold 
increase in relative FcRn protein expression compared to other age groups (Figure 4-5). 
 
The difference in the relative FcRn protein expression was also compared 
between males and females within each age group. The results of this analysis, however, 
showed that there was no significant sex difference in relative FcRn protein expression in 
any age group or tissue (Figure 4-8). 
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Figure 4-3. Ontogeny of FcRn protein expression in mouse skin 
No significant difference in the relative FcRn protein expression was observed in the skin 
of 2-, 10-, 21-, 42-, and 70-day old mice. 
 
 
 
 
 
 
Figure 4-4. Ontogeny of FcRn protein expression in mouse liver 
Relative expression of FcRn protein in mouse liver was significantly increased in 10-day 
old mice compared to other age groups. The p-values are reported above the lines 
associated with each paired comparison. 
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Figure 4-5. Ontogeny of FcRn protein expression in mouse kidney 
Relative expression of FcRn protein in mouse kidney was significantly increased in 10- 
and 42-day old mice compared to other age groups. The p-values are reported above the 
lines associated with each paired comparison. 
 
 
 
 
 
 
Figure 4-6. Ontogeny of FcRn protein expression in mouse lung 
Relative expression of FcRn protein in mouse lung was significantly increased in 10-day 
old mice compared to 2- and 70-day old animals. The p-values are reported above the 
lines associated with each paired comparison. 
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Figure 4-7. Ontogeny of FcRn protein expression in mouse spleen 
There was no significant difference in the relative expression of FcRn protein in mouse 
spleen across age groups. 
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Figure 4-8. Sex-specific relative FcRn protein expression during postnatal 
development in mouse skin, liver, kidney, lung, and spleen 
There was no significant difference in FcRn protein expression between males and 
females during development in mouse skin (A), liver (B), kidney (C), lung (D), and 
spleen (E). 
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Unfortunately, the difference in the relative quantitation of FcRn expression 
across various mouse tissues within each age group could not be determined due to the 
preliminary results that showed the different levels of GAPDH protein expression across 
the tissue observed in a 70-day old mouse (Figure B-6). 
 
 
Discussion 
 
 Western blotting successfully determined the protein expression of FcRn relative 
to GAPDH in all organs and tissue samples. Under the reducing conditions of 
electrophoresis, double bands and broad bands of FcRn protein were observed at the 
molecular weight ? 45 ? 55 kDa in mouse liver samples. FcRn protein also produced 
broad bands in this molecular weight range in mouse kidney samples. This observation 
was not surprising, however, as detection of FcRn protein expression as double bands or 
broad bands hasbeen observed in other studies in rat small intestine and hepatocytes [61-
63, 75, 76]. The broad band of FcRn protein expression was also detected in human 
glomerular extract [71]. The double bands and broad bands at 45 ? 55 kDa may indicate 
various degrees of posttranslational modification of the FcRn receptor, such as 
glycosylation [62, 72, 75]. N-linked oligosaccharides were also shown to significantly 
contribute to the heterogeneity in molecular size of the IgE receptor that resulted in 
diffuse bands in the 45 ? 62 kDa region [90]. In addition, dimerization of FcRn seemed to 
exist, as FcRn proteins from mouse liver could be detected at the molecular weight ? 140 
? 150 kDa. FcRn protein dimers were also observed in another study, but the molecular 
weight was described as 110 kDa [75]. 
 
 According to the Western blot results, FcRn may be presented in various 
glycosylated species in some mouse organs such as liver and kidney. Moreover, the 
dimerization of FcRn may be more frequent in mouse liver since the bands related to 
FcRn dimers (? 140 ? 150 kDa) were very apparent even under the reducing condition of 
electrophoresis. Interestingly, the degree of dimerization seemed to show an ontogenic 
pattern with the lowest (? 10%) observed in 10-day-old mice (p < 0.005 compared to 21- 
and 70-day old groups; Table B-1). The maximal level of FcRn dimers was reached at 
21-day-old (? 30%) and was constantly expressed later on in 42- and 70-day-old mice. 
Comparison of age-dependent expression of FcRn in mouse liver between FcRn 
monomers and total FcRn proteins (a mixture of monomers and dimers) across all age 
groups showed a similar pattern. However, a less-pronounced effect of ontogeny was 
observed when total FcRn protein expression was taken into account, resulting in a 
significant difference in total FcRn expression only between day 2 and day 10 age groups 
(p < 0.005; Figure B-7). 
 
 The current analysis assumed that FcRn was uniformly distributed throughout the 
organs and tissues. However, uneven FcRn mRNA and protein expressions have been 
reported in rat small intestine, with maximal expression in the proximal duodenum region 
and a gradual decline toward the distal small intestine [66, 74-76, 79, 91, 92]. This 
differential distribution of FcRn along the intestine may contribute to the negligible 
amount of immunoglobulin absorption in the distal small intestine [61, 79, 91-94]. A 
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differential distribution of FcRn also appears in the kidney, as high expression of FcRn 
was observed with a proximal to the distal gradient in the renal tubular system [66]. 
Moreover, the white pulp of the spleen was devoid of FcRn expression, whereas strong 
expression was detected in the sinusoids of splenic red pulp [66]. The regional variability 
of FcRn expression in organs may due to the differential distribution of endothelial cells 
in the organs and may be one of the factors that contributed to the variability of relative 
FcRn expression on the Western blots. If possible, these factors should be taken into 
account in the future studies. 
 
 The ontogeny of FcRn expression was investigated with C57BL/6J mice as a 
surrogate animal for the ontogeny of human FcRn. Animals of 2-, 10-, 21-, 42-, and 70-
day postnatal age were selected as representative age groups for neonates, infants, 
children, adolescents, and adults. Our results showed a two-fold increase in relative 
expression of FcRn in liver and lung of 10-day old mice compared to neonates and adults. 
Similarly, relative expression of FcRn was doubled in the kidneys of 10- and 42-day-old 
mice. However, the ontogeny of FcRn expression did not seem to exist in mouse skin and 
spleen. These results suggested an organ-specific developmental expression of FcRn. 
These organ-specific developmental patterns of expression of FcRn are consistent with 
the observation of the different patterns of developmental FcRn expression in intestine 
and brain capillaries [74-76, 81]. Downregulation of FcRn expression during 
development is observed in mouse intestine [74-76], whereas upregulation occurs during 
aging in brain capillaries [81]. 
 
 Relative FcRn expression in liver and lungs showed ontogenic development with 
low expression at birth, peak expression at 10 days, and diminishing expression to adult 
levels around weaning age (21 days). This developmental FcRn expression exhibits a 
similar pattern as in rat intestine [74-76]. The maximal level of duodenal FcRn mRNA 
expression exists between 1 and 19 days of age, but is undetectable during fetal life, at 
birth, and after weaning [74]. FcRn protein expression is also shown to disappear from 
the proximal small intestine of 23-day-old rats (weaning age) [75]. Thus, concordance 
between transcription and translation (i.e. mRNA vs. protein expression) seems to exist 
for this salvage receptor. 
 
 FcRn seems to have distinctive expression patterns in different species. Unlike in 
rodents, FcRn is also expressed in human fetal stomach and colon [78]. Moreover, the 
differential FcRn expression along the intestine in rodents does not seem to exist in 
humans [78]. In contrast, another study reported an increasing proximal-distal gradient of 
mucosal FcRn mRNA and protein expression in the adult human intestine, which 
translated to higher serum mAb levels after ileum-proximal colon infusion than after 
administration to the stomach or proximal small intestine [79]. The difference between 
these studies may be due to the ontogenic effect on the differential FcRn expression 
pattern along the intestine with the insignificant differential distribution of FcRn in the 
human fetus, but an increasing proximal-distal gradient observed in the adult human 
intestinal mucosa. The age-dependent expression of FcRn in human intestine and colon 
seems to show the reverse direction compared to rodents. Upregulation of FcRn 
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expression is observed in the small intestine as well as the colon in older child and 
adolescents compared to younger children [78]. 
 
 The variability in the FcRn expression pattern in various mouse organs during 
development might indicate a complex regulatory system that controls the expression of 
this receptor. A possible factor that regulates developmental expression of FcRn may be 
Fcgrt transcription [95]. The selective temporal and spatial availability of specific 
transcription factors within the Fcgrt proximal promoter region may contribute to the 
developmental and tissue-specific regulation of Fcgrt expression, which can be observed 
as different age-dependent expression patterns of FcRn in different mouse organs. 
Although exogenous corticosteroids and thyroid hormone can downregulate FcRn 
expression, the endogenous forms of adrenal corticosteroids are assumed to not play a 
significant role in regulating the programmed pattern of FcRn expression [96]. 
 
 Unfortunately, the level of FcRn protein expression could not be compared across 
various tissues within each age group of C57BL/6J mice. This was due to the observed 
inconsistent expression level of GAPDH that was used as a reference protein in various 
tissues. GAPDH has been reported as an inappropriate housekeeping gene for relative 
quantitation using RT-PCR or northern blot in, due to variation in expression in various 
mouse tissues [97]. However, different levels of endothelial cells expressed across 
various organs may result in the variation of FcRn expression in various mouse tissues. 
 
 A correlation between the ontogenic pattern of FcRn mRNA expression and IgG 
absorption has been described [74]. Postnatal absorption of IgG via FcRn is limited to the 
suckling phase in rodents and abruptly decreases at weaning [74, 94]. This alteration 
coincides with a significant induction of FcRn mRNA expression during the first day of 
life and a substantial decline in expression at the age of weaning [74]. Thus, the 
developmental alterations in the relative expression of FcRn may have an impact on the 
pharmacokinetics of therapeutic proteins that bind to this receptor. A prolonged half-life 
might be observed during the ages of high expression if liver, lung, and/or kidneys are the 
major organs of drug disposition. However, the endothelial cells in skin, muscle, and 
liver, along with the hematopoietic cells, have been shown to be the primary sites of 
functional FcRn expression in adult mice. This may indicate that these organs are the 
major sites of serum IgG homeostasis [68]. The primary sites of FcRn that are 
responsible for maintaining the IgG levels in adult mice have been shown to be 
endothelial cells and hematopoietic cells [89]. Moreover, based on physiologically based 
pharmacokinetic modeling, the contribution of various organs to the elimination of 
endogenous IgG was estimated to be 33%, 24%, 16%, and 12% for skin, muscle, liver 
and gut tissue, respectively [4]. Consequently, the ontogenic patterns of FcRn expression 
observed in mouse liver, kidney, and lung might not have a significant impact on the 
pharmacokinetics of therapeutic proteins that can bind to this salvage receptor. To further 
elucidate this question, a pharmacokinetic study using a therapeutic protein with its 
disposition largely affected by FcRn in different age groups of mice is needed. This 
pharmacokinetic study was performed and the results are reported and discussed in the 
next chapter. 
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CHAPTER 5.    PHARMACOKINETICS OF A HUMAN MONOCLONAL 
ANTIBODY DURING THE POSTNATAL DEVELOPMENT PROCESS IN MICE 
 
 
Introduction 
 
 In recent years, there is an increasing number of antibody-based therapeutic 
proteins have been approved for pediatric use, spanning from intact mAbs to IgG Fc-
fusion proteins. However, the application of therapeutic proteins in pediatrics has often 
been based on the extrapolation of clinical findings from adults. This is frequently due to 
the lack of evidence of the efficacy and safety in pediatric populations, the difficulties in 
conducting pediatric clinical trials, a lack of financial incentives, and no mandatory 
regulatory requirements for pediatric development in the past [8, 26]. Although 
extrapolation may be useful when lacking pediatric data, this approach may significantly 
compromise the prediction of efficacy and safety in pediatric patients if the dissimilarities 
between children and adults are not well understood. Thus, the rational application of 
therapeutic mAbs in children requires a fundamental understanding of the similarities and 
differences in disease pathophysiology, pharmacokinetics, and pharmacodynamics 
(PK/PD) between children and adults, and informative clinical trials to define the optimal 
dosage regimens for children and evidence-based pediatric treatment guidelines. 
 
 As a first step toward achieving a better understanding of the pharmacokinetics of 
therapeutic mAbs in growth and maturation, the pharmacokinetics of AMG589, a fully-
human mAb, was studied in various age groups of C57BL/6J mice. AMG589 was in this 
context solely used as a model compound for a mAb and does not bind to a specific target 
in mice. The effect of several factors, including weight and age, were explored and 
evaluated in this study to determine their impact on the pharmacokinetics of mAbs during 
postnatal development in mice. Due to the rapid growth of mice during the early phase of 
their development relative to the long half-life of mAbs, body size measures such as 
weight are expected to be the major factor that affects the pharmacokinetics of AMG589. 
Because of the significant influence of FcRn on the half-life of mAbs, the effect of 
developmental changes in FcRn expression level in various organs on the 
pharmacokinetics of AMG589 is one potential covariate affecting mAb disposition and 
was investigated across all age groups of mice. Other factors that needed to be considered 
are the promiscuity in the binding of mouse FcRn to human IgG and potential 
immunogenic events, such as the formation of anti-drug antibodies that might occur 
during the study. 
 
 The results of the relative quantification of FcRn expression in various organs of 
2, 10, 21, 42, and 70 day old C57BL/6J mice as described in Chapter 4 showed no 
difference in the relative FcRn protein expression across age groups in skin and spleen. 
However, the relative FcRn protein expression exhibited organ-specific ontogenic 
patterns in liver, lung, and kidney. Two-fold increases in FcRn expression were observed 
in liver and lung of 10-day old mice, whereas FcRn expression in kidney showed two-
fold increases in 10 and 42 day old mice. This organ-specific pattern in the ontogeny of 
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FcRn expression may have an effect on the pharmacokinetics of AMG589 in the 
contribution of the organ to the overall clearance of mAbs. 
 
 The skin has been shown to contribute most to the homeostasis and the 
elimination of IgG [68]. Recent reports suggest FcRn may play a role in subcutaneous 
absorption and degradation of mAbs [55]. Although the presence of FcRn in 
subcutaneous tissue has not been reported beyond endothelial and some immune cells, 
FcRn expression has been detected in the epidermis, dermis, and skeletal muscle. 
Because quantitation of FcRn expression in skin in Chapter 4 did not reveal any 
ontogenic pattern, the pharmacokinetics of AMG589 should not be affected by FcRn 
expression in the skin across age groups. 
 
 FcRn expression in bronchial and/or alveolar epithelial cells has been shown to 
enhance the pulmonary absorption of IgG and Fc-fusion proteins [55]. However, 
AMG589 was administered via a subcutaneous route in this study. Thus, intuitively, the 
increased expression of FcRn in the lungs of 10 days old C57BL/6J mice should not have 
any influence on the pharmacokinetics of AMG589 in this study if the lungs are not a 
major elimination organ for IgG. 
 
 FcRn has been shown to facilitate transport of IgG across both the glomerular and 
proximal tubule membranes. This provides an efficient recycling mechanism that 
prevents accumulation of IgG along the podocyte slit diaphragms [55]. However, the 
renal impairment has minor or no effect on the systemic clearance of therapeutic mAbs 
[55, 98]. Thus increasing FcRn expression in the kidneys of 10- and 42-day-old mice may 
not render any effect on the pharmacokinetics of AMG589. 
 
 Based on the current evidence in the literature and the results of the ontogeny of 
FcRn expression in Chapter 4, we hypothesized that the pharmacokinetics of AMG589 
in different age groups of C57BL/6J mice would not be affected by the organ-specific 
ontogenic patterns of FcRn expression observed in mouse liver, lung, and kidney after 
accounting for the alteration in body size during postnatal development. To test this 
hypothesis, a population pharmacokinetic analysis approach was used to delineate the 
factors that influence the pharmacokinetics of AMG589 during the development of 
C57BL/6J mice. 
 
 
Method 
 
 
Animals 
 
 Nine timed-pregnant C57BL/6J mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME) and were shipped to arrive on day 13 of gestation. All 
timed-pregnant mice were housed with free access to food and water in the animal 
facility at the University of Tennessee Health Science Center for 1 week. The day of birth 
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of the offspring was assigned as their first day of life (day 1). The offsprings were raised 
to pre-determined postnatal ages including 2, 10, and 21 days. All pups were weaned at 
21 days. Male and female pups were separately housed in different cages at weaning. 
 
 Due to one mouse not being pregnant, only ten 21 day old mice were available. 
However, at least 18 mice in each age group were needed for the pharmacokinetic study 
in order to get at least three mice at each blood sampling point. As a result, eight 
additional 21 day old C57BL/6J mice (4 males and 4 females) were purchased from The 
Jackson Laboratory (Bar Harbor, ME). For the 42 and 70 day old groups, nine male and 
nine female C57BL/6J mice of each age group were also purchased from The Jackson 
Laboratory (Bar Harbor, ME). All animals were housed in standard laboratory cages 
throughout the study. The study was conducted according to the guidelines of the Animal 
Welfare Act and the Public Health Service Policy on Humane Care and Use of 
Laboratory Animals, and the protocol was approved by the Institutional Animal Care and 
Use Committee of the University of Tennessee Health Science Center. The number of 
animals in each age group and their demographic characteristics are shown in Table 5-1. 
 
 
Pharmacokinetic Study 
 
 AMG 589, a fully-human monoclonal antibody, was kindly provided by Amgen 
Inc. (Thousand Oaks, CA) and was used as a model drug for studying the 
pharmacokinetics in different age groups of mice. AMG 589 was subcutaneously 
administered at 39 mg/kg in 2 day old mice and at 50 mg/kg in 10, 21, 42, and 70 day old 
C57BL/6J mice. Blood was collected by cardiac puncture from 3 or 4 mice in each age 
group at 2, 24, 72, 168, 336, and 504 hours post-dose, except 42 day old mice, in which 3 
mice were sacrificed at 2, 24, 96, 168, 336, and 504 hours post-dose. All dosing and 
blood sampling schemes are shown in Table 5-2. Blood was kept in BD Vacutainer® Plus 
plastic serum tubes with additive clot activator and gel for serum separation (Franklin 
Lakes, NJ). Serum was separated by centrifugation for 16 minutes at 2500 × g at 4?C. All 
mouse serum samples were subsequently stored at -70?C before shipping to Amgen Inc. 
(Thousand Oaks, CA) for further analysis. 
 
 
Quantification of AMG589 in Mouse Serum Samples 
 
 Courtesy of Amgen Inc (Thousand Oaks, CA), all mouse serum samples from the 
pharmacokinetic study were quantified for AMG589 using ELISA according to the 
company protocol. The variability of the assay was about 15%. The calibration range of 
the assay was 10 ? 10,000 ng/mL, and LLOQ was 10 ng/mL. Due to the limited volume 
of serum acquired from one animal of the 2-day group at the 2-hour sampling time, only 
two samples were quantified at this time point. 
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Table 5-1. Demographic characteristics of C57BL/6J mice included in the 
pharmacokinetic study of AMG 589 
 
Characteristics Average weight (g) (Range) Number of animals 
Day 2a 
Day 10 
    Male 
    Female 
Day 21 
    Male 
    Female 
Day 42 
    Male 
    Female 
Day 70 
    Male 
    Female 
0.9 (0.9 ? 0.9) 
 
3.6 (2.9 ? 4.3) 
3.6 (3.0 ? 4.9) 
 
10.7 (2.5 ? 16.1) 
9.6 (6.4 ? 14.0) 
 
15.6 (13.0 ? 19.0) 
12.7 (11.0 ? 15.0) 
 
19.4 (16.3 ? 23.5) 
15.1 (11.0 ? 18.0) 
20 
 
8 
11 
 
8 
10 
 
9 
9 
 
9 
9 
 
a Based on mouse anatomy, sex determination was not possible in the day 2 age group. 
 
 
 
 
Table 5-2. Dosing and blood collection scheme for the pharmacokinetic study of 
AMG589 in different age groups of C57BL/6J mice 
 
Age at 
dosing 
(days) 
Dose 
(mg/kg) 
Total 
number 
of mice 
Number of mice at each sampling time point 
2 h 24 h 72 h/ 
96 h 
168 h 336 h 650 h 
2 39 20 3 1 M 
2 F 
2 M 
1 F 
1 M 
2 F 
2 M 
2 F 
3 M 
1 F 
10 50 19 1 M 
2 F 
1 M 
2 F 
1 M 
2 F 
2 M 
1 F 
1 M 
2 F 
2 M 
2 F 
21 50 18 2 M 
1 F 
1 M 
2 F 
1 M 
2 F 
2 M 
1 F 
1 M 
2 F 
1 M 
2 F 
42a 50 18 1 M 
2 F 
2 M 
1 F 
1 Ma 
2 Fa 
2 M 
1 F 
1 M 
2 F 
2 M 
1 F 
70 50 18 2 M 
1 F 
1 M 
2 F 
2 M 
1 F 
1 M 
2 F 
2 M 
1 F 
1 M 
2 F 
 
Note: M and F represent male and female, respectively. 
a 42 day old mice were sacrificed at 96 hours instead of 72 hours after dosing. 
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Pharmacokinetic Data Analysis 
 
 The full dataset contained one observation from each mouse at each sampling 
time point. Due to insufficient serum obtained from one mouse in the day 2 age group, 92 
observations were obtained in total. The sex of the mice in the 2 days old age group could 
not be identified at the 2-hour sampling time point. In this case, all animals in this group 
and time point were assigned to be male in the dataset. Weights of male and female mice 
in each age group at the time of dosing were imputed for each data record before data 
analysis. 
 
In an exploratory data analysis that plotted the serum concentration-time profiles 
of AMG589 in different age groups of C57BL/6J mice, high variation at 24 hours in 42 
day old mice (RSD ~87%) may have been caused by experimental error. Thus, two 
datasets were created?one with and one without these questionable data points. The 
dataset that excluded serum concentrations of AMG589 at the 24-hour time point was 
first analyzed and used for population model building. The full dataset that included the 
serum concentrations of AMG589 at the 24-hour sampling time was then subsequently 
analyzed with the same modeling approach as that used for the first data set. 
 
 
Non-Compartmental Analysis 
 
 A non-compartmental pharmacokinetic analysis of the concentration-time data 
was performed using PhoenixTM WinNonlin® version 6.3. By this approach, the 
pharmacokinetic profiles of AMG589 were separately analyzed according to age group 
with uniform weighing in the two datasets--the one excluding serum concentration-time 
profile of AMG589 at the 24-hour time point and the full dataset. 
 
 
Population Pharmacokinetic Analysis 
 
To explore covariates  that may affect the pharmacokinetics of AMG589 in 
different age groups of C57BL/6J mice, a population pharmacokinetic approach using 
nonlinear mixed effects modeling was applied using NONMEM software version 7.2 
(ICON Development Solutions, Hanover, MD) with the Pirana version 2.9.0 platform 
(®Pirana Software & Consulting BV, http://www.pirana-software.com). R (The R 
Foundation for Statistical Computing) with Xpose and ggplot2 packages was used within 
Pirana version 2.9.0 for graphical visualization of the results [99]. The effects of body 
weight, age, and FcRn expression on the pharmacokinetics of AMG589 in different age 
groups of C57BL/6J mice were explored. The population pharmacokinetic model was 
developed using the dataset that excluded serum concentration-time data of AMG589 in 
C7BL/6J mice at the 24-hour time point. The final model was then applied to the full 
dataset. 
 
 Based on the serum concentration-time profiles of AMG589 in different age 
groups of C57BL/6J mice that exhibited a single phase of distribution and elimination, 
 
 
65 
 
along with the information that subcutaneous injection was the route of administration for 
AMG589, a one-compartment linear model with first-order absorption was chosen to 
build the structural model. The FOCE method within NONMEM was used throughout 
the model-building process. 
 
 Between-subject variability (?) for AMG589 pharmacokinetic parameters was 
assumed to follow a log-normal distribution with zero mean and variance ?2. Thus, an 
exponential error model was applied for the estimation of ? (Equation 5-1). A 
proportional error model was applied for the estimation of the residual error (?ij) that was 
assumed to be normally distributed with zero mean and variance ?2 (Equation 5-2). The 
choice of the proportional residual error model is supported by the fact that all measured 
serum concentrations were far larger than the lower limit of quantification of the assay. 
 
?? ? ?? ???? 
(Eq. 5-1) 
 
???????????? ? ???? ???????? ?? ?? ?????? 
(Eq. 5-2) 
 
 The covariate effect was then explored and subsequently added to the structural 
model. Pharmacokinetic parameters such as clearance (CL) and volume of distribution 
(V) are usually functions of body size; thus the effect of body size can overlay and may 
potentially mask the effect of other covariates. To identify covariates other than body 
size, these pharmacokinetic parameters should first be adjusted to an appropriate body 
size measure [100]. According to this consideration, body weight was the first covariate 
incorporated into the structural model by the widely used allometric scaling approach [8, 
100]. After accounting for the body size effect, other covariates such as age and FcRn 
expression were subsequently evaluated. 
 
 Rapid growth during the first phase of development in the C57BL/6J mice 
resulted in great relative changes in body weight throughout the sampling period, which 
potentially had an impact on the pharmacokinetics of AMG589 during the study period. 
As a result, mouse body weight was incorporated in the structural model with 
consideration of the incremental changes in mouse body weight during development. The 
first step was to explore the growth pattern of C57BL/6J mice by plotting the mean body 
weights of male and female mice against age at the time of dosing from each studied age 
group (Figure 5-1) and comparing them with the reported growth curves for C57BL/6J 
mice. The mean body weights of male and female mice at various time points were then 
derived from Equation 5-3. 
 
??? ? ???? ?
???? ?? ??????
?????
? ????????
 
(Eq. 5-3) 
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Figure 5-1. Growth curves of male and female C57BL/6J mice 
Comparison of the actual growth curves of male and female C57BL/6J mice in the study 
and the growth curves of male and female C57BL/6J mice obtained from information at 
Jackson Laboratories 
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 BWP is the predicted body weight (g) of male or female C57BL/6J mice at 
various time points during the study period, 0.9 is the mean body weight (g) of 2 day old 
C57BL/6J mice in the study, Wmax is the maximal body weight (g) of the male or female 
C57BL/6J mice presented in the growth curve, Age is the age of mice (days) at individual 
time points, N is the sex-specific hill coefficient that describes the growth curve of male 
or female C57BL/6J mice in the study, and Age50 is the age of male or female mice 
(days) at which they reach 50% of maximal body weight. 
 
 Age (days), which represents the age of C57BL/6J mice at individual time points, 
can be estimated from the age at dosing or AAD (days) and time after dosing, TAD 
(days), as shown in Equation 5-4. 
 
Age = (AAD) + TAD 
(Eq. 5-4) 
 
 When comparing the growth curves of C57BL/6J mice in this study to those of 
the same mouse species from the Jackson Laboratories, there was some deviation (Figure 
5-1). To account for this deviation, nominal body weights of male and female mice at the 
time of dosing were first determined from the growth curve by Equation 5-5 (similar to 
Equation 5-3). 
 
????? ? ???? ?
???? ?? ????
?????
? ??????
 
(Eq. 5-5) 
 
 By replacing the age of mice (days) at individual time points with the age of mice 
at the time of dosing (days), nominal body weights (g) of male and female C57BL/6J 
mice at the age of dosing can be determined from the growth curve. A multiplier, or 
correction factor (F), to account for the differences between nominal and actual body 
weights, was defined by dividing the actual body weight (Wt) of male and female mice at 
the time of dosing with the corresponding nominal body weight at the age of dosing, 
BWAAD (Equation 5-6). The sex-specific multiplier (F) was then used to adjust the 
predicted body weights of male and female mice (BW) for their actual body weight at the 
time of dosing (Equation 5-7). 
? ? ?
??
?????
 
(Eq. 5-6) 
 
?? ? ?? ?????? 
(Eq. 5-7) 
 
The body weight (BW) was subsequently incorporated into the structural model 
by the allometric scaling approach using Equation 5-8. 
 
 
 
68 
 
? ? ??? ???
??
?????
?
?
 
(Eq. 5-8) 
 
 P is the pharmacokinetic parameter that represents clearance (CL), or volume of 
distribution (V). ?? is the typical value of each pharmacokinetic parameter. BW is the 
predicted mouse body weight at various time points, and BW70d is the average body 
weight in g of a 70 day old male C57BL/6J mouse. b is the allometric exponent that 
describes the relationship between the pharmacokinetic parameter and body weight. 
 
 Due to the limited and sparse data in this study, the exponent (b) of the power 
function in allometric scaling may be inaccurately estimated [8]. Moreover, fixing the 
allometric exponent helps in delineating the size effect from other covariates which may 
show a high degree of collinearity with body size [8, 100]. Thus, the allometric exponent 
was fixed to 1 for the volume of distribution (V). Because of disagreement in the 
scientific literature over the appropriate exponent on CL for mAbs, the exponent on CL 
was tested and selected between two options, 0.75 and 0.85, before fixing [101]. 
 
 After the effect of mouse body weight was accounted for and incorporated into 
the structural model, the effects of age and FcRn expression from various organs were 
subsequently explored. Different patterns of covariate effects were investigated 
(Equations 5-9 to 5-13). 
 
? ? ??? ???
??
?????
?
?
????? ?
???
??????
? 
(Eq. 5-9) 
 
? ? ??? ???
??
?????
?
?
????? ? ??? ?
???
??????
?? 
(Ep. 5-10) 
 
? ? ??? ???
??
?????
?
?
? ???? ??? ?
???
??????
? 
(Ep. 5-11) 
 
? ? ??? ???
??
?????
?
?
????
? ?????????
? 
(Eq. 5-12) 
 
 
? ? ??? ???
??
?????
?
?
???
???
??????
?
??
 
(Eq. 5-13) 
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 P, ?P, b, BW, and BW70d represent the parameters that were already described. 
COV represents the covariate of interest including age and relative FcRn expression in 
various organs in different age groups of C57BL/6J mice. COV70M is the mean value of 
the covariate of interest in 70 day old male C57BL/6J mice. ?C is the parameter to be 
estimated that best describes the relationship between the pharmacokinetic parameter and 
the covariate. 
 
 Relative FcRn protein expression in various organs during postnatal development 
of C57BL/6J mice was obtained from the study described in Chapter 4. Mean FcRn 
expression results from the sample set with 20 ?g protein loading were used for the 
investigation of covariate effects. (Table 5-3). Mean FcRn expression of mice in each 
age group was normalized to mean FcRn expression of 70 day old C57BL/6J mice in the 
model. 
 
 The covariate model was built using a stepwise forward addition/backward 
deletion modeling approach [102]. The criterion for inclusion of a covariate in the model 
was a decrease in objective function value (OFV) of 3.84 (p < 0.05). Due to the multiple 
comparisons inherent in the forward addition procedure, more stringent criteria with a 
change in OFV of 10.8 (p < 0.001) was required for a covariate to remain in the model 
during the backward deletion step [103]. Moreover, goodness-of-fit plots and changes in 
between-subject variability, along with the standard error of the parameter estimates, 
were considered criteria for model selection. The final model was subsequently applied to 
the full dataset that included the serum concentration-time data of AMG589 at the 24-
hour time point. 
 
 
Population Pharmacokinetic Model Evaluation 
 
The precision and stability of the final model estimates were evaluated by 
nonparametric bootstrap analysis, and the ability of the final population pharmacokinetic 
model to adequately describe the observed data in the full dataset was determined by 
visual predictive check. The full dataset was used for model qualification, which was 
performed by using PsN (GNU General Public License, version 2) [104] using the Pirana 
version 2.9.0 platform (®Pirana Software & Consulting BV, http://www.pirana-
software.com). Graphical visualization of the results was performed using the ggplot2 
package in R (The R Foundation for Statistical Computing) via the Pirana version 2.9.0 
platform. 
 
 
Bootstrap Analysis 
 
500 bootstrap datasets were created by repeatedly random sampling with 
replacement from the original full dataset. Each bootstrap dataset contained the same 
sample size as the original dataset. With the stratified sampling approach on age at 
dosing, the same ratio of samples in each age group as those in the original dataset were 
created. The population parameters were subsequently estimated for each bootstrap  
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Table 5-3. FcRn expression in various organs during development in C57BL/6J 
mice 
 
Age FcRn expression (20 ?g loading sample set) 
(days) Skin Liver Kidney Lung Spleen 
2 0.68 0.66 0.63 0.75 1.17 
10 0.57 1.45 2.29 1.93 0.96 
21 0.80 0.81 1.15 1.10 0.39 
42 0.75 0.81 2.29 1.12 0.59 
70 0.46 0.71 0.94 0.70 0.43 
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dataset using the final population pharmacokinetic model. Based on 500 estimations, the 
median and 90% confidence intervals (CIs) for each parameter were derived and 
compared to the final estimates obtained from the original dataset. 
 
 
Visual Predictive Check 
 
1000 simulations were performed using the final population pharmacokinetic 
model with the final parameter estimates and their distributions. To preserve the data 
distribution in each age group of the original dataset, the simulations were stratified on 
age at dosing of mice. The median and 90% CIs of AMG589 plasma concentration at 
each time point were subsequently determined from the simulated plasma concentrations 
data. The median and 90% CIs obtained from simulated plasma concentrations data were 
plotted and overlaid with the observed concentrations. 
 
 
Results 
 
 Serum concentration-time profiles of AMG589 following subcutaneous (SC) 
administration at 39 mg/kg in 2-day old mice, and at 50 mg/kg in 10, 21, 42, and 70 day 
old mice were similar across all age groups (Figure 5-2). A single phase of distribution 
and elimination was observed in the serum concentration-time profiles of AMG589 in all 
age groups of mice. Lower serum concentrations of AMG589 were observed in the 2 day 
old C57BL/6J mice. Scaling the SC dose administered in 2-day old mice from 39 mg/kg 
to 50 mg/kg (Day 2 (50 mg/mL) in Figure 5-2) showed a slight increase in AMG589 
systemic exposure, but did not significantly change the non-compartmental 
pharmacokinetic analysis results (Table 5-4). Compared to other age groups, a slightly 
flatter terminal disposition phase was observed in the serum concentration-time profile of 
42 day old C57BL/6J mice. The pharmacokinetic parameters obtained by standard non-
compartmental analysis are listed in Table 5-4. 
 
 The results of the non-compartmental analysis revealed smaller values for 
apparent clearance (CL/F) and apparent volume of distribution (V/F) in the full dataset 
compared to those in the dataset that excluded serum concentration-time data of 
AMG589 at the 24-hour time point. However, both data sets showed the same pattern of 
changes in CL/F across all age groups of C57BL/6J mice. Decreasing CL/F was observed 
as mice aged, until the age of 42 days. 70 day old C57BL/6J mice showed increased CL/F 
of AMG589 compared to 42 day old mice. The value of CL/F in 70 day old mice was the 
same as that in 21-day old mice. V/F of AMG589 in both datasets also exhibited a similar 
pattern of change across all age groups of C57BL/6J mice. Decreased V/F of AMG589 
was observed during the developmentof C57BL/6J mice until the age of 42 days. In the 
full dataset, V/F of AMG589 in 42 day old mice was of the same magnitude as that in 70 
day old mice, whereas increased V/F was observed in 70 day old C57BL/6J mice in the 
dataset that excluded AMG589 serum concentration-time data at 24 hours. 
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Figure 5-2. Serum concentration-time profiles of AMG 589 in different age 
groups of C57BL/6J mice (n = 3- 4) in the full dataset 
 
 
 
 
Table 5-4. Non-compartmental pharmacokinetic parameters of AMG589 
following SC administration in different age groups of C57BL/6J mice 
 
Parameters Units Age Day 2a Day 2b Day 10 Day 21 Day 42 Day 70 
Exclusion of 
24-hour data 
CL/F 
V/F 
?z 
t1/2 
Full dataset 
CL/F 
V/F 
?z 
t1/2 
 
 
mL/day/kg 
mL/kg 
1/day 
day 
 
mL/day/kg 
mL/kg 
1/day 
day 
 
 
58.4 
550. 
0.106 
7 
 
53.7 
506 
0.106 
7 
 
 
60.0 
565 
0.106 
7 
 
54.1 
510. 
0.106 
7 
 
 
24.8 
271 
0.0913 
8 
 
22.3 
245 
0.0913 
8 
 
 
9.85 
159 
0.0619 
11 
 
9.26 
150. 
0.0619 
11 
 
 
6.34 
126 
0.0501 
14 
 
6.22 
124 
0.0501 
14 
 
 
11.0 
140. 
0.0781 
9 
 
9.97 
128 
0.0781 
9 
 
a Instead of the 50 mg/kg SC dosing of AMG589, 39 mg/kg was SC administered in 2 
day old mice. 
b The pharmacokinetic parameters were derived from the plasma concentrations that were 
scaled to those after SC dosing at 50 mg/kg.  
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 The elimination rate constants (?z) and half-lives (t1/2) of AMG589 in C57BL/6J 
mice were the same between the two datasets. ?z dropped from the first day of life until 
the age of 42 days and rose again in 70-day old mice. As a consequence, t1/2 of AMG589 
increased until the age of 42 days and then dropped in 70 day old C57BL/6J mice. 
 
 A one-compartment model with first-order absorption was applied to the 
structural model in the population pharmacokinetic modeling. Inclusion of body weight 
(BW) by the allometric scaling approach with fixed allometric exponent (b) (Equation  
5-8) on CL (b = 0.75) and V (b = 1) resolved the problem that was encountered in the 
structural model regarding the estimates were near the boundary, decreased the objective 
function value (OFV) by approximately 50.8, and improved the goodness-of-fit plots. 
Comparison of the allometric exponent (b) on CL between 0.75 and 0.85 showed 
comparable results in the OFV and values of parameter estimates (Table 5-5). However, 
a b value of 0.75 yielded less %RSE of the parameter estimates compared to the b value 
of 0.85. Fixing the exponent at 0.75 seems to follow an underlying physiological 
principle [8, 100] and has been successfully used in the population pharmacokinetics of 
ciprofloxacin in pediatric patients [103]. Thus b was fixed at 0.75 for CL and at 1 for V 
before the next step in the modeling process. 
 
 The effects of the remaining covariates were subsequently explored. The plots of 
the between-subject variability (ETA) of each pharmacokinetic parameter (CL, V, and 
Ka) versus each covariate (sex, age, and FcRn expression in each organ) suggested a 
potential effect of age and FcRn expression on CL and V (Figures C-1 to C-4). Between-
subject variability of Ka seemed not to be explainable by any of these covariates (Figures 
C-5 to C-6). Additional age effects on CL and V were first explored with the stepwise 
forward addition criteria (at p ? 0.05, the decrease in OFV should be at least 3.84).Age 
was included in the model with a power effect on V, and resulted in a decrease in OFV 
about 11.7. After accounting for the age effect, the between-subject variability (BSV; ?2) 
reduced from 0.198 to 0.175 for CL, and from 0.212 to 0.148 for V. However, the BSV 
for Ka slightly increased from 0.573 to 0.610. The parameter estimate for the age effect 
on V was -0.331, which indicated that volume of distribution decreased during 
development. 
 
 The effect of FcRn expression in various organs of different age groups of mice 
was then explored. During the screening with the criteria of the stepwise forward addition 
approach, relative FcRn expression in skin and kidney were found to have an influence 
on CL, whereas FcRn expressions in skin, liver, lung, and spleen were found to have an 
effect on V. The effect of FcRn expression in skin on CL was first included in the model 
due to the biggest reduction in OFV (-15.116). Accounting for the effect of skin FcRn 
expression on CL further reduced the BSV from 0.175 to 0.00608 for CL, from 0.148 to 
0.0905 for V, and from 0.61 to 0.469 for Ka. After adding the effect of skin FcRn 
expression on CL, FcRn expression in the spleen was the only covariate that had a 
significant effect on V (change in OFV was -4.36). However, during the backward 
deletion step with stricter criteria (increase in OFV at least 10.8; p ? 0.001), FcRn 
expression in the spleen was excluded in the final model. 
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Table 5-5. Comparison between two values of the allometric exponent (b) on CL 
 
Parameters 
b = 0.75 (OFV = 1708.13)  b = 0.85 (OFV = 1709.74) 
Parameter 
estimate 
%RSE  Parameter 
estimate 
%RSE 
CL (mL/day) 
?CL 
V (mL) 
?V 
Ka (day-1) 
?Ka 
BSV 
?2CL 
?2V 
?2Ka 
Residual error 
?2ij 
 
0.135 
 
3.37 
 
2.63 
 
0.198 
0.212 
0.573 
 
0.0260 
 
11.9 
 
15.9 
 
36.7 
 
65.2 
47.6 
87.6 
 
 
  
0.142 
 
3.44 
 
2.64 
 
0.221 
0.227 
0.618 
 
0.0179 
 
12.3 
 
14.5 
 
40.9 
 
92.3 
101 
152 
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Due to the very low BSV for CL (0.006) with very high %RSE (1318.3), 
removing this parameter from the final model resulted in almost the same final parameter 
estimates with significantly reduced %RSE of BSV for V and for proportional error 
(decreasing from 179% to 63.5% and 118.8% to 30.5%, respectively) observed in the 
model-building dataset (results not shown). When we applied this approach to the full 
dataset, almost the same final parameter estimates with comparable %RSE were observed 
(results not shown). The final model thus contained only BSV for V and Ka. The 
parameter estimates obtained from the final model are shown in Table 5-6 and the 
goodness-of-fit plots are shown in Figure 5-3. 
 
The final model was successfully applied to the full dataset that included serum 
concentration-time data of AMG589 at the 24-hour time point. The parameter estimates 
obtained from the final model in the full dataset are presented in Table 5-6. The 
goodness-of-fit plots of the final model applied in the full dataset are depicted in Figure 
C-7 in Appendix C. The final parameter estimates obtained from both datasets were 
comparable. 
 
The precision of the final parameter estimates obtained from the final model was 
subsequently qualified by bootstrap analysis. The medians along with 90% CIs of the 
parameter estimates obtained from the nonparametric bootstrap are tabulated in Table  
5-6. The median population parameter estimates from the bootstrap analysis were 
generally within 3% of the estimates from the final model applied to the full dataset, 
except for those of BSV on V and residual error, which showed larger deviations. These 
results confirm the stability and robustness of the final population pharmacokinetic 
model. The 90% CIs for the covariate effects did not include zero, supporting the 
statistical significance of the covariates included in the final model. 
 
The predictive capability of the final model was further evaluated by visual 
predictive check plots (Figure 5-4). 1000 simulations with age stratification based on the 
final model showed the observations in the full dataset (dots) were reasonably-well 
predicted by the median (black line) and mostly captured within the simulated 90% 
prediction interval (red lines) in all age groups. Based on these qualification results, the 
final population pharmacokinetic model seems suitable to describe the observed 
pharmacokinetics of AMG589 in different age groups of C57BL/6J mice. 
 
 
Discussion 
 
 The two objectives of this study were to explore the pharmacokinetics of mAbs in 
different age groups of mice and to determine the covariates that potentially have a 
significant impact on the pharmacokinetics of therapeutic mAbs during development and 
maturation. The effect of FcRn expression is of special interest due to published evidence 
that suggests a role for this recycling receptor in the pharmacokinetics of mAbs and the 
potential for postpartum ontogeny of FcRn expression. Thus AMG589, a fully-human 
mAb, was used as a model drug to study the changes in pharmacokinetics of mAbs in 2,  
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Table 5-6. Parameter estimates obtained from the final population pharmacokinetic model 
 
Model Parameters 
Model building dataset  Full dataset  Bootstrapa 
Parameter 
estimate 
%RSE %Shrinkage  Parameter 
estimate 
%RSE %Shrinkage  Parameter 
estimate 
90%CI 
CL (mL/day) 
??? ???
??
????
?
????
???
????????
????
?
??????????
 
 
?CL 
 
0.191 
 
8.30 
   
0.184 
 
8.40 
   
0.183 
 
0.161-0.219 
V (mL) 
?? ? ?
??
????
? ?
???
???
??? ? ??
?
????
 
 
?V 
 
2.42 
 
10.7 
   
2.17 
 
8.70 
   
2.20 
 
1.91-2.57 
Ka (1/day) 
??? 
 
?Ka 
 
3.08 
 
38.0 
   
3.02 
 
21.6 
   
2.97 
 
2.05-4.53 
Covariates 
FcRn expression in mouse 
skin 
Age 
 
?skin_FcRn 
 
?Age 
 
-1.36 
 
-0.336 
 
23.8 
 
24.2 
   
-1.17 
 
-0.375 
 
25.6 
 
14.4 
   
-1.18 
 
-0.368 
 
(-1.87)-(-0.631) 
 
(-0.445)-(-0.278) 
Between-subject 
variability (BSV) 
?? ? ?? ?????? 
??? ? ??? ????
???  
 
 
?2V 
?2Ka 
 
 
0.0816 
0.460 
 
 
63.5 
91.1 
 
 
53 
67 
  
 
0.0341 
0.604 
 
 
120. 
64.2 
 
 
65 
65 
  
 
0.0479 
0.608 
 
 
0.00655-0.127 
0.0760-1.95 
Residual variability 
????????????
? ???? ????????? 
? ?? ?????? 
 
?2  
 
0.0893 
 
30.5 
 
18 
  
0.101 
 
28.7 
 
13 
  
0.0853 
 
0.0462-0.124 
 
a Bootstrap analysis was performed on full dataset. 
BW is mouse body weight calculated as described by Equations 5-4 to 5-7. 
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Figure 5-3. Goodness-of-fit plots of the final model applied to the model building 
data set 
 
 
 
 
 
 
Figure 5-4. Visual predictive check for the final population pharmacokinetic 
model applied to the full dataset  
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10, 21, 42, and 70 day old C57BL/6J mice that were selected as representative age groups 
for neonates, infants, children, adolescents, and adults. 
 
 The results from the non-compartmental analysis of the pharmacokinetics of 
AMG589 in different age groups of C57BL/6J mice revealed comparable values for the 
parameter estimates with slightly lower values for apparent clearance (CL/F) and 
apparent volume of distribution (V/F) observed in the full dataset when compared to the 
dataset that excluded data at the 24-hour sampling time. The results of this analysis, 
however, should be interpreted with caution. The methodology for the non-
compartmental analysis assumes a constant clearance during the sampling period, but due 
to weight and potential maturational changes this is clearly not the case in our analysis. In 
addition, some pharmacokinetic parameters are normalized for weight at dosing, but 
again, weight changes dramatically over the sampling interval, especially in the younger 
animals. Thus, the results of the non-compartmental analysis give a time-averaged 
estimate for initial comparisons between the age groups, but the subsequent model-based 
analysis provides a more precise assessment of the age-associated changes of AMG589 
disposition in mice.  
 
In the full dataset, CL/F and V/F across all age groups were 6.22 ? 53.7 
mL/day/kg and 124 ? 506 mL/kg, respectively, whereas 6.34 ? 58.4 mL/day/kg of CL/F 
and 126 ? 550 mL/kg of V/F were observed in the dataset that excluded data at the 24-
hour sampling time. Scaling the original SC dose of 39 mg/kg in two day old mice to 50 
mg/kg yielded similar pharmacokinetic parameters. The highest values for CL/F and V/F 
were observed in the youngest age group. Both parameters had a tendency to decrease in 
value as the animals aged. Although these observations indicate that CL and V of the 
younger animals were higher than those of the adults, they could also suggest the 
possibility of low bioavailability (F) during the beginning of life. However, a potentially 
lower bioavailability occurring in neonates is difficult to mechanistically explain due to 
many potential factors, such as the thickness of skin and lymphatic supply at the injection 
site, which might have influenced the absorption process [8, 26]. 
 
CL/F and V/F of AMG589 in 70 day old mice were comparable to those of 
rituximab (CL ? 13.8 mL/day/kg and Vss ? 156 mL/kg) after IV administration at 40 
mg/kg in male C57BL/6J mice (average weight ? 18 ? 22 g) [105]. Terminal half-lives 
(?z) were the same in both datasets and ranged from 7 ? 14 days. Half-life was shortest in 
the two youngest age groups (2- and 10- days old) and increased slightly in older groups 
until the age of 21 days. The half-life of AMG589 in 70 day old mice (9 days) was also 
comparable to that observed for rituximab (8 days) [105] and other mouse IgG1s (9 days) 
[106] in mice. 
 
 Although developmental changes in body composition with decreased total body 
water:body fat ratio during maturation have been suggested to not have any significant 
impact on the biodistribution of mAbs [8], decreasing volumes of distribution of 
AMG589 during development in mice seems to mimic what occurs with the 
pharmacokinetics of hydrophilic drugs [107]: a reduction in volume with decreasing 
percentage of body water during growth and maturation. However, alterations in the 
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biodistribution of AMG589 may also be affected by other changes in body composition 
and amount of circulating plasma proteins. 
 
 The longest half-life of AMG589 observed in 42 days old C57BL/6J mice 
suggests age-dependent pharmacokinetics, which may be the result of several factors. The 
drug disposition processes of AMG589 are most likely regulated by common factors and 
mechanisms for mAbs, such as their large size, charge, the degree and nature of 
glycosylation, and the Fc region [6, 55, 101, 105]. In many cases, mAb elimination is 
dominated by affinity for the FcRn receptor and their susceptibility to proteolysis. In 
contrast, the ontogeny of small molecular drug transporters in the liver and kidney, along 
with the alteration of hepatic drug-metabolizing enzymes during development [25, 107], 
should not have any effect on the pharmacokinetics of these macromolecules. 
 
 One of the factors that can influence the pharmacokinetics of mAbs is 
immunogenicity [4]. In this study, a fully-human mAb, AMG 589, was administered to 
mice. This xenogenic antibody can trigger an immune response that may lead to anti-drug 
antibody formation, immune complex formation, and ultimately alterations in the 
distribution and the elimination rate of AMG 589. This change in distribution and 
clearance might have an impact on the efficacy of therapy. However, immunogenicity 
seems unlikely in this study since serum concentration-time profiles of AMG589 did not 
show any pattern of abrupt decline in the terminal elimination phase, and therapy was 
limited to a single dose followed over 3 weeks 
 
 The ontogeny of FcRn expression is a major factor of interest since this recycling 
receptor contributes to the prolonged half-life of antibody-based therapeutic proteins [70, 
88, 106, 108]. The results of our characterization of the ontogeny of FcRn expression in 
C57BL/6J mice described in Chapter 4 revealed specific patterns of the ontogeny of 
FcRn expression in liver, kidney, and lungs. However, only FcRn expression in the 
kidney showed a 2-fold increase at the age of 42 days, which coincides with the 
prolonged half-life observed in this age group. The role of renal FcRn in regulating IgG 
homeostasis is not clear. Although FcRn has been shown to be involved in the recycling 
process of IgG in the kidneys, renal impairment seems to have only minor or no effect on 
the elimination of therapeutic mAbs [55, 98]. Thus, the ontogeny of FcRn expression in 
the kidneys may not have any impact on the pharmacokinetics of AMG589 in different 
age groups of mice. 
 
 To explore the covariate effect on the pharmacokinetics of AMG589 in different 
age groups of C57BL/6J mice, a population pharmacokinetic modeling approach was 
used. A one-compartment linear model with first-order absorption was selected as the 
structural model based on the serum concentration-time profile of AMG589 that showed 
in a log-linear plot a single terminal disposition phase, which is typical for a non-binding 
antibody [109]. Target receptor-mediated metabolism was assumed to be absent in the 
elimination of AMG589, a fully-human mAb, since it binds only to its human target 
antigen but not the murine homologue. Thus, a simple model such as the one-
compartment linear model with first-order absorption rather than a target-mediated drug 
 
 
80 
 
disposition model seems to be a reasonable structural model for describing the 
pharmacokinetics of AMG589 in mice. 
 
 To account for the effect of body weight on the pharmacokinetics of AMG589, an 
allometric scaling approach was applied. One of the assumptions underlying this 
technique includes the absence of nonlinear pharmacokinetics, which might not hold true 
for most therapeutic antibodies [5]. However, this assumption should be applicable for 
the pharmacokinetics of AMG589 due to the lack of clearance through target receptor-
mediated metabolism. Accounting for the body weight effect using the allometric scaling 
approach resulted in the reduction in OFV and a better goodness-of-fit plot, which 
coincides with reports that reveal body size as the most frequently-identified and 
clinically-relevant covariate that influences the pharmacokinetics of antibody-based 
therapeutic proteins [8]. 
 
 Even though several reports have shown that after accounting for the effect of 
body size, age has rarely been identified as a covariate that influences the 
pharmacokinetics of therapeutic proteins [8], the results in the present study suggested 
otherwise. After accounting for the effect of body weight, age was found to affect the 
volume of distribution. During development, the volume of distribution of AMG589 
seemed to decrease. This finding corresponds to the results obtained from the non-
compartmental analysis. As already discussed, this may due to decreasing the percentage 
of body water during maturation or it may due to other changes in body composition and 
the amount of circulating plasma proteins. Surprisingly, FcRn expression in the skin was 
found to be a covariate that affects clearance of AMG589 even though there was no 
significant difference in FcRn expression across age groups of C57BL/6J mice (Results 
are described and discussed in Chapter 4). With increasing level of FcRn in the skin, 
clearance decreased. This result agrees with another study that shows that functional 
FcRn receptors are expressed in endothelial cells of the small arterioles and capillaries in 
the skin which principally contribute to the homeostasis of IgG [68]. Thus, the 
discrepancies between the results of the ontogeny of FcRn expression and population 
pharmacokinetic results may disappear when FcRn expression is quantified from the 
extracted endothelial cells in skin or the amount of endothelial cells in the skin is taken 
into account during data analysis. The population pharmacokinetic results suggested that 
the effect of skin FcRn expression and age can cause clearance and volume of 
distribution to change by 0 ? 29% and 69 - 279%, respectively. 
 
 Although using a fully-human mAb in this pharmacokinetic study may raise 
concern regarding the species differences in FcRn binding affinity [5, 6], the half-life of a 
fully-human mAb in rodents had been shown to be comparable to that of mouse mAb 
versions [55]. However, the 2.5-fold higher binding affinity of human IgG to mouse 
FcRn compared to mouse IgG to mouse FcRn [19] may result in masking the potential 
effect of FcRn expression in other organs on the pharmacokinetics of AMG589 in 
different age groups of mice. To account for species differences in FcRn binding affinity, 
a human FcRn transgenic mouse model may potentially be used as a surrogate for 
pharmacokinetic studies of humanized or fully-human mAbs [106]. Alternatively, mouse 
IgGs could be used as model drugs for the pharmacokinetic study in wild-type mice. 
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 A sparse dataset with limited observations per individual as analyzed in the 
present study has not surprisingly resulted in parameter estimates with relatively high 
values of shrinkage for between-subject variability (53 - 67% and 65% shrinkage in 
model-building dataset and full dataset, respectively). As a consequence, the final model 
derived by the stepwise model-building procedure may suffer from model selection bias, 
especially when model selection is based on the graphical evaluation of the goodness-of-
fit plots. However, the final model showed reasonable goodness-of-fit. Moreover, the 
final model did not show the perfect fit phenomenon in which the values of individual 
predictions shrink towards the actual observations [110, 111] which may result from high 
shrinkage (over 20 ? 30%). Although high shrinkage may lead to bias in the model 
selection, this selection bias may be of minor importance in the present study because the 
purpose of the population modeling was to explore and determine covariates that have 
significant influence on the pharmacokinetics of mAbs during the developmental process 
in mice, rather than the assessment of between-animal variability. 
 
 The findings in this study suggest that body weight along with age are significant 
factors that should be considered for dose optimization of therapeutic mAbs in different 
age populations. Current practice has also shown that the successful dose extrapolation 
from adults to pediatric patients for most therapeutic proteins can be achieved using body 
weight or body surface area-adjusted strategies [8, 26]. Using body weight and body 
surface area-adjusted dosing strategies, the pharmacokinetics are comparable between 
pediatric patients and adults once maturation of drug disposition processes has been 
completed. Therefore, the decreasing volume of distribution during maturation may be a 
maturation-related factor to consider for the application of therapeutic mAbs in different 
age populations. In addition, inter-individual differences in skin FcRn expression 
accounted for some of the observed between-subject variability, although no age-
associated changes for skin FcRn expression were observed, at least in mice. 
 
The age groups of mice that were used in this study might not truly represent the 
human developmental age; since human newborns are most comparable to 7-day-old 
mice in term of immunological development [112]. However, the effect of body weight 
on the pharmacokinetics of therapeutic mAbs should be emphasized in pediatrics due to 
differential growth rates at young ages that results in a much larger variability in body 
size for children than for adults [8, 100]. Moreover, unlike AMG589, many antibody-
based therapeutic proteins generally include target receptor-mediated metabolism as a 
major elimination pathway. In that case, the prediction of pharmacokinetics in different 
age populations becomes more challenging since target antigen levels may be an 
additional covariate that influences the pharmacokinetics of the therapeutic mAb. Thus, 
differences in target antigen levels between pediatric patients and adults should be 
considered during dose optimization in pediatrics for therapeutic proteins that are 
eliminated via this saturable disposition process [8]. 
 
 In conclusion, this study revealed age-dependent pharmacokinetics of AMG589 
during the developmental process in mice with the longest exposure observed in 42-day 
old animals. The study revealed the effect of body weight, age, and FcRn expression in 
the skin as factors that influenced the observed age-dependent pharmacokinetics of 
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AMG589 in mice. The importance of body weight adjusted dosing should be emphasized, 
especially in pediatrics, since body size rapidly changes during the early period of life. 
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CHAPTER 6.    SUMMARY OF DISSERTATION RESEARCH 
 
 
Advancements in biotechnology have transitioned therapeutic modality from the 
use of small chemically-defined molecules to biological macromolecules. Consequently, 
a large and increasing number of therapeutic macromolecules are being launched in the 
market. Similar to what is necessary with the therapeutic application of small-molecule 
therapeutic agents, successful therapy with biotechnologically-derived therapeutic agents 
can be achieved by rational therapeutic regimens that are designed based on the 
understanding of their pharmacokinetics and pharmacodynamics. However, their 
complex structure endows these therapeutic macromolecules with a complicated 
disposition pattern that depends on various factors and results in many challenges with 
regard to their pharmacokinetic assessment and interpretation. Two challenges that need 
to be considered during the interpretation of pharmacokinetic results and the design of 
dosage regimens for therapeutic proteins and monoclonal antibodies (mAbs) were 
explored in Chapters 3 to 5 of this dissertation: 1) The error of bioavailability 
assessment, by using the conventional bioavailability estimation that can be observed 
during subcutaneous (SC) administration of therapeutic macromolecules that undergo 
target-mediated drug disposition (TMDD) and 2) the ontogeny of FcRn expression along 
with its effect on the pharmacokinetics of mAbs during development. 
 
 One advantage of therapeutic macromolecules over conventional small-molecule 
drugs is their high affinity and specific binding, which result in limited off-target 
toxicities. Due to high specificity and affinity of binding to the target receptor, receptor-
mediated metabolism is often the dominant pathway of clearance. This receptor-mediated 
metabolism is usually well described by TMDD. However, the limited availability of 
target receptors leads to saturation of binding upon dosing, which results in saturation of 
the clearance process. The saturation of target receptors under therapeutic concentrations, 
along with the high contribution of this process to the overall elimination pathways, can 
result in the observed nonlinear pharmacokinetics with decreasing clearance upon 
increasing the dose. The nonlinear pharmacokinetics observed for many therapeutic 
proteins can have an impact on bioavailability estimation. Bioavailability estimation 
based on the classic AUC approach can be erroneous, which is mainly due to the 
assumption of dose-independent constant clearance that cannot be applied to therapeutic 
proteins that undergo TMDD. To shed light on this issue, we hypothesized that there is a 
dose-dependent error in the bioavailability assessment for therapeutic proteins that 
undergo TMDD if the classical approach of dose-normalized AUCs is used. The error 
becomes apparent when different doses of IV and SC administration are used for 
bioavailability estimations, since the clearances at different IV and SC doses are not 
equal and change over time, which is dependent on the achieved concentrations. 
 
 The results in Chapter 3 support this first hypothesis. Various degrees of error in 
the bioavailability estimation were observed after the bioavailability of filgrastim and 
denosumab were estimated by a conventional method, using different combinations of 
simulated dose-normalized AUCs at various IV and SC doses (0.01 ? 10000 ?g/kg for 
filgrastim and 0.66 ? 210 mg for denosumab). The error became obvious when 
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significantly different IV and SC doses were used for the evaluation of bioavailability. 
The overestimations were extreme when high SC and low IV doses of both protein drugs 
were used for the estimations, whereas the underestimations were exactly the reverse. 
The error in the bioavailability estimation originated from different dose-normalized 
AUCs observed at various doses. 
 
These variations of dose-normalized AUCs indicated disproportional 
characteristic changes in drug plasma concentration-time profiles, which resulted from 
changes in clearance upon dose alteration. The transition from low plasma concentration 
(at low dose) to high plasma concentration (at high dose) shifted the major elimination 
pathway from TMDD to the linear clearance pathways. At low plasma concentration of 
the therapeutic protein target receptors have full capacity for elimination; thus TMDD is 
the dominant elimination pathway. In contrast, high plasma concentrations at high doses 
of protein drugs saturate all target receptors and shift the main elimination pathway to be 
governed by linear clearance. The relationship between the simulated plasma 
concentrations at different IV doses to the corresponding clearances of both protein drugs 
were investigated. The dynamics of the alteration of clearances and dose-normalized 
AUCs was parallel and very obvious in the dose range of 0.1 ? 5 ?g/kg for filgrastim and 
below 60 mg for denosumab; thus care should be taken when bioavailability of these two 
therapeutic proteins is estimated in these dose ranges. To minimize the error that occurs 
when using conventional bioavailability estimation, the bioavailability should be 
estimated using dose-normalized AUCs at similar IV and SC doses, or the assessment 
should be performed in dose ranges that yield constant dose-normalized AUCs that may 
result from concentration-independent clearance (0.01 ? 0.1 ?g/kg or 5 ? 10000 ?g/kg for 
filgrastim, and 60 ? 210 mg for denosumab). Moreover, an alternative approximation 
method could be applied that determines the ratio of IV and SC doses that generate equal 
AUCs, as suggested by Gibiansky et al. [51]. Overall, model-based bioavailability 
assessment seems to be the most precise approach for therapeutic proteins that undergo 
TMDD. 
 
 The second challenge related to the ontogeny of FcRn expression and its effect on 
the pharmacokinetics of mAbs in different age populations should be of special concern 
if therapeutic mAbs are used in pediatric populations. Currently, the dosing regimens for 
therapeutic proteins in pediatrics have been generalized from the clinical practice in 
adults [8, 26]. Physiological differences in body composition and organ function between 
pediatric patients and adults may lead to the age-dependent pharmacokinetics and 
pharmacodynamics. The understanding of the developmental changes in the 
physiological factors that cause age-dependent pharmacokinetics and pharmacodynamics 
are prerequisites for developing effective dosage regimens with maximal efficacy and 
low toxicity. 
 
 FcRn has been considered a salvage pathway from lysosomal clearance for mAbs 
and Fc conjugated proteins [4-7]. This salvage pathway functions through a pH-
dependent binding process, and can prolong the existence of therapeutic proteins in 
systemic circulations. The influence and contribution of the FcRn receptor to the 
elimination of mAbs and Fc-conjugated proteins have been shown in many publications 
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and have been applied in molecular engineering to generate improved versions of mAbs 
and Fc-conjugated proteins with desirable half-lives. The influence of the ontogeny of 
FcRn expression on the pharmacokinetics of therapeutic proteins, however, has never 
been investigated. The age-dependent expression of FcRn was observed in mouse 
intestine with detectable amounts observed up to 3 weeks postpartum [62, 74]. Reduced 
expression of FcRn during early developmental stages may result in alterations of the 
pharmacokinetics of mAbs upon dosing. Thus, a second hypothesis was established that 
the down-regulation of FcRn expression levels during development would result in a 
shortened half-life of AMG589 in mice. To test this second hypothesis, three 
experimental aims were framed. In the first aim, the levels of FcRn expression in organs 
of C57BL/6J mice from postnatal days 2 through 70 were examined. In the second aim, 
the pharmacokinetics of AMG589 were studied in different age groups of C57BL/6J 
mice. Finally, in the third aim the FcRn expression levels and pharmacokinetics of 
AMG589 in the different age groups of mice were correlated using a nonlinear-mixed 
effects modeling-based population pharmacokinetic approach. 
 
 The findings on the ontogeny of FcRn expression in C57BL/6J mice in Chapter 4 
and the results of the pharmacokinetics of AMG589 in various age groups of C57BL/6J 
mice in Chapter 5 led to conclusions that negated the second hypothesis. Although FcRn 
expression showed an ontogenic pattern, its occurrence was significant in only three 
organs: liver, lungs, and kidneys. Moreover, the age-associated expression of FcRn 
revealed organ-specific patterns of ontogeny. Two-fold increases in FcRn expression 
were observed in liver and lungs of 10 days old mice, whereas the FcRn expression in 
kidneys was doubled in 10- and 42-days old mice. This ontogeny of FcRn expression 
could not be correlated with the prolonged half-life of AMG589 that was observed in 42 
day old mice. Although a doubling of FcRn expression was observed in mouse kidneys at 
this age, the contribution of this organ to the overall elimination processes of mAbs 
seems to be limited. Moreover, the function of FcRn expressed in kidneys is still 
controversial. The negligible influence of the ontogeny of FcRn expression on the 
pharmacokinetics of AMG589 in various age groups of mice was confirmed by the 
population pharmacokinetic analysis. The population pharmacokinetic analysis revealed 
that after the effect of body weight was adjusted by allometric scaling, age and FcRn 
expression in skin were the additional factors that influenced the pharmacokinetics of 
AMG589 in different age groups of mice. The volume of distribution of AMG589 was 
affected by age with decreasing volume of distribution during development. Interestingly, 
variability in the clearance of AMG589 could be partially explained by the expression of 
FcRn in the skin, even though FcRn expression in skin did not show any ontogeny. 
Although the experimental results in mice suggested three significant factors (body 
weight, age, and FcRn expression in the skin) that should be considered during dosage 
regimen design for mAbs, there are several limitations that might limit the generalization 
of this finding to humans. One of these limitations is potential species differences in 
developmental growth rate and the ontogenic pattern of FcRn expression. Regardless of 
the species difference in physiology, however, body weight should be taken into account 
during the dosage regimen design, especially for pediatric patients who usually exhibit an 
expeditious increase in body size at an early age. 
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 The findings in this dissertation have highlighted some challenges and 
determinants that should be considered during the pharmacokinetic interpretation and the 
dosage regimen design for therapeutic proteins. To explore the error in the conventional 
bioavailability estimation of therapeutic proteins that undergo TMDD, potential effects of 
FcRn were considered to have a negligible effect on the pharmacokinetics of the model 
drugs used. Similarly, TMDD was not considered to be a relevant pharmacokinetic 
process in the disposition of AMG589 in mice. In reality, however, these two factors may 
affect some therapeutic proteins, depending on the contribution of each process to the 
overall pharmacokinetics. Moreover, other processes and determinants of drug 
disposition of therapeutic proteins, ????????????????????????????????????????????????-
receptors and other proteolytic processes, may affect and further complicate the 
pharmacokinetic behavior of proteins. Although a thorough understanding of the role and 
limitations of each of these processes is necessary to fully understand the disposition of 
individual therapeutic proteins, the findings in the studies presented in this dissertation 
should be able to be generalized to other therapeutic proteins with similar 
pharmacokinetic properties. 
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Table A-1. Dose effect on the bioavailability estimation of filgrastim with reference bioavailability (Fref) equals to 1.0a 
 
IV dose SC dose (?g/kg) 
(?g/kg) 0.01 0.05 0.1 0.5 1 2.5 5 10 50 100 500 1000 1500 5000 10000 
0.01 0.991 
(-0.936) 
1.01 
(1.49) 
1.05 
(5.21) 
1.59 
(59.4) 
2.29 
(129) 
3.07 
(207) 
3.44 
(244) 
3.66 
(266) 
3.89 
(289) 
3.92 
(292) 
3.95 
(295) 
3.96 
(296) 
3.96 
(296) 
3.96 
(296) 
3.96 
(296) 
0.05 0.961 
(-3.87) 
0.985 
(-1.52) 
1.02 
(2.09) 
1.55 
(54.7) 
2.22 
(122) 
2.98 
(198) 
3.34 
(234) 
3.55 
(255) 
3.77 
(277) 
3.80 
(280.) 
3.84 
(284) 
3.84 
(284) 
3.84 
(284) 
3.85 
(285) 
3.85 
(285) 
0.1 0.909 
(-9.13) 
0.931 
(-6.91) 
0.965 
(-3.49) 
1.46 
(46.2) 
2.10 
(110.) 
2.82 
(182) 
3.15 
(215) 
3.36 
(236) 
3.56 
(256) 
3.60 
(260.) 
3.63 
(263) 
3.63 
(263) 
3.63 
(263) 
3.64 
(264) 
3.64 
(264) 
0.5 0.500 
(-50.0) 
0.512 
(-48.8) 
0.531 
(-46.9) 
0.804 
(-19.6) 
1.16 
(15.6) 
1.55 
(55.0) 
1.73 
(73.4) 
1.85 
(84.7) 
1.96 
(96.0) 
1.98 
(97.8) 
1.99 
(99.4) 
2.00 
(99.7) 
2.00 
(99.8) 
2.00 
(99.9) 
2.00 
(99.9) 
1 0.378 
(-62.2) 
0.387 
(-61.3) 
0.402 
(-59.8) 
0.608 
(-39.2) 
0.875 
(-12.5) 
1.17 
(17.3) 
1.31 
(31.3) 
1.40 
(39.8) 
1.48 
(48.3) 
1.50 
(49.7) 
1.51 
(50.9) 
1.51 
(51.1) 
1.51 
(51.2) 
1.51 
(51.3) 
1.51 
(51.3) 
2.5 0.306 
(-69.4) 
0.313 
(-68.7) 
0.325 
(-67.5) 
0.492 
(-50.8) 
0.708 
(-29.2) 
0.949 
(-5.12) 
1.06 
(6.20) 
1.13 
(13.1) 
1.20 
(20.0) 
1.21 
(21.1) 
1.22 
(22.1) 
1.22 
(22.3) 
1.22 
(22.3) 
1.22 
(22.4) 
1.22 
(22.4) 
5 0.281 
(-71.9) 
0.288 
(-71.2) 
0.298 
(-70.2) 
0.452 
(-54.8) 
0.650 
(-35.0) 
0.871 
(-12.9) 
0.974 
(-2.57) 
1.04 
(3.77) 
1.10 
(10.1) 
1.11 
(11.1) 
1.12 
(12.0) 
1.12 
(12.2) 
1.12 
(12.2) 
1.12 
(12.3) 
1.12 
(12.3) 
10 0.267 
(-73.3) 
0.273 
(-72.7) 
0.284 
(-71.6) 
0.430 
(-57.0) 
0.618 
(-38.2) 
0.828 
(-17.2) 
0.927 
(-7.33) 
0.987 
(-1.30) 
1.05 
(4.72) 
1.06 
(5.67) 
1.07 
(6.55) 
1.07 
(6.68) 
1.07 
(6.73) 
1.07 
(6.79) 
1.07 
(6.81) 
50 0.254 
(-74.6) 
0.260 
(-74.0) 
0.270 
(-73.0) 
0.409 
(-59.1) 
0.588 
(-41.2) 
0.788 
(-21.2) 
0.882 
(-11.8) 
0.940 
(-6.03) 
0.997 
(-0.292) 
1.01 
(0.613) 
1.01 
(1.45) 
1.02 
(1.57) 
1.02 
(1.62) 
1.02 
(1.69) 
1.02 
(1.70) 
100 0.252 
(-74.8) 
0.258 
(-74.2) 
0.268 
(-73.2) 
0.406 
(-59.4) 
0.584 
(-41.6) 
0.782 
(-21.8) 
0.876 
(-12.4) 
0.932 
(-6.75) 
0.989 
(-1.06) 
0.998 
(-0.164) 
1.01 
(0.668) 
1.01 
(0.790) 
1.01 
(0.834) 
1.01 
(0.900) 
1.01 
(0.916) 
500 0.250 
(-75.0) 
0.257 
(-74.3) 
0.266 
(-73.4) 
0.403 
(-59.7) 
0.580 
(-42.0) 
0.777 
(-22.3) 
0.869 
(-13.1) 
0.926 
(-7.42) 
0.982 
(-1.78) 
0.991 
(-0.884) 
0.999 
(-0.0584) 
1.00 
(0.0632) 
1.00 
(0.106) 
1.00 
(0.172) 
1.00 
(0.187) 
1000 0.250 
(-75.0) 
0.256 
(-74.4) 
0.266 
(-73.4) 
0.402 
(-59.8) 
0.579 
(-42.1) 
0.776 
(-22.4) 
0.868 
(-13.2) 
0.925 
(-7.52) 
0.981 
(-1.88) 
0.990 
(-0.990) 
0.998 
(-0.165) 
1.00 
(-0.0437) 
1.00 
(0.000581) 
1.00 
(0.0648) 
1.00 
(0.0803) 
1500 0.250 
(-75.0) 
0.256 
(-74.4) 
0.266 
(-73.4) 
0.402 
(-59.8) 
0.579 
(-42.1) 
0.775 
(-22.5) 
0.868 
(-13.2) 
0.924 
(-7.56) 
0.981 
(-1.92) 
0.990 
(-1.03) 
0.998 
(-0.203) 
0.999 
(-0.0819) 
1.00 
(-0.0388) 
1.00 
(0.0266) 
1.00 
(0.0421) 
5000 0.250 
(-75.0) 
0.256 
(-74.4) 
0.265 
(-73.5) 
0.402 
(-59.8) 
0.578 
(-42.2) 
0.775 
(-22.5) 
0.867 
(-13.3) 
0.924 
(-7.61) 
0.980 
(-1.97) 
0.989 
(-1.09) 
0.997 
(-0.261) 
0.999 
(-0.140) 
0.999 
(-0.0969) 
1.00 
(-0.0316) 
1.00 
(-0.0161) 
10000 0.250 
(-75.0) 
0.256 
(-74.4) 
0.265 
(-73.5) 
0.402 
(-59.8) 
0.578 
(-42.2) 
0.775 
(-22.5) 
0.867 
(-13.3) 
0.924 
(-7.62) 
0.980 
(-1.99) 
0.989 
(-1.10) 
0.997 
(-0.275) 
0.998 
(-0.154) 
0.999 
(-0.111) 
1.00 
(-0.0455) 
1.00 
(-0.0299) 
 
a %Prediction errors are reported in the brackets. Bioavailabilities with minimum bias are reported in bold. 
Light gray area demonstrates overestimated bioavailability with prediction error exceeds 20%. 
Dark gray area demonstrates underestimated bioavailability with prediction error exceeds 20%.  
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Table A-2. Dose effect on the bioavailability estimation of denosumab with the reference bioavailability (Fref) equals to 1.0a 
 
IV dose SC dose (mg) 
(mg) 0.66 1.98 6 6.6 14 15 19.8 30 60 66 100 120 198 210 
0.66 0.919 
(-8.13) 
1.70 
(70.1) 
6.57 
(557) 
7.18 
(618) 
11.8 
(1084) 
12.2 
(1123) 
13.7 
(1269) 
15.6 
(1457) 
17.9 
(1691) 
18.2 
(1716) 
19.1 
(1809) 
19.4 
(1843) 
20.2 
(1919) 
20.3 
(1926) 
1.98 0.440 
(-56.0) 
0.815 
(-18.5) 
3.15 
(215) 
3.44 
(244) 
5.67 
(467) 
5.86 
(486) 
6.56 
(556) 
7.46 
(646) 
8.58 
(758) 
8.70 
(770.) 
9.14 
(814) 
9.31 
(831) 
9.67 
(867) 
9.70 
(870.) 
6 0.129 
(-87.1) 
0.239 
(-76.1) 
0.921 
(-7.87) 
1.01 
(0.649) 
1.66 
(66.0) 
1.71 
(71.5) 
1.92 
(92.0) 
2.18 
(118) 
2.51 
(151) 
2.55 
(155) 
2.68 
(168) 
2.72 
(172) 
2.83 
(183) 
2.84 
(184) 
6.6 0.119 
(-88.1) 
0.220 
(-78.0) 
0.851 
(-14.9) 
0.930 
(-6.99) 
1.53 
(53.4) 
1.58 
(58.4) 
1.77 
(77.4) 
2.02 
(102) 
2.32 
(132) 
2.35 
(135) 
2.47 
(147) 
2.52 
(152) 
2.62 
(162) 
2.63 
(163) 
14 0.0754 
(-92.5) 
0.140 
(-86.0) 
0.539 
(-46.1) 
0.589 
(-41.1) 
0.972 
(-2.79) 
1.00 
(0.398) 
1.12 
(12.4) 
1.28 
(27.9) 
1.47 
(47.1) 
1.49 
(49.1) 
1.57 
(56.8) 
1.60 
(59.5) 
1.66 
(65.8) 
1.66 
(66.4) 
15 0.0732 
(-92.7) 
0.136 
(-86.4) 
0.523 
(-47.7) 
0.572 
(-42.8) 
0.943 
(-5.67) 
0.974 
(-2.58) 
1.09 
(9.10) 
1.241 
(24.1) 
1.43 
(42.7) 
1.45 
(44.7) 
1.52 
(52.1) 
1.55 
(54.8) 
1.61 
(60.9) 
1.61 
(61.5) 
19.8 0.0658 
(-93.4) 
0.122 
(-87.8) 
0.471 
(-52.9) 
0.514 
(-48.6) 
0.848 
(-15.2) 
0.876 
(-12.4) 
0.981 
(-1.88) 
1.12 
(11.6) 
1.283 
(28.3) 
1.30 
(30.1) 
1.37 
(36.8) 
1.39 
(39.2) 
1.45 
(44.7) 
1.45 
(45.2) 
30 0.0583 
(-94.2) 
0.108 
(-89.2) 
0.417 
(-58.3) 
0.455 
(-54.5) 
0.751 
(-24.9) 
0.776 
(-22.4) 
0.869 
(-13.1) 
0.988 
(-1.20) 
1.14 
(13.6) 
1.15 
(15.2) 
1.21 
(21.1) 
1.23 
(23.3) 
1.28 
(28.1) 
1.29 
(28.6) 
60 0.0510 
(-94.9) 
0.0944 
(-90.6) 
0.365 
(-63.5) 
0.398 
(-60.2) 
0.657 
(-34.3) 
0.678 
(-32.2) 
0.760 
(-24.0) 
0.864 
(-13.6) 
0.994 
(-0.621) 
1.01 
(0.773) 
1.06 
(5.94) 
1.08 
(7.81) 
1.12 
(12.0) 
1.12 
(12.4) 
66 0.0503 
(-95.0) 
0.0931 
(-90.7) 
0.360 
(-64.0) 
0.393 
(-60.7) 
0.648 
(-35.2) 
0.669 
(-33.1) 
0.750 
(-25.0) 
0.853 
(-14.7) 
0.981 
(-1.95) 
0.994 
(-0.572) 
1.05 
(4.53) 
1.06 
(6.37) 
1.11 
(10.5) 
1.11 
(10.9) 
100 0.0479 
(-95.2) 
0.0887 
(-91.1) 
0.343 
(-65.7) 
0.374 
(-62.6) 
0.618 
(-38.2) 
0.638 
(-36.2) 
0.714 
(-28.6) 
0.812 
(-18.8) 
0.934 
(-6.57) 
0.947 
(-5.26) 
0.996 
(-0.407) 
1.01 
(1.35) 
1.05 
(5.32) 
1.06 
(5.70) 
120 0.0471 
(-95.3) 
0.0872 
(-91.3) 
0.337 
(-66.3) 
0.368 
(-63.2) 
0.607 
(-39.3) 
0.627 
(-37.3) 
0.702 
(-29.8) 
0.799 
(-20.1) 
0.919 
(-8.14) 
0.932 
(-6.85) 
0.979 
(-2.07) 
0.997 
(-0.342) 
1.04 
(3.56) 
1.04 
(3.94) 
198 0.0454 
(-95.5) 
0.0841 
(-91.6) 
0.325 
(-67.5) 
0.355 
(-64.5) 
0.585 
(-41.5) 
0.604 
(-39.6) 
0.677 
(-32.3) 
0.770 
(-23.0) 
0.885 
(-11.5) 
0.898 
(-10.2) 
0.944 
(-5.63) 
0.960 
(-3.96) 
0.998 
(-0.202) 
1.00 
(0.162) 
210 0.0453 
(-95.5) 
0.0838 
(-91.6) 
0.324 
(-67.6) 
0.354 
(-64.6) 
0.583 
(-41.7) 
0.602 
(-39.8) 
0.674 
(-32.6) 
0.767 
(-23.3) 
0.882 
(-11.8) 
0.894 
(-10.6) 
0.940 
(-5.97) 
0.957 
(-4.30) 
0.994 
(-0.560) 
0.998 
(-0.197) 
 
a %Prediction errors are reported in the brackets. Bioavailabilities with minimum bias are reported in bold. 
Light gray area demonstrates overestimated bioavailability with prediction error exceeds 20%. 
Dark gray area demonstrates underestimated bioavailability with prediction error exceeds 20%. 
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APPENDIX B. CHAPTER 4 SUPPLEMENTAL RESULTS 
 
 
 
 
Figure B-1. Ontogeny of FcRn protein expression in mouse skin 
No significant difference in the relative FcRn protein expression was observed in the skin 
of 2-, 10-, 21-, 42-, and 70-day old mice. The difference of relative FcRn protein 
expression between 20 ?g and 40 ?g loading sample sets was statistically significant (p < 
0.0001). 
 
 
 
 
 
 
Figure B-2. Ontogeny of FcRn protein expression in mouse liver 
Relative expression of FcRn protein in mouse liver was significantly increased in 10-day 
old mice compared to other age groups. The statistical p-values are reported above the 
line associated with each pair of comparison. The difference of relative FcRn protein 
expression between 20 ?g and 40 ?g loading sample sets was statistically significant (p < 
0.0001). 
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Figure B-3. Ontogeny of FcRn protein expression in mouse kidney 
Relative expression of FcRn protein in mouse kidney was significantly increased in 10-
and 42-day old mice compared to other age groups. The significant statistical p-values are 
reported above the line associated with each pair of comparison. The relative FcRn 
protein expressions in 20 ?g and 40 ?g loading sample sets were statistically significantly 
different (p = 0.0240). 
 
 
 
 
 
 
Figure B-4. Ontogeny of FcRn protein expression in mouse lung 
Relative expression of FcRn protein in mouse lung was significantly increased in 10-day 
old mice compared to 2- and 70-day old animals. The significant statistical p-values are 
reported above the line associated with each pair of comparison. The relative FcRn 
protein expressions in 20 ?g and 40 ?g loading sample sets were statistically significantly 
different (p = 0.0005). 
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Figure B-5. Ontogeny of FcRn protein expression in mouse spleen 
There was no significant difference in the relative expression of FcRn protein in mouse 
spleen among all age groups. The difference of relative FcRn protein expressions 
between 20 ?g and 40 ?g loading sample sets was statistically significant (p = 0.008). 
There was no result of 40 ?g loading set in spleen from 2-day old mice. 
 
 
Figure B-6. Protein expression of FcRn and GAPDH in various organs of a 70 
days old mouse 
Protein that was loaded in each lane were protein ladder (A), recombinant mouse FcRn 
(positive control; B), Bovine serum albumin (negative control; C), total protein extracts 
from liver (D), kidney (E), lung (F), heart (G), spleen (H), skin (I), stomach (J), and 
pancreas (K) of a 70 days old C57BL/6J mouse. 
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Table B-1. Expression ratio of FcRn monomer and dimer per total FcRn protein 
expression and total FcRn expression in mouse liver across different age groups 
 
Age Monomer Complex Monomer + Complex 
Mean %RSD Mean %RSD Mean %RSD 
Day 2 0.84 15.58 0.16 83.57 0.73 36.96 
Day 10 0.93 7.37 0.07a 103.11 1.57 31.08 
Day 21 0.71 22.91 0.29 56.30 1.13 42.64 
Day 42 0.70 24.80 0.30 58.07 1.19 28.99 
Day 70 0.68 23.88 0.32 51.13 1.02 34.19 
 
a p < 0.005 when compared to mice from day 21, and 70 age groups 
 
 
 
 
 
 
Figure B-7. Expression of FcRn monomer and total FcRn protein in mouse liver 
across all age groups 
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APPENDIX C. CHAPTER 5 SUPPLEMENTAL RESULTS 
 
 
 
 
Figure C-1. Correlation between inter-subject variability on CL (ETA1) and 
covariates (sex, age, FcRn expression in skin, and FcRn expression in liver) 
 
 
 
 
 
 
Figure C-2. Correlation between inter-subject variability on CL (ETA1) and 
covariates (FcRn expressions in kidney, lung, and spleen) 
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Figure C-3. Correlation between inter-subject variability on V (ETA2) and 
covariates (sex, age, FcRn expression in skin, and FcRn expression in liver) 
 
 
 
 
 
 
Figure C-4. Correlation between inter-subject variability on V (ETA2) and 
covariates (FcRn expressions in kidney, lung, and spleen) 
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Figure C-5. Correlation between inter-subject variability on Ka (ETA3) and 
covariates (sex, age, FcRn expression in skin, and FcRn expression in liver) 
 
 
 
 
 
 
Figure C-6. Correlation between inter-subject variability on Ka (ETA3) and 
covariates (FcRn expressions in kidney, lung, and spleen) 
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Figure C-7. Goodness-of-fit plots of the final model applied in full dataset 
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